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In upper motor neuron diseases, like spinal cord injury, multiple sclerosis, cerebral palsy and 
stroke, motor areas in the brain and/or spinal cord are damaged or fail to develop normally. 
Cerebral palsy is due to abnormal development or damage in the developing brain and occurs 
in about 2 per 1000 life births1;2. Stroke is now the second leading cause of death worldwide 
and third most common cause of disability-adjusted life-years3-5 and the incidence of stroke 
increases with the graying of the society6;7. Improvement in acute stroke care results in a greater 
proportion of patients surviving stroke, but consequently a larger number of people that needs 
to deal with stroke related disabilities. Activities of daily living and quality of life are affected 
by motor, cognitive, speech and language disorders, depression and dementia8;9. Interfering 
motor disorders are stiffness, i.e. increased resistance to movement, decreased range of motion, 
flexion deformity resulting in a shift of joint rest angle towards flexion and paresis, i.e. the 
inability to voluntarily and selectively generate muscle strength and power10.  
Rehabilitation interventions at the ICF11 level of body functions and structures focus on 
reduction of stiffness and maintenance or increasing joint range of motions and correction of 
abnormal joint rest angle shifts. Clinically, the combination of stiffness and muscle over-
activity is often called “spasticity”, but the definition is under debate10;12. In stroke about 20-
30% of all patients suffer from spasticity13. Spasticity was assumed to originate from neurally 
induced reflexive stiffness, i.e. velocity dependent resistance of joint to passive stretching, 
according to the definition of Lance14. However nowadays it becomes accepted that in 
“spasticity”, the neural and non-neural components intermingle15-17. Neural and non-neural 
tissue components continuously interact within a closed loop: The tight coupling between 
afferent sensory information, the central neural system, efferent commands and motor 
properties16;18. Neural activity may modulate tissue properties; tissue shortening may alter 
reflexive thresholds. Moreover, the neural and non-neural properties are environment- and task 
dependent10;16. 
This poses a challenge to assess and quantify the neural, i.e. reflexive stiffness and involuntary 
background activation, and non-neural, i.e. muscle shortening and stiffening, components15;19. 
At these contributors selective treatment should be aimed, i.e. either targeted at the neural 
component or at the non-neural component. The clinical Ashworth and Tardieu tests20-22 are 
applied to quantify the joint stiffness by the observer while manually rotating the joint 
throughout its range of motion. These clinical tests do not differentiate between the neural 
 
reflexive and non-neural tissue components, besides being notoriously insensitive, ordinal and 
insufficient valid and reliable as a measure for spasticity16;23;24.  
 
The neural and non-neural components can be disentangled using a system identification and 
parameter estimation approach (SIPE). System identification uses robotic devices to deliver 
precise force and position perturbations to a joint to allow for assessment of input- output 
relations which can be used to describe the properties of a system18;25-27. Subsequent 
neuromuscular modeling allows for describing the neuromuscular system into clinically 
interpretable parameters. Linear SIPE techniques have been applied for analysis of the 
underlying neuromuscular system in patients with dystonia and stroke28;29 and analysis of 
standing balance in Parkinson’s disease and healthy elderly30-32. In these SIPE techniques, the 
non-linearity, e.g. increased resistance against movement near the maximal range of motion, of 
the (neuromuscular) system is described by a linear technique. Use of these linear techniques 
requires small deviations of e.g. joint angle and muscle contraction. These small deviations in 
movements and contraction do not resemble functional movement. Furthermore, the non-linear 
force-length and force-velocity properties of the connective and contractile tissue and the 
quantification of thresholds of spinal reflexes require non-linear methods16;33;34. Non-linear 
models were applied to predict recorded forces from ramp-and-hold joint perturbations by 
optimizing parameter values of the model of the wrist and ankle in healthy subjects and to 
discriminate groups of patient with stroke from controls35;36. 
 
Non-linear models are necessary to quantify underlying neural and non-neural contributors of 
increased joint stiffness, diminished range of motion and shift of joint rest angle. This 
quantification is important for understanding of underlying mechanisms of functional recovery 
and the effect of therapy on the underlying components to diminish or eventually prevent 
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The aim of the present thesis is:  
 
1. To quantify neural reflexive and non-neural tissue contributors in patients with upper 
motor neuron disease to understand underlying pathophysiological mechanism of 
increased joint stiffness, diminished range of motion and shifted joint rest angle. 
Therefore, an instrumented and EMG driven non-linear neuromuscular modeling 
approach is developed and validated that allows for high precision quantification of 
behavior of the neuromuscular system and by disentanglement of its underlying 
components (chapter 2, 3 and 4).  
2. The method will be used to understand underlying mechanisms of functional recovery 
and the effect of therapy in stroke:  
a) The development of aforementioned components over time will be analyzed in 
the sub-acute phase post-stroke to address possible targeted preventive measures 
and to improve understanding of underlying mechanisms of functional recovery 
(chapter 5). 
b) The effect of botulinum toxin A treatment on the neural reflexive and non-neural 
tissue properties in patients post-stroke will be determined to make a first step 
in predicting which patients will benefit from this therapy (chapter 6). 
 
The present thesis was founded on two research projects, i.e. ROBIN (STW) and Explicit Stroke 
(ZonMw). ROBIN (ROBot aided system identification: novel tools for diagnosis and 
assessment in Neurological rehabilitation) aimed to develop the required tools for applying 
SIPE techniques to clinical practice. The techniques developed in ROBIN were applied to 
clinical data obtained in Explicit-Stroke. The Explicit-Stroke project was a multi-center 
randomized controlled trial which studied the effect of early therapy on post-stroke recovery of 
the upper limb37;38. It further aimed to understand the underlying mechanisms of upper 
extremity functional recovery, encompassing brain plasticity by fMRI39 and end-point wrist 
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Spastic paresis in cerebral palsy (CP) is characterized by increased joint stiffness that may be 
of neural origin, i.e. improper muscle activation caused by e.g. hyperreflexia or non-neural 
origin, i.e. altered tissue viscoelastic properties (clinically: “spasticity”  vs. “contracture”). 
Differentiation between these components is hard to achieve by common manual tests. We 
applied an assessment instrument to obtain quantitative measures of neural and non-neural 
contributions to ankle joint stiffness in CP. 
Twenty-three adolescents with CP and eleven healthy subjects were seated with their foot 
fixated to an electrically powered single axis footplate. Passive ramp-and-hold rotations were 
applied over full ankle range of motion (RoM) at low and high velocities. Subject specific tissue 
stiffness, viscosity and reflexive torque were estimated from ankle angle, torque and triceps 
surae EMG activity using a neuromuscular model. 
In CP, triceps surae reflexive torque was on average 5.7 times larger (p=.002) and tissue 
stiffness 2.1 times larger (p=.018) compared to controls. High tissue stiffness was associated 
with reduced RoM (p<.001). Ratio between neural and non-neural contributors varied 
substantially within adolescents with CP. Significant associations of SPAT (spasticity test) 
score with both tissue stiffness and reflexive torque show agreement with clinical phenotype. 
Using an instrumented and model-based approach, increased joint stiffness in CP could be 
mainly attributed to higher reflexive torque compared to control subjects. Ratios between 
contributors varied substantially within adolescents with CP. Quantitative differentiation of 
neural and non-neural stiffness contributors in CP allows for assessment of individual patient 






Cerebral palsy (CP) comprises a variety of non-progressive upper motor neuron (UMN) lesions 
occurring in the developing fetal or infant brain. The resulting movement and posture disorders 
are generally characterized by loss of muscle strength, i.e. paresis, improper muscle activation 
by e.g. increased reflexes and loss of coordination by e.g. flexion synergies. In addition, changes 
of tissue viscoelastic properties may modulate the characteristics of the primary motor 
disorders1;2. Spastic CP is the most common type of CP3, which is characterized by increased 
joint stiffness (resistance to movement). Increased joint stiffness in the relaxed condition can 
be of either neural (hyperreflexia, “spasticity”) or non-neural origin (altered tissue viscoelastic 
properties “contracture”)4. Treatment of spastic CP is generally aimed at diminishment of joint 
stiffness in order to improve passive and active joint range of motion. In case of suspected 
neural origin, therapy is aimed at reducing muscle activation and blocking the stretch reflex 
loop by botulinum toxin5, intra thecal baclofen6 or selective dorsal rhizotomy7. In case of 
suspected non-neural origin, i.e. changes in viscoelastic properties of muscle and connective 
tissues, corrective casting, splinting and surgical lengthening can be applied8. Current manual 
tests, like the Ashworth9 and Tardieu10, are based on the paradigm of increased reflex activity 
as a result of neural damage, leading to a velocity dependent joint resistance or spasticity11. 
This paradigm is however an oversimplification4. Inherently, by manual testing, it is not 
possible to quantitatively discriminate between underlying neural and non-neural contributors 
to joint stiffness as each of these contributors may generate a velocity dependent joint 
resistance. This makes the selection of treatment aiming at the dominant contributor difficult. 
De Vlugt et al.12 developed an instrumented method to quantify neural and non-neural 
contributors to joint stiffness for the ankle joint in patients with chronic stroke. The ankle was 
rotated in a precise and controlled way using a robotic manipulator. Using neuromuscular 
modeling, the key neural and non-neural contributors to ankle joint stiffness were quantified 
from recorded ankle torque and EMG of leg (below the knee) muscles. Compared to healthy 
subjects, patients with stroke showed increased tissue stiffness and to a lesser extent increased 
reflex activity. 
The objective of the present study was to quantify neural and non-neural contributors to ankle 
joint stiffness in patients with spastic CP and to assess its validity and reliability. A quantitative 
discrimination between the neural and non-neural components of joint stiffness in CP gives 
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Twenty-three adolescents with CP (mean age (SD) and range: 14.9 (2.4) y, 12-19 y, fifteen 
male) were recruited from the outpatient clinics of the Rijnlands Rehabilitation Centre and the 
Department of Rehabilitation Medicine of the Leiden University Medical Centre, Leiden, the 
Netherlands. Table 2.1 provides the patient characteristics. Inclusion criteria comprised 
diagnosis of spastic CP and a gross motor function13 (GMFCS) of I, II or III. Patients with a 
GMFCS of IV were excluded because of possible interference of the outcome with muscle 
disuse or atrophy. Other exclusion criteria were concomitant neurological diseases, orthopedic 
problems of the lower extremities, casting, botulinum toxin A injections within the previous 4 
months, previous orthopedic surgery or tendon and tissue surgery of the leg, orthopedic surgery 
of other body parts within the last 12 months, previous selective dorsal rhizotomy or intra thecal 
baclofen treatment and inability to participate in the tests. Eleven healthy subjects (mean age 
(SD) and range: 15.1 (2.1) y, 12-18 y, six males), matched for age and sex, were recruited as a 
control group. Required sample size estimation was based on previous data12. The medical 
ethics committee of the Leiden University Medical Centre approved the study. Written 
informed consent was obtained from participants. 
 
Instrumentation 
Subjects were seated with their foot fixated onto an electrically powered single axis footplate 
(Nissan Motor Company, Japan). Subjects were seated with their hip and knee positioned at 
approximately 80° and 70° of flexion respectively (Figure 2.1). The thigh was held in place 
through the seat support of the chair; movement of the shank in cranial- caudal direction was 
ensured by careful aligning axis of rotation of the motor with the ankle axis. Movement of the 
shank in medio-lateral was limited by fixation of the thigh. The ankle was positioned at zero 
degrees onto the footplate of the manipulator, perpendicular to the leg (neutral position). A 
 
positive rotation of the manipulator was defined to equal dorsiflexion of the foot and a negative 
rotation, plantar flexion of the foot. Range of motion of the manipulator was mechanically 
constrained to plus and minus 30 degrees with respect to the neutral position.  
 
Table 2.1: Characteristics of study population.  
Characteristics of study 
population 
Cerebral palsy  




Age, years (SD) 14.9 (2.4) 15.1 (2.1) 
Male gender, n (%) 15 (65) 6 (55) 
Unilateral, n (%)  8 (35) Na 
GMFCS* I, II, III, n (%) 20 (87), 2 (9), 1 (4) Na 
Ashworth, median (range) 1 (0-2)*** Na 
SPAT**, median (range) 2 (0-3)*** Na 
* GMFCS = Gross Motor Function Classification System **SPAT = Spasticity test  
***From one patient data is missing 
 
The axis of rotation of the ankle and footplate were aligned by visually minimizing knee 
translation in the sagittal plane during manual rotation of the footplate. The motor was driven 
to rotate the ankle by either a torque for the assessment of ankle range of motion (RoM), or by 
a position to impose ramp-and-hold (RaH) rotational stretches of the triceps surae for the 
identification of joint stiffness. During movement, flat foot placement was ensured by visual 
inspection. Muscle activation of the tibialis anterior (TA) and triceps surae muscles (TS: soleus, 
lateral and medial gastrocnemius) was recorded by surface electrodes (electromyography, 
EMG), using a Delsys Bagnoli 4 system (Delsys, Boston MA, USA). Inter electrode distance 
was 10 mm. EMG signals were sampled at 2500 Hz, online band pass filtered (20-450 Hz) and 
offline rectified and low pass filtered (3th-order Butterworth) at 20 Hz. Reaction torque and 
ankle rotational angle were recorded at 250 Hz sample rate and low pass filtered at 20 Hz (3th-
order Butterworth). 
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Figure 2.1: Measurement set-up (left) and applied ankle joint rotations (right). Ankle joint rotations were applied 
at 4 different velocities over the individual range of motion. 
 
Protocol 
Measurements were performed on the most affected ankle of each patient and at the right ankle 
in case of controls. Maximum plantar and dorsal flexion angles were assessed by a gradually 
increasing flexion torque from 0 to a maximum value of 15 Nm. RoM was defined as the 
difference between the maximum plantar and dorsal flexion angle and used as boundary for the 
subsequent RaH rotations. During the RaH rotations, the ankle was rotated at 4 different angular 
velocities (15, 30, 60, 120 deg/sec) over the individually assessed RoM, starting in maximal 
plantar flexion. RaH rotations were started at random time instants. The hold phase lasted 4 
seconds after which the ankle was moved back again to the neutral position. Time to cover a 
complete RaH rotation did not exceed 15 sec. Rest periods of about 30 sec were introduced 
between each RaH rotation to avoid hysteresis effects14. All RaH rotations were performed 
twice. Thus, the complete experimental procedure consisted of 1 RoM and 2 times 4 RaH 
rotations. Subjects were asked to remain relaxed during the entire experiment and not actively 
resist any motion. EMG prior to RaH rotation was offline checked to be between minus and 
plus 3 times standard deviation from the lowest EMG value over the whole signal as determined 
by a moving average procedure (window width 1 sec.). RaH rotations not fulfilling this 
requirement were discarded from further analysis. 
 
 
Model description and validation 
To distinguish between the neural and non-neural contributions to ankle joint stiffness, a 
nonlinear neuromuscular model of the ankle joint was used by which the ankle torque was 
predicted and matched to the measured ankle torque using EMG and ankle angle as input. The 
model included a Hill-type muscle model to describe the torque contribution from muscle 
activation induced by stretch reflexes. Hill-type models account for the effect of muscle length 
and lengthening velocity on muscle force. Passive torque from viscoelasticity (parallel elastic 
element) was modeled by exponential force-length and force-velocity functions. Tendon 
stiffness (series elastic element) was assumed to be infinitely stiff12. The full description of the 
model can be found in de Vlugt et al.12. The model was fitted to the measured ankle torque 
defined within a time frame starting 0.5 sec before the start of the ramp till 0.5 sec after the end 
of the ramp, which was in the hold phase. Model parameters where estimated for each single 
RaH rotation by minimizing the quadratic difference (error function) between the measured and 
predicted ankle torque. The validity of the model was determined for each RaH rotation by the 






































VAF       (2.1) 
 
With i the sample time and n the number of data points used for the parameter estimation. 
imeasuredT , is the measured ankle reaction torque and ielT ,mod the predicted ankle torque. Those 
rotations exhibiting a VAF score lower than the mean VAF over all rotations minus 2 times 
standard deviation were excluded from analysis. 
Primary outcome parameters were RoM, tissue stiffness and viscosity and torque from triceps 
surae (TS) and tibialis anterior (TA) stretch reflexes. As passive tissue stiffness and viscosity 
strongly depend on joint angle, values at the maximal common dorsal flexion angle of all 
subjects were calculated for inter-subject analysis. This particular angle was chosen as 
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exhibiting probably the largest contrast between subjects12. Model simulations and data 
analyses were performed in MATLAB (The Mathworks Inc., Natick MA). An extensive 
validity and reliability analysis of the used method and the estimated model parameters was 
performed previously12.  
 
Statistical analysis 
Difference in RoM between patients with CP and healthy controls was tested using an unpaired 
t-test. A linear mixed model was used to determine the difference in primary outcome variables 
between healthy controls and patients with CP (random factor) and to assess the effect of 
velocity (fixed, repeated factor). Stepwise linear regression procedures and one-way ANOVA 
with Bonferroni correction were applied to assess associations of primary outcome variables 
with RoM and secondary outcome variables i.e. speed of ankle rotation, age, gender, GMFCS13, 
Ashworth9 and spasticity test (SPAT)15 scores. Inter-trial variability was assessed using 
intraclass correlation coefficients (ICC, 2-way mixed model). Statistical analysis was 
performed using SPSS 17.0 (SPSS Inc.) and GraphPad Prism 5 (Graphpad Software) with a 
significant level of .05. 
 
Results 
One subject (healthy) could not complete the RaH measurement due to insufficient relaxation 
and in this particular case only the RoM was used. In 2 other healthy subjects 1 RaH rotation 
had to be excluded due to technical problems. In total, 16 of the 256 RaH rotations from 9 
subjects (8 CP), were excluded due to poor model fits (10, 4% of 256 RaH rotations) or 
insufficient relaxation (6, 2 % of 256 RaH rotations). The VAF of the remaining RaH rotations 





Range of motion 
RoM in dorsiflexion was significantly smaller in CP (t=2.10, p=.044), see Figure 2.2 (top left). 
Of all subjects, 4 patients with CP (12%) and 7 healthy controls (64%) had a RoM of at least 
60 deg. The smallest maximal dorsal flexion angle among all subjects was 2 deg.  
 
Non-neural contributors to joint stiffness: tissue stiffness and viscosity  
Tissue stiffness was independent of velocity (F=0.35, df=3, p=.79) and was significantly larger 
in CP compared to healthy controls (F=6.28, df=1, p=.018), see Figure 2.2 (bottom left). There 
was a large variation in tissue stiffness within the CP group. Viscosity decreased with angular 
velocity (F=9.86, df=3, p<.001). We found no significant difference between the groups 
regarding ankle viscosity (F=1.35, df=1, p=.254). 
 
Neural contributor to joint stiffness: reflexive torque 
TS reflexive torque (Figure 2.2, top right) was higher in CP than in healthy controls (F=11.6, 
df=1, p=.002) and the difference increased with velocity (F=4.61, df=3, p=.009). TS reflexive 
torque showed a large variation within the group with CP. TA reflexive torque was not 
significantly different between CP and healthy controls (F=2.864, df=1, p=.104) and did not 
change with velocity (F=0.602, df=3, p=.620). 
 
Relation tissue stiffness and range of motion 
Tissue stiffness at the lowest ankle rotation speed appeared to be the best predictor of ankle 
RoM (β=-0.45 se 0.06, p<.001, Figure 2.3) with a total explained variance of 84%. 
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Range of motion 
RoM in dorsiflexion was significantly smaller in CP (t=2.10, p=.044), see Figure 2.2 (top left). 
Of all subjects, 4 patients with CP (12%) and 7 healthy controls (64%) had a RoM of at least 
60 deg. The smallest maximal dorsal flexion angle among all subjects was 2 deg.  
 
Non-neural contributors to joint stiffness: tissue stiffness and viscosity  
Tissue stiffness was independent of velocity (F=0.35, df=3, p=.79) and was significantly larger 
in CP compared to healthy controls (F=6.28, df=1, p=.018), see Figure 2.2 (bottom left). There 
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velocity (F=9.86, df=3, p<.001). We found no significant difference between the groups 
regarding ankle viscosity (F=1.35, df=1, p=.254). 
 
Neural contributor to joint stiffness: reflexive torque 
TS reflexive torque (Figure 2.2, top right) was higher in CP than in healthy controls (F=11.6, 
df=1, p=.002) and the difference increased with velocity (F=4.61, df=3, p=.009). TS reflexive 
torque showed a large variation within the group with CP. TA reflexive torque was not 
significantly different between CP and healthy controls (F=2.864, df=1, p=.104) and did not 
change with velocity (F=0.602, df=3, p=.620). 
 
Relation tissue stiffness and range of motion 
Tissue stiffness at the lowest ankle rotation speed appeared to be the best predictor of ankle 






Figure 2.2: Primary outcome parameters. Range of motion (top left), triceps surae reflexive stiffness (top right), 
tissue stiffness (bottom left) and viscosity (bottom right) for patients with cerebral palsy (CP) and healthy controls 
(H). The dotted line gives the mean value with the corresponding standard error. Each dot represents an individual 
result of a subject. Tissue stiffness and viscosity were determined at the same ankle angle for all subjects, which 





Figure 2.3: Relation between tissue stiffness and range of motion for adolescents with cerebral palsy (CP). Tissue 
stiffness (15 deg/sec) was determined at 2 deg ankle dorsal flexion. Each dot represents the result of an individual 
subject. A linear regression line with its 95% confidence interval is fitted through the data. The total explained 
variance was 84%. 
 
Relation tissue stiffness and reflexive torque 
For patients with CP, tissue stiffness at the lowest ankle rotation speed (15 deg/sec) was on 
average 4.2 times higher than reflexive torque at the highest ankle rotation speed (120 deg/sec) 
with a standard deviation of 3.3 indicating a substantially variation between subjects. Total 
explained variation of reflexive torque (120 deg/sec) by tissue stiffness (15 deg/sec) was 38%. 
Association between tissue stiffness and reflexive torque was low (ICC: less than .5).  
 
Relation with clinical phenotype 
Using stepwise linear regression SPAT score was the only variable that was significantly 
associated with tissue stiffness (β=15.8 se 4, p=.001). For reflexive torque, both SPAT score 
and age were significant positive contributors (β=3.8 se 1.46, p=.02 and β=0.88 se 0.41, 
p=.049). Tissue stiffness (15 deg/sec, p=.002), TS reflexive torque (120 deg/sec, p=.032) and 
RoM (p=.001) differed significantly with respect to SPAT but not Ashworth score (Figure 2.4). 
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Tissue stiffness showed a good conformity between the two repetitive RaH rotations especially 
at the lowest ankle rotation speed: ICC .93 at 15 deg/sec. For reflexive torque, inter-trial 
reliability was especially good at the highest ankle rotation speed: ICC .80 at 120 deg/sec. 
Reliability was similar for CP and healthy subjects. 
 
Discussion 
Ankle joint stiffness in CP was successfully separated into its neural and non-neural 
components using an instrumented and model-based approach. Compared to healthy subjects, 
patients with CP showed a smaller RoM, higher TS reflexive torque and higher tissue stiffness. 
Ratios between contributors varied substantially within the group with CP. 
 
Higher tissue stiffness and smaller range of motion in cerebral palsy 
Previously, in larger groups of children with CP, RoM was associated with level of spasticity 
as expressed by Ashworth score and GMFSC I-II16-19. Decreased RoM in CP is explained by 
increased passive tissue stiffness17, likely originating from changes in the mechanical property 
of fiber bundles and/or fewer sarcomeres (in series) which might result in increased sarcomere 
length20-22 or actively, i.e. hypertonia23. In vivo measurements in CP show that muscles 
appeared to undergo much higher stresses with increased muscle length21 and torque-angle 
relationships are much steeper in CP24, which is supported in our study by the correlation 
between tissue stiffness and RoM (Figure 2.3). RoM measurements at low speed may therefore 
represent passive tissue stiffness, i.e. “static” contracture23. Note that despite the instruction to 
the subjects to relax, tissue stiffness may be modulated by a constant level of (increased muscle 





Clinical implication: variation in tissue stiffness and reflexive torque 
Even in this relatively mild affected group of adolescents with CP, a large inter-subject variation 
was found for the ratio between TS reflexive torque and tissue stiffness. Association between 
the two was low. This variation is the rationale for pursuing the development of personalized 
therapy. A variation in CP may be induced by ageing and the corresponding growth spurt in 
puberty since we measured adolescents in a wide age range (12-19 years). It was suggested 
previously that the role of passive stiffness may increase over reflex activity with age in children 
with spastic diplegic CP26 and that the range of dorsiflexion of the ankle joint in CP decreases 
on average 19 deg during the first 18 years of life18.  We found an association of reflex activity 
but not tissue stiffness with age in the present study. The present study was however not 
designed to study age effects.  
Correlation of SPAT score with both tissue stiffness and reflexive torque underlines the fact 
that it is difficult to split the neural and non-neural component with the manual tests such as 
SPAT. In future work we will measure more patients and with a wider range of GMFCS and 
SPAT scores to study this correlation more extensively. 
The present and former12 studies show that the instrumented approach can be used in different 
patient groups to quantitatively determine neural and non-neural contributors of ankle joint 
stiffness. 
 
Non-neural and neural components in cerebral palsy compared to stroke 
TS reflexive torque was more dominant in CP than in stroke12. For the patients with an 
Ashworth score of 1, the ratio between TS reflexive torque at the highest ankle rotation speed 
and tissue stiffness at the lowest ankle rotation speed was for CP three times higher than for 
stroke (CP ≈ 0.3 and stroke ≈ 0.1). In contrast to stroke, viscosity was not significantly increased 
in CP. RoM was smaller in stroke compared to CP, reflecting also the higher tissue stiffness 
component in the stroke group. CP differs from stroke by onset of the disease with respect to 
age. The main question is whether the differences between stroke and CP may be explained by 
purely an age effect or whether there might be etiological differences. 
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Figure 2.4: Relation of outcome parameters with Ashworth and spasticity test (SPAT). Mean with standard error 
for tissue stiffness (15 deg/sec), triceps surae (TS) reflexive torque (120 deg/sec) and range of motion (RoM) for 
groups of patients with different Ashworth and SPAT scores. *significantly different (p<.05) by one-way ANOVA 
with a Bonferroni post-hoc test. 
 
  




































































Reliability and validity 
Tissue stiffness and reflexive torque could both be reliably estimated: tissue stiffness especially 
at the low ankle rotation speed and reflexive torque at the high speeds. This illustrates the 
feasibility of the method to distinguish contributors to joint stiffness on an individual basis. As 
expected, reflexive torque and not tissue stiffness was significantly influenced by ankle rotation 
speed and especially tissue stiffness was associated with RoM at low speed. Significant 




We selected patients with CP with a relatively high GMFSC score (median of 1) to create a 
homogenous population. This limits validity of the present study and prevents more extensive 
elaboration of the relation with clinical phenotype which will be important for goal directed 
therapy. There were only 3 patients with a GMFCS score higher than 1, so correlations of 
GMFCS with neuromuscular parameters could not be studied well. The present study did not 
differentiate contributions of gastrocnemius and soleus and was performed at 1 knee angle. 
Joint stiffness should also be assessed in relation to functional movements, like walking using 
static and dynamic measurements27. In this study we were able to split neural and non-neural 
contributors to increased joint stiffness. However, the neural component in this study comprised 
only the reflex activity and not cross bridge dynamics and background muscle activity during 
passive (and active) conditions. Achilles tendon stiffness was assumed to be of a magnitude 
greater than the total (active and passive) muscle stiffness for the current conditions applied in 
this study28 and was taken in our model as infinitely stiff, considering the low torque and passive 
conditions12 applied in the present study.  
Future work will comprise the assessment of Achilles tendon stiffness by ultrasound 
measurements, the assessment of joint stiffness as a function of ankle rotation angle in a more 
detailed way, measurements at different knee angles and under functional (loaded) conditions.  
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Using a novel instrumented assessment technique, patients with CP showed a smaller RoM and 
higher tissue stiffness and reflexive torque compared to control subjects. Good reliability and 
validity of the assessment technique combined with considerable intra-individual variance are 
a base for individual tailored therapy. 
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Non-invasive estimation of the neural reflexive and non-neural tissue contributors viz. passive 
and active muscle force length characteristics, to increased joint stiffness after central neural 
motor lesions like stroke will contribute to fundamental understanding, clinical diagnosis, 
development and evaluation of therapy. Hereto we proposed an electromyography (EMG)-
driven model approach. 
Ramp-and-hold ankle rotations were applied and torques were measured by a robotic 
manipulator in 13 patients post-stroke (> 6 months, 59.9, SD 7.1 years) and 15 age matched 
healthy volunteers (64.0, SD 1.2 years). Stiffness coefficient and slack length of the passive and 
optimal length of the active force-length characteristics of triceps surae and tibialis anterior 
muscles were estimated together with the neural reflexive torque by minimizing the least 
squares difference between measured and simulated torque. Internal model validity, test-retest 
reliability, sensitivity and external validity were addressed. 
Internal model validity was good and test-retest reliability fair to good. Model parameters were 
sensitive for knee angles and disease. The neural reflexive torque, the stiffness coefficient and 
the slack length of the triceps surae were increased in patients post-stroke. 
Valid, reliable and sensitive estimations of passive and active force-length characteristics next 
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triceps muscles is expected to be observed in the passive and active force-length parameters 
(slack length, optimal length). Knee angle is expected to have no influence on the passive and 
active force-length parameters of the tibialis anterior. External validity is assessed by 
comparing healthy subjects to patients post-stroke and using the minimal detectable change 
(MDC) of healthy subjects. It is expected that patients differ from healthy subjects by an 
increased peripheral tissue stiffness due to stiffer and shortened muscles of the triceps surae and 
an increased reflexive torque of the triceps surae. Individual observations are compared to the 
clinical Ashworth score and it is expected that especially patients with a high Ashworth score 
(>2) have deviated outcome measures as defined by the MDC. To show the potential for 
longitudinal observations, e.g. to evaluate treatment, the MDC of stroke patients is assessed.  
 
Methods 
Study setting and participants 
Thirteen chronic stroke patients (115 months post-stroke, mean age 59.9 SD 7.1 years, 6 male, 
Table 3.1) and 15 healthy volunteers (mean age 64.0 SD 1.2 years, 8 male) were included in 
the study. Patients with clinically determined increased ankle stiffness were selected from the 
outpatient clinic of the department of rehabilitation medicine of the Leiden University Medical 
Center (LUMC). Exclusion criteria were concomitant neurological and/or orthopedic disorders, 
any new medical intervention within the last four months having possible interference with 
ankle joint stiffness; surgery of leg/foot within the last 12 months and total paralysis of the 
ankle. The medical ethics committee of the LUMC approved the study (P12.125, 
NL4083.058.12). Written informed consent was obtained from all participants. 
 
Measurement protocol 
Participants were measured during two consecutive visits within a time interval of 1-2 weeks. 
Each participant underwent two measurement sessions during the first visit, and one session 
during the second visit. At each session, measurements were performed at two knee flexion 
angles (20°, 70°) in order to discriminate the relative contribution of the gastrocnemius 
 
components of the triceps surae. During each visit, the Ashworth score28 was determined by an 
independent physician. 
 
Table 3.1: Characteristics of included patients. 





1 56 F Hemorrhage L 72 19.5 3 
2 65 F Hemorrhage L 368 18.4 2 
3 60 F Ischemia L 177 9.7 1 
4 65 M Hemorrhage R 204 23.8 0 
5 57 M Ischemia R 108 7.3 4 
6 51 F Ischemia R 80 1.2 1 
7 46 F Ischemia R 11 13.2 3 
8 70 M Hemorrhage R 14 3.3 4 
9 57 M Ischemia L 6 19.5 1 
10 57 M Ischemia R  153 6.8 0 
11 67 M Ischemia R 76 13.7 2 
12 69 F Ischemia R 42 27.2 2 
13 59 F Ischemia R 185 23.5 3 
F: female, M: male, L: left hemisphere, R: right hemisphere 
 
Instrumentation 
Participants were seated on a car seat with their foot fixated onto an electrically powered single 
axis rotating footplate (Achilles, MOOG FCS Inc., Nieuw-Vennep, The Netherlands, 
Figure 3.1). The footplate was aligned visually at 25° plantar flexion with respect to the line 
connecting the head of the fibula and the lateral malleolus.  
Muscle activation of the tibialis anterior (tib) and triceps surae muscles (tri: soleus, SOL; lateral 
gastrocnemius, GL; medial gastrocnemius, GM) was recorded using surface electromyography 
(EMG, Porti, TMSi B.V. Oldenzaal, The Netherlands) according to the SENIAM guidelines29 
(Appendix 3A). Dorsal- and plantar flexion (positive and negative rotation respectively) was 
limited by individually pre-set manipulator hardware and software stops. During ramp-and-
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were sampled at 1000 Hz, offline high pass filtered (20Hz, 3th-order Butterworth), rectified and 
low pass filtered (20 Hz zero overshoot filter). Rest EMG, i.e. the minimal EMG determined 
for each muscle by applying a moving window of 8 ms, was subtracted from the total EMG 
because it was assumed not to contribute to ankle torque (noise). Torque and ankle angle were 




Figure 3.1: Left: Measurement set-up. Measurements were performed at 70° (see figure) or 20° knee flexion. 
Right: Example of imposed angular rotation (bottom) and torque response with model fit (top row) for a healthy 
participant (extended knee, 15°/sec VAF=99.97%). 
 
Protocol 
Measurements were performed at the right ankle (healthy volunteers) or at the hemiparetic side 
(patients). Maximum dorsal- and plantar flexion angles within the predefined tolerated range 
of motion (RoM) were assessed by imposing torques of 15 Nm (dorsiflexion) and -7.5 Nm 
(plantar flexion). The resulting RoM defined the boundaries for the subsequent RaH rotations.  
During the RaH measurements, the ankle was rotated at two different angular velocities, 15°.s-1 
and 100°.s-1, starting from maximal plantar flexion and ending at maximal dorsiflexion (first 
ramp). After a hold phase the ankle was moved back to the maximal plantar flexion angle 
(second ramp, Figure 3.1). RaH rotations were started at random (thus unpredictable) time 
instants. A single session thus comprised one RoM assessment and four RaH trials (twice for 
 




A biomechanical model-based on a previous developed Hill-type muscle element ankle model4 
was adapted to estimate parameters of the passive and active force-length relationship of the 
connective and contractile tissue contribution of the triceps surae and tibialis anterior 
(Appendix 3B).  
The net ankle torque, Tmod, applied onto the manipulator was estimated based on 15 parameters 
(Appendix 3A) describing the inertial torque (I), the torque generated by the plantar flexors (tri) 
and the torque generated by the dorsiflexors (tib) as a function of time (t) and the combined 
gravitational torque of the foot and foot plate as a function of ankle angle (θ) (Eq. 3.1): 
𝑇𝑇𝑇𝑇���(𝑡𝑡𝑡𝑡) = 𝐼𝐼𝐼𝐼?̈?𝐼𝐼𝐼(𝑡𝑡𝑡𝑡) + 𝑇𝑇𝑇𝑇���(𝑡𝑡𝑡𝑡) − 𝑇𝑇𝑇𝑇���(𝑡𝑡𝑡𝑡) + 𝑇𝑇𝑇𝑇����(𝐼𝐼𝐼𝐼)   (3.1) 
The measured joint torque (Tmeas) was simulated (Tmod) from ankle position and EMG by 
optimizing 15 parameters (Appendix 3) using a least squares gradient search algorithm 
(lsqnonlin, MATLAB). Primary outcome measures were:  
1) Slack length (lp,slack,m) and stiffness coefficient (km) for both dorsiflexors (m=tib) and 
plantar flexors (m=tri), represent the passive force-length relation of the parallel 
connective tissues. The higher km, the stiffer the muscle; the lower lp,slack,m the shorter 
the muscle. 
2) Optimal length (lopt,m), i.e. the length at which the activated plantar (tri) and dorsiflexor 
(tib) muscles generate their maximum force.  
3) Peripheral tissue stiffness (Kjoint) selectively derived from the (parallel) connective 
tissue model components at angle position  = 0o, i.e. foot perpendicular to the lower 
leg. 
4) Reflexive torque Treflex,m, i.e. the root mean square of the active muscle torque for the 
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Simulation and analysis was performed in MATLAB (The Mathworks Inc., Natick MA) and 
statistical analysis was performed using IBM SPSS statistics 22 and GraphPad Prism 6. 
 
Internal model validity, test-retest reliability, sensitivity and external validity 
Internal model validity: Model fit and parameter reliability 


























VAF   (3.2) 
 
with Tmean being the average of Tmod and Tmeas. VAF values less than 99% were disregarded from 
analysis for test-retest reliability, sensitivity and external validity. 
The standard error of the mean (SEM) represents the parameter reliability and is based on the 
partial derivatives of each parameter to the error function4. Low SEM values indicated that the 
specific parameter has substantial contribution to the error function. High values may indicate 
high co-variances or over-parameterization. SEM values were estimated for each trial before 
rejection based on low VAF value. 
For interpretation of the results we defined the following inclusion demands: Optimal lengths 
(lopt,m) were only included in the analysis in case of sufficient muscle activity, i.e. reflexive 
torque, Treflex,m larger than .75 Nm, combined with SEM’s lower than 0.1 Nm and for optimal 
length values that did not meet predefined parameter boundaries. Optimal tibialis length (lopt,tib) 
was excluded from further analysis when the model parameter Gtib, i.e. EMG weighting factor 
of tibialis anterior, was extremely high (>1*108) thereby introducing noise amplification. This 
was not an issue for the optimal triceps surae length (lopt,tri) because three EMG weighting 
factors were used to define the triceps surae muscle activation. 
 
Test-retest reliability 
Repeated measures were averaged for each participant for comparison between sessions on the 
same day and between days. Between-trial reliability of consecutive trials within a session, 
between-session reliability (on the same day) and between-day reliability with 1-2 weeks in 
between were assessed using the intra-class correlation coefficient (ICC using the two-way 
 
mixed model for absolute agreement and interpreted according to Fleiss30 (>.75 excellent, .4-.75 
fair to good, <.4 poor).   
 
Sensitivity for knee angle 
Repeated measures were averaged for each participant to compare groups of participants. 
Optimal length estimates were averaged for 15°.s-1 and 100°.s-1 observations. A paired t-test 
was used to compare outcome measures between flexed and extended knee condition in healthy 
subjects and stroke patients.   
 
External validity 
A linear mixed model was used to determine the difference in model parameters between 
healthy controls and stroke patients after transforming data to obtain a normal distribution using 
the square root of the estimated primary outcome measures. Data from the slow trials (15°.s-1) 
were used to estimate non-neural parameters while for the reflexive torques data from the fast 
trials (100°.s-1) were used, as reliability for passive parameters proved to be highest for slow 
movements and reflexive torques proved to be highest for fast movements22. Individual 
observations were compared to the clinical Ashworth score. The minimal detectable change 
(MDC)31;32 with a 95% confidence interval was used to identify deviated parameters in patients 
post-stroke relative to healthy volunteers, i.e. parameters exceeding the mean value +/- MDC. 
MDC values were calculated using the standard error of measurement (SEM) using ICC from 
healthy participants calculated between sessions on different days, Eq. 3.3: 
 
ICCSDSEM  1*       (3.3) 
EMSMDC *2*96.1       (3.4) 
 
MDC values were also calculated based on ICC from stroke patients to determine the potential 
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From three patients and one healthy volunteer, the data of the second visit was missing or 
excluded due to muscular pain, measurement problems and medication possibly influencing 
muscle function. In total 640 trials from 28 participants were included for analysis of internal 
model validity. The requirements of sufficient muscle activation to optimal length analysis were 
met for 345 trials of 27 participants (13 stroke patients). Eight trials (1.25%) were excluded due 
to low VAF values not exceeding 99%. Data from 24 participants (10 patients) were available 
to assess between-day reliability. In 25 sessions of eight (out of 28) participants, RaH’s were 
not performed over the whole [-7.5–15 Nm] RoM at dorsiflexion (7 times, 5 participants) and 
plantar flexion (22 times, 5 participants). In these cases, safety stops were set at smaller ranges 
because of e.g. pain or discomfort. Dorsal passive RoM of patients post-stroke, 16.5° (SD 8.7) 
was reduced (p=.025) compared to healthy participants, 25.5° (SD 9.2).  
Detailed overview of all model parameter estimates and SEM values are presented in Appendix 
3A. Median VAF values of all 640 trials, i.e. including VAF < 99% observations, was 99.9% 
for both knee angles. Median SEM values were equal or below 0.1 for all estimated parameters 
except the EMG weighting factors.  
Test-retest reliability of model parameters varied dependent on ankle rotation speed and knee 
angle and was fair to excellent for parameters related to the passive force-length of the triceps 
(ktri, lp,slack,tri) (Table 3.2). For the optimal length of the triceps (lopt,tri), test-retest reliability was 
fair to good except for between-trial reliability with extended knee. Test-retest reliability for 
reflexive torque of the triceps (Treflex,tri) was poor at 15°.s-1 between days for the extended knee 
condition. Test-retest reliability of the peripheral tissue stiffness (Kjoint) was in all cases higher 
than 0.8 and excellent in 6 out of 12 conditions (ICC>.9). 
For healthy volunteers, peripheral tissue stiffness was higher in extended knee condition 
compared to flexed knee condition (P=.017) and slack length (P<.001), stiffness coefficient 
(P=.003) and optimal length (P=.024) of the triceps surae were increased in flexed knee 
condition (Figure 3.2, Table 3.3 and Table 3.4). There were no significant changes for the 




Table 3.2: Intraclass correlation coefficients over observations of controls and patients for flexed and extended 
knee for movement velocity of 15°.s-1 and 100°.s-1. For analysis of the optimal lengths the parameters per knee 
angle were averaged due to small number of trials as not all trials met the requirements of sufficient muscle 
activation to estimate lopt,m. 
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Flexed knee       
ktri [m-1] .636 .811 .948 .903 .937 .598 
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lslack,tri [m] .683 .563 .812 .778 .705 .564 
lslack,tib [m] .883 .859 .922 .839 .484 .775 
lopt,tri [m]* .600 .735 .565 
lopt,tib [m]* .569 .476 .050 
Kjoint [Nm.rad-1] .909 .986 .846 .861 .833 .823 
Treflex,tri [Nm] .722 .701 .839 .908 .707 .719 
Treflex,tib [Nm] .074 .390 .578 .805 .165 .246 
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ktib [m-1] .585 .747 .617 .846 .679 .387 
lslack,tri [m] .739 .578 .831 .830 .689 .423 
lslack,tib [m] .604 .722 .553 .760 .736 .385 
lopt,tri [m]* .333 .756 .470 
lopt,tib [m]* .736 .097 .158 
Kjoint [Nm.rad-1] .916 .989 .899 .919 .930 .878 
Treflex,tri [Nm] .506 .631 .647 .775 .110 .647 
Treflex,tib [Nm] .732 .788 .690 .883 .203 .546 
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condition (Figure 3.2, Table 3.3 and Table 3.4). There were no significant changes for the 
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Table 3.3: Model outcome parameters (mean, SD) for healthy and stroke participants for flexed and extended knee 
condition.  
           Flexed knee          Extended knee 
 Healthy Stroke Healthy Stroke 
ktri [m-1] 270 (33) 328 (73) 252 (37) 321 (65) 
ktib [m-1] 210 (47) 188 (58) 204 (31) 197 (42) 
lslack,tri [m] .022 (.0028) .023 (.0029) .019 (.0029) .022 (.0030) 
lslack,tib [m] .067 (.0065) .060 (.015) .066 (.0048) .064 (.0068) 
lopt,tri [m] .050 (.0054) .046 (.0058) .046 (.0042) .043 (.0042) 
lopt,tib [m] .072 (.0050) .074 (.015) .073 (.011) .081 (.0097) 
Kjoint [Nm.rad-1] 53 (39) 94 (65) 65 (42) 103 (80) 
Treflex,tri [Nm] .85 (.39) 1.6 (1.1) 1.1 (.48) 2.0 (1.2) 
Treflex,tib [Nm] .61 (.46) .79 (.97) 1.4 (1.4) .76 (1.0) 
 
 
Reflexive torque of the tibialis anterior in extended knee condition was increased (P=.013) 
compared to the flexed knee condition. In patients post-stroke, optimal muscle length of the 
triceps surae was smaller (P=.016) and reflexive torque of the triceps surae higher (P=.003) in 
extended knee condition compared to flexed knee condition. Parameters involved in the passive 
force-length relationship of the triceps surae, i.e. the stiffness coefficient (ktri) and the slack 
length (lp,slack,tri), and the reflexive torque (Treflex,tri) of the triceps surae were higher in patients 
post-stroke relative to healthy volunteers (Figure 3.2, Table 3.3 and Table 3.4). No significant 
differences were found for the optimal length of the triceps surae and all tibialis anterior 
parameters between stroke patients and healthy controls. Based on calculated MDCs, individual 
patients could be identified with respect to healthy volunteers (Table 3.5). The variability in 
terms of individual parameters was high, as illustrated in Figure 3.2B.  
Non-neural tissue properties tended to be more prominent for the low Ashworth scores (0, 1 
and 2) and reflexive torque for the high Ashworth scores (3 and 4) (Table 3.6). MDCs of stroke 
patients were comparable with MDCs of healthy subjects (Table 3.7). Only for the reflexive 
torque of tibialis and slack length of tibialis in flexed knee condition, the MDC was more than 




Figure 3.2: A: Comparison between stiffness coefficient (ktri), slack length (lp,slack,tri), optimal length (lopt,tri), 
peripheral tissue stiffness (Kjoint) and reflexive torque (Treflex,tri) of the triceps surae between healthy participants 
(H) and stroke patients (P). Figures show boxplots. Asterisks denote significant differences (p<.05). B: The Venn 
diagram of outcome parameters for extended knee. Values indicate nine patients with deviated values for one or 
more outcome measures. The patient with increased stiffness coefficient (ktri), slack length (lp,slack,tri), tissue stiffness 
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Flexed versus extended knee** 
 
Healthy Stroke 
ktri [m-1] .003 .003 .38 
ktib [m-1] .319 .63 .40 
lslack,tri [m] .046 <.001 .22 
lslack,tib [m] .157 .79 .16 
lopt,tri [m] .243 .024 .016 
lopt,tib [m] .509 .82 .13 
Kjoint [Nm.rad-1] .051 .017 .44 
Treflex,tri [Nm] .011 .087 .003 
Treflex,tib [Nm] .354 .013 .87 
* Statistical analysis: linear mixed model **Statistical analysis: paired t-test 
 
 
Table 3.5: Minimal detectable change (MDC) and threshold (Th) to determine “deviated” values in stroke. The 
number of patients identified as deviated from healthy controls are indicated per parameter. The threshold and 
minimal detectable change for the optimal length of the tibialis anterior for the flexed knee condition was not 
determined because the intraclass correlation coefficient was zero for this parameter. 
 
 
Flexed knee Extended knee 
 Th;  MDC # deviating  
patients 
Th MDC # deviating  
patients 
ktri [m-1] > 301 32.3 7 > 318 65.3 7 
ktib [m-1] < 134 75.5 3 < 141 6.8 2 
lslack,tri [m] > .0267 .0047 1 > .0254 .0060 2 
lslack,tib [m] < .0547 .0119 3 < .0580 .0079 2 
lopt,tri [m] < .0357 .0133 1 < .0379 .0083 1 
lopt,tib [m] -  - <.0429 .0287 0 
Kjoint [Nm.rad-1] > 119 64.7 4 >114 48.1 4 
Treflex,tri [Nm] > 1.97 1.07 5 > 2.70 1.55 4 





Table 3.6: Ashworth scores related to outcome measures. Percentage of patients with Ashworth score that show 
deviated values on outcome measures. 
Ashworth 
score Kjoint ktri lslack,tri lopt,tri Treflex,tri 
0 (n=2) 50% 50% 0% 0% 0% 
1 (n=3) 67% 100% 0% 0% 33% 
2 (n=3) 0% 67% 33% 0% 0% 
3 (n=3) 0% 33% 0% 0% 67% 
4 (n=2) 50% 50% 50% 50% 100% 
 
 
Table 3.7: Intraclass correlation coefficients (ICC) and minimal detectable changes (MDC) of stroke patients. 
The ICC and MDC for the optimal length of the tibialis anterior for the extended knee condition were not 
determined because the intraclass correlation coefficient was negative for this parameter. 
 Flexed knee Extended knee 
 ICC MDC ICC MDC 
ktri [m-1] .937 49.1 .567 122 
ktib [m-1] .613 100 .777 56.4 
lslack,tri [m] .76 .0043 .728 .0046 
lslack,tib [m] .44 .030 .776 .00875 
lopt,tri [m] .658 .011 .234 .012 
lopt,tib [m] .947 .0086 - - 
Kjoint [Nm.rad-1] .925 46.7 .955 49.9 
Treflex,tri [Nm] .8 1.26 .665 2.02 
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The aim of this study was to estimate the passive and active tissue properties, i.e. the stiffness 
coefficient and slack length of the passive force-length relationship and the optimal length of 
the active force-length relationship, of the triceps surae and tibialis anterior muscles non-
invasively in patients and healthy volunteers. Valid, reliable and sensitive estimations of 
passive and active force-length characteristics next to neural reflexive torque could be obtained 
using an EMG-driven ankle model. Increased ankle joint stiffness was explained by an increase 
in triceps stiffness next to an elevated reflexive torque, but not by a shorter triceps surae. Values 
for minimal detectable change were such that individual patients could be discerned from 
healthy volunteers further substantiating the clinical potential of the method.  
 
Internal model validity 
With the extension of the model relative to the preceding model of de Vlugt et al. (2010) 
additional parameters were introduced which generally resulted in a higher goodness of fit, but 
at a risk of over-parameterization. The internal model validity indicated high VAF values in 
98% of the cases without being over-parameterized as indicated by the low SEMs.  
 
Test-retest reliability 
Ramp velocity affected the test-retest reliability for tissue parameters and reflexive torque 
differently with optimal validity with velocities of 15°.s-1 and 100°.s-1 respectively. Sensitivity 
for the ramp velocity on the test-retest reliability of the outcome measures was also observed 
in patients with cerebral palsy20;22. The test-retest reliability of the triceps surae was higher than 
the test-retest reliability of the tibialis anterior, especially for the reflexive torque and optimal 
muscle length. 
 
Sensitivity to knee angle 
Changing the knee angle induces changes in the bi-articular muscle length and thus in the 
relative contribution of the mono-articular soleus and the bi-articular gastrocnemii and affected 
as expected the passive and active force-length characteristics of the bi-articular triceps surae 
in contrast to the mono-articular tibialis anterior thereby increasing the peripheral tissue 
stiffness in extended knee condition as was also shown in literature33;34.  
 
External validity  
Patients post-stroke showed an increased stiffness coefficient of the triceps surae in 
combination with an increased triceps surae slack length and increased reflexive torque of the 
triceps surae. Difference between stroke patients and healthy volunteers for the stiffness 
coefficient suggests the presence of tissue changes after stroke coinciding with increased 
reflexive torque of the triceps as prior observed in the ankle4;17 and wrist15;18;27. Stiffening of 
the muscle may be due to a change in collagen compound and/or structure in the extracellular 
matrix as was found in cerebral palsy26. It can be speculated that stiffer tissue in series with 
proprioceptive organs (muscle spindles and golgi tendon organs) may result in higher efferent 
responses and consequently higher reflexive torques.  
Increased slack length in patients post-stroke may be the result of reduced pennation angle as a 
consequence of muscle atrophy35. Pennation angles are not separately addressed by the current 
approach. 
The combination of the stiffness coefficients and slack muscle lengths of the triceps surae and 
tibialis anterior, determines the peripheral tissue stiffness. It is important to be aware that 
conclusions on joint stiffness depend on the ankle angle at which participants are compared. 
The difference in ankle angle of 3o dorsiflexion in our previous study4 and 0o dorsiflexion in 
the current study, may explain why significant differences of Kjoint were only found in the first 
study and not just in the current study (P=.051).  
Estimation of the stiffness coefficient and slack length of the passive force-length relationship 
in either triceps surae or tibialis anterior in patients helps to better characterize the underlying 
tissue changes of increased peripheral tissue stiffness (stiffened and/or shortened). Different 
combinations of neural reflexive and non-neural tissue parameters were found but overall, a 
high Ashworth score coincided with a high reflexive torque. Using the MDC values of healthy 
subjects, deviated parameters were found in both flexed and extended knee condition and can 
be used to identify deviated neural reflexive and non-neural tissue properties in patients. This 
method might be helpful in muscle specific treatment selection by measuring at different knee 
angles dependent on the muscle of interest, e.g. to assess the non-neural tissue parameters of 
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MDC values of the passive and active force-length characteristics of stroke patients being 2-7 
times smaller than the average parameter values showed the potential for longitudinal 
observations e.g. to evaluate treatment.   
 
Limitations and recommendations 
The series elastic muscle tendon and the pennation angle both affect the (optimal) length 
characteristic of a muscle, but were not yet included within the model. Van de Poll showed by 
simulation, that including an Achilles tendon did not significantly affects the model 
parameters36. Pennation angle is a potential covariate of the length parameters, and affects the 
passive and active force-length characteristics of the model structure. Increased slack length in 
patients post-stroke may also be the result of a reduced pennation angle compared to healthy 
volunteers as a consequence of muscle atrophy35. Further addressing pennation (or muscle fiber 
length) requires direct observations, e.g. by ultrasound recordings.  
Rest EMG, i.e. the minimal EMG determined for each muscle, was subtracted from the total 
EMG because assumed not to contribute to ankle torque. However, important information of 
background muscle activation, which might be elevated in stroke patients37, was discarded. In 
case of increased background activation this might be accounted for by other parameters, e.g. 
the peripheral tissue stiffness, muscle stiffness coefficient and (optimal) muscle length, due to 
changed pennation angle. 
 
Conclusion 
A non-invasive EMG-driven neuromuscular modeling approach was demonstrated to estimate 
the properties of the passive and active force-length relationship of the triceps surae and tibialis 
anterior next to neural reflexive torque in patients and healthy volunteers. The model provided 
for valid, reliable and sensitive parameters and can be used to identify deviated neural reflexive 
and non-neural tissue properties in stroke patients. Non-invasive quantification of underlying 
contributors to increased joint stiffness post-stroke is important for proper and tailored patient 
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MDC values of the passive and active force-length characteristics of stroke patients being 2-7 
times smaller than the average parameter values showed the potential for longitudinal 
observations e.g. to evaluate treatment.   
 
Limitations and recommendations 
The series elastic muscle tendon and the pennation angle both affect the (optimal) length 
characteristic of a muscle, but were not yet included within the model. Van de Poll showed by 
simulation, that including an Achilles tendon did not significantly affects the model 
parameters36. Pennation angle is a potential covariate of the length parameters, and affects the 
passive and active force-length characteristics of the model structure. Increased slack length in 
patients post-stroke may also be the result of a reduced pennation angle compared to healthy 
volunteers as a consequence of muscle atrophy35. Further addressing pennation (or muscle fiber 
length) requires direct observations, e.g. by ultrasound recordings.  
Rest EMG, i.e. the minimal EMG determined for each muscle, was subtracted from the total 
EMG because assumed not to contribute to ankle torque. However, important information of 
background muscle activation, which might be elevated in stroke patients37, was discarded. In 
case of increased background activation this might be accounted for by other parameters, e.g. 
the peripheral tissue stiffness, muscle stiffness coefficient and (optimal) muscle length, due to 
changed pennation angle. 
 
Conclusion 
A non-invasive EMG-driven neuromuscular modeling approach was demonstrated to estimate 
the properties of the passive and active force-length relationship of the triceps surae and tibialis 
anterior next to neural reflexive torque in patients and healthy volunteers. The model provided 
for valid, reliable and sensitive parameters and can be used to identify deviated neural reflexive 
and non-neural tissue properties in stroke patients. Non-invasive quantification of underlying 
contributors to increased joint stiffness post-stroke is important for proper and tailored patient 
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Appendix 3A: Supplementary tables 
 
Table 3A: Electrode placement according to seniam guidelines (www.seniam.org) 
Muscle Location 
Tibialis anterior At 1/3 on the line between the tip of the fibula and the tip of the medial malleolus. 
Soleus At 2/3 of the line between the medial condylis of the femur to the medial malleolus. 
Gastrocnemius medialis On the most prominent bulge of the muscle. 




Table 3B: Description of model parameters (n=15) and optimization values (initial value and min and max)  
 
Model parameters Description Initial value  [Min Max] 
M Mass [kg] 1.5 [1.2 3] 
ktri, ktib  Stiffness coefficients [m-1] 200 [10 600] 
lp,slack,tri,  
lp,slack,tib 




[0.01 0.11]            
Gtri,(3x)  Gtib EMG weighting factors [-] 1*104 [0 1010]  (all muscles) 
f0 Activation cutoff frequency [Hz] 2 [0.5 4] 
Beta Relative damping [-] 1 [0.5 1.25] 
Lopt,tri 
lopt,tib 





taurel Tissue relaxation time constant [s] 2 [0.1 6] 
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Appendix 3B: Ankle model 
The model structure was based on the ankle model from de Vlugt et al.1 with the following 
adaptations: 
a) the model is able to describe plantar- and dorsiflexion forces during both dorsi-flexion 
and plantar flexion motions2 estimating parameters that model the relaxation effects 
during the hold phase where Sloot et al.2 used an offset torque constant to account for 
the relaxation effect. 
b) Optimal muscle length parameters, i.e. the length at which the muscle can generate its 
maximum force, of the contractile element of the Hill-models were estimated 
c) Other equations were used for the moment arm and muscle length to better resemble  
literature  
The total ankle reaction torque, Tmod [Nm], applied by the ankle to the manipulator was modeled 
and described by: 
𝑇𝑇𝑇𝑇���(𝑡𝑡𝑡𝑡) = 𝐼𝐼𝐼𝐼?̈?𝐼𝐼𝐼(𝑡𝑡𝑡𝑡) + 𝑇𝑇𝑇𝑇���(𝑡𝑡𝑡𝑡) − 𝑇𝑇𝑇𝑇���(𝑡𝑡𝑡𝑡) + 𝑇𝑇𝑇𝑇����(𝐼𝐼𝐼𝐼)   (A3.1) 
where t is the independent time variable [s], 𝐼𝐼𝐼𝐼?̈?𝐼𝐼𝐼(𝑡𝑡𝑡𝑡) the ankle angular acceleration [rad/s2], I the 
inertia of ankle plus footplate [kg.m2], Ttri the torque generated by the plantar flexion muscles 
(tri: SL, GL, GM) or triceps surae [Nm], Ttib the torque generated by the dorsiflexion muscle 
(tib: TA) [Nm], and Tgrav the torque due to gravity [Nm]. 
Muscle torques for tri and tib muscle were described by: 
)()),,()((),( ,,  mmactmelasm rlvFlFtT      (A3.2) 
with Felas,m the elastic force of the parallel connective tissues [N/m], Fact,m the active or 
“reflexive” muscle forces and )(mr  the angle dependent moment arm [m] of the tendon: 
0480.0*0104.0)(  trir      (A3.3) 
0393.0*0171.0)(  tibr       (A3.4) 
 
Muscle length (lm) was obtained from its muscle moment arm (rm) from tri and tib using data 
from literature3;4 
118.0)(*67.1  tritri rl       (A3.5) 
136.0)(*56.1  tibtib rl       (A3.6)  
Inertia of ankle plus footplate was modeled as a point mass m [kg] at distance la (fixed at 0.10 
m) from the center of rotation, i.e. 2aI ml  [kg.m2]. Torque due to gravity equals: 
)cos( fgndagrav mglT         (A3.7) 
Where g is the gravitational acceleration (g = 9.8 m/s2). θfgnd represents the angle of the foot 
with respect to the horizontal (ground) at zero degrees ankle angle [rad] using the anatomical 
reference angle.         
The elastic components were modeled as follows: 
𝐹𝐹𝐹𝐹����,�(𝑡𝑡𝑡𝑡) = 𝑒𝑒𝑒𝑒��(��(�)���,�����,�)      (A3.8) 
Where km is the stiffness coefficient of the muscle and lp,slack,m the slack length of the connective 
tissue. Muscle connective tissue under tension exhibits relaxation or force decrease5-7, which is 




𝐹𝐹𝐹𝐹����,�(𝑠𝑠𝑠𝑠)     (A3.9) 
with rel the tissue relaxation time constant and relk the tissue relaxation factor. In the previous 
version of the ankle model by de Vlugt et al.1 tissue relaxation was approximated by a viscous 
damper.    
For clinical comparison between subjects, peripheral tissue stiffness, Kjoint, was calculated at a 
unique joint angle (comp) for all subjects and patients. This angle was set at zero degrees (foot 
perpendicular to the lower leg). 
, ,( ) 2
joint,m ( )m m comp p slack
k l l
m m compK k e r 
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with rel the tissue relaxation time constant and relk the tissue relaxation factor. In the previous 
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where lm,comp is the muscle length at comp. Eq. (A3.10) was obtained by differentiation of Eq. 
(A3.8) with respect to muscle length and multiplied by the squared moment arm. The total 
tissue stiffness was derived by summation of the stiffness from both muscles: 
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Neural muscle activity for tri and tib due to stretch reflexes was estimated from corresponding 
EMG signals according to: 
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with U the excitation input to the muscle model (1/Volt) of the muscle serving as input to the 
Hill-type muscle model; G the dimensionless EMG weight scaling factors and EMG the activity 
of each muscle. 
The neural excitations of both muscles were filtered with a linear second order filter to describe 
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αm is the dimensionless active state of the muscle m, mf ,00 2   the cut off frequency of the 
activation filter, s the Laplace operator denoting the first time derivative, βm the relative 
damping and Um (s) the modeled neural muscle activity. 
The Hill-type muscle model was used to compute the muscle force from the active state and the 
muscle length and velocity according to: 
mmoptlmvmact llfvfF ),()( ,,        (A3.15) 
with fv the force-velocity relationship and fl the force-length relationship. The optimal muscle 
lengths (lopt,m ) were estimated by the model and used to derive the force-length relationships 
by 
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With wfl,m a shape factor defined as: 
 
2
,, * moptmfl lcfw                                                                                   (A3.17) 
 
with cf the shape parameter of the force-length relationship with value 0.1 to resemble the force-
generating range of the muscles. 
By introducing the optimal muscle length, the active component was uncoupled from the 
passive component, i.e. the slack length of the muscle which is often assumed to be equal to the 
optimal muscle length8-10. 
 
References 
 (1)  de Vlugt E, de Groot JH, Schenkeveld KE, Arendzen JH, van der Helm FC, Meskers CG. The relation 
between neuromechanical parameters and Ashworth score in stroke patients. J Neuroeng Rehabil 
2010;7:35. 
 (2)  Sloot LH, van der Krogt MM, de Gooijer-van de Groep KL, Van Eesbeek S, de Groot JH, Buizer AI et 
al. The validity and reliability of modelled neural and tissue properties of the ankle muscles in children 
with cerebral palsy. Gait Posture . 2015.  
 
 (3)  Maganaris CN, Baltzopoulos V, Sargeant AJ. Changes in Achilles tendon moment arm from rest to 
maximum isometric plantarflexion: in vivo observations in man. J Physiol 1998;510 ( Pt 3):977-985. 
 (4)  Maganaris CN. Imaging-based estimates of moment arm length in intact human muscle-tendons. Eur J 
Appl Physiol 2004;91:130-139. 
 (5)  Magnusson SP, Simonsen EB, Dyhre-Poulsen P, Aagaard P, Mohr T, Kjaer M. Viscoelastic stress 
relaxation during static stretch in human skeletal muscle in the absence of EMG activity. Scand J Med 
Sci Sports 1996;6:323-328. 
 (6)  McNair PJ, Dombroski EW, Hewson DJ, Stanley SN. Stretching at the ankle joint: viscoelastic responses 





where lm,comp is the muscle length at comp. Eq. (A3.10) was obtained by differentiation of Eq. 
(A3.8) with respect to muscle length and multiplied by the squared moment arm. The total 
tissue stiffness was derived by summation of the stiffness from both muscles: 
tibjotrijojo KKK int,int,int        (A3.11) 
Neural muscle activity for tri and tib due to stretch reflexes was estimated from corresponding 
EMG signals according to: 
)()()()( tEMGGtEMGGtEMGGtU GMGMGLGLSOLSOLtri    (A3.12) 
)()( tEMGGtU TATAtib        (A3.13) 
with U the excitation input to the muscle model (1/Volt) of the muscle serving as input to the 
Hill-type muscle model; G the dimensionless EMG weight scaling factors and EMG the activity 
of each muscle. 
The neural excitations of both muscles were filtered with a linear second order filter to describe 














       (A3.14) 
αm is the dimensionless active state of the muscle m, mf ,00 2   the cut off frequency of the 
activation filter, s the Laplace operator denoting the first time derivative, βm the relative 
damping and Um (s) the modeled neural muscle activity. 
The Hill-type muscle model was used to compute the muscle force from the active state and the 
muscle length and velocity according to: 
mmoptlmvmact llfvfF ),()( ,,        (A3.15) 
with fv the force-velocity relationship and fl the force-length relationship. The optimal muscle 
lengths (lopt,m ) were estimated by the model and used to derive the force-length relationships 
by 
 
     mwfllll moptmef
,/2,        (A3.16) 
With wfl,m a shape factor defined as: 
 
2
,, * moptmfl lcfw                                                                                   (A3.17) 
 
with cf the shape parameter of the force-length relationship with value 0.1 to resemble the force-
generating range of the muscles. 
By introducing the optimal muscle length, the active component was uncoupled from the 
passive component, i.e. the slack length of the muscle which is often assumed to be equal to the 
optimal muscle length8-10. 
 
References 
 (1)  de Vlugt E, de Groot JH, Schenkeveld KE, Arendzen JH, van der Helm FC, Meskers CG. The relation 
between neuromechanical parameters and Ashworth score in stroke patients. J Neuroeng Rehabil 
2010;7:35. 
 (2)  Sloot LH, van der Krogt MM, de Gooijer-van de Groep KL, Van Eesbeek S, de Groot JH, Buizer AI et 
al. The validity and reliability of modelled neural and tissue properties of the ankle muscles in children 
with cerebral palsy. Gait Posture . 2015.  
 
 (3)  Maganaris CN, Baltzopoulos V, Sargeant AJ. Changes in Achilles tendon moment arm from rest to 
maximum isometric plantarflexion: in vivo observations in man. J Physiol 1998;510 ( Pt 3):977-985. 
 (4)  Maganaris CN. Imaging-based estimates of moment arm length in intact human muscle-tendons. Eur J 
Appl Physiol 2004;91:130-139. 
 (5)  Magnusson SP, Simonsen EB, Dyhre-Poulsen P, Aagaard P, Mohr T, Kjaer M. Viscoelastic stress 
relaxation during static stretch in human skeletal muscle in the absence of EMG activity. Scand J Med 
Sci Sports 1996;6:323-328. 
 (6)  McNair PJ, Dombroski EW, Hewson DJ, Stanley SN. Stretching at the ankle joint: viscoelastic responses 




 (7)  Bressel E, McNair PJ. The effect of prolonged static and cyclic stretching on ankle joint stiffness, torque 
relaxation, and gait in people with stroke. Phys Ther 2002;82:880-887. 
 (8)  Winters JM. An improved muscle-reflex actuator for use in large-scale neuro-musculoskeletal models. 
Ann Biomed Eng 1995;23:359-374. 
 (9)  Thelen DG. Adjustment of muscle mechanics model parameters to simulate dynamic contractions in older 
adults. J Biomech Eng 2003;125:70-77. 
 (10)  de Vlugt E, de Groot JH, Wisman WH, Meskers CG. Clonus is explained from increased reflex gain and 





 (7)  Bressel E, McNair PJ. The effect of prolonged static and cyclic stretching on ankle joint stiffness, torque 
relaxation, and gait in people with stroke. Phys Ther 2002;82:880-887. 
 (8)  Winters JM. An improved muscle-reflex actuator for use in large-scale neuro-musculoskeletal models. 
Ann Biomed Eng 1995;23:359-374. 
 (9)  Thelen DG. Adjustment of muscle mechanics model parameters to simulate dynamic contractions in older 
adults. J Biomech Eng 2003;125:70-77. 
 (10)  de Vlugt E, de Groot JH, Wisman WH, Meskers CG. Clonus is explained from increased reflex gain and 





Estimation of tissue stiffness, reflex activity, 
optimal muscle length and slack length in stroke 
patients using an electromyography driven 
antagonistic wrist model
Authors:
Karin L. de Gooijer-van de Groep, Erwin de Vlugt, 
Hanneke J. van der Krogt, Áróra Helgadóttir, J. Hans Arendzen, 
Carel G.M. Meskers, Jurriaan H. de Groot





About half of all chronic stroke patients experience loss of arm function coinciding with 
increased stiffness, reduced range of motion and a flexed wrist due to a change in neural and/or 
structural tissue properties. Quantitative assessment of these changes is of clinical importance, 
yet not trivial. The goal of this study was to quantify the neural and structural properties 
contributing to wrist joint stiffness and to compare these properties between healthy subjects 
and stroke patients. 
Stroke patients (n=32) and healthy volunteers (n=14) were measured using ramp-and-hold 
rotations applied to the wrist joint by a haptic manipulator. Neural (reflexive torque) and 
structural (connective tissue stiffness, optimal muscle lengths and slack lengths of connective 
tissue) parameters were estimated using an electromyography driven antagonistic wrist model. 
Kruskal-Wallis analysis with multiple comparisons was used to compare results between 
healthy subjects, stroke patients with modified Ashworth score of zero and stroke patients with 
modified Ashworth score of one or more. 
Stroke patients with modified Ashworth score of one or more differed from healthy controls 
(P<0.05) by increased tissue stiffness, increased reflexive torque, decreased optimal muscle 
length and decreased slack length of connective tissue of the flexor muscles.  
Non-invasive quantitative analysis, including estimation of optimal muscle lengths, enables to 
identify neural and non-neural changes in chronic stroke patients. Monitoring these changes in 






Movement disorders of central neurological origin, like stroke and cerebral palsy, are 
characterized by increased resistance to imposed movement in the relaxed condition. Increased 
joint stiffness can be of neural origin (hyperreflexia, “spasticity”) and/or non-neural, structural 
origin (altered tissue viscoelastic properties, “contracture”)1;2. Separation of joint stiffness into 
neural and non-neural contributions has gained much attention recently, both from technical 
and clinical research, resulting in new and promising instrumented methods2;3. The separation 
of joint stiffness into different components is important for treatment selection aiming to 
improve joint dexterity. In case of suspected neural origin, botulinum toxin may be 
administered4;5, while in case of suspected non-neural origin patients may benefit from 
corrective casting, splinting or surgical lengthening6-8. The use of an instrumented joint 
manipulator and an electromyography driven biomechanical model was successfully used 
previously to quantitatively discriminate joint stiffness into contributions from connective 
tissue viscoelasticity and stretch reflex activity in the ankle of patients with stroke9 and cerebral 
palsy10;11. 
About half of all stroke survivors experience loss of arm function12;13 often due to a flexed 
position of the wrist at the affected side due to developing contractures at about 0.5 degrees per 
week in the first 8 months post-stroke14. The origin of these contractures is not fully clear, but 
may be the result of reduced number of sarcomeres in series15-18 and/or shortened optimal 
sarcomere length17, increased stiffness of the extracellular matrix18, functional 
immobilization14;19 and co-activation synergies20. Biomechanically, these tissue changes mean 
a shift in slack length of the connective tissues and/or shift of the muscle force-length curve and 
a reduction of the optimal muscle length of the flexor muscles, i.e. the length of the muscle 
where it generates highest forces.  
In the acute and sub-acute phase post-stroke, quantification of neural and non-neural 
contributors to joint stiffness, including optimal muscle length and slack length of connective 
tissue, could help understanding the mechanism of (poor) recovery after stroke and 
characterization of changes over time using longitudinal observations21;22. Also the effect of 
therapies, like botulinum toxin, on the neural and non-neural parameters is not yet understood 
and should be measured to evaluate and optimize treatment23. 
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The goal of this study was to quantify the neural and non-neural contributions to wrist joint 
stiffness from both flexor and extensor muscles in a cohort of chronic stroke patients. The 
current model is an extended version of a previous ankle model9 now including an antagonistic 
pair of muscle elements to allow for property analysis of both wrist flexor and extensor muscle 
groups. Three demands were imposed to the model: The structure of the model should represent 
the (non-linear) joint physiology, the predicted torques should resemble the measured torques 
and the parameters should be sensitive to discriminate clinical different patients from healthy 
subjects. Optimal muscle lengths, slack muscle lengths, tissue stiffness and reflexive torques 
from both flexor and extensor muscles were estimated by model optimization and compared 
between healthy subjects, stroke patients with a modified Ashworth score of 0 (MAS = 0) and 
stroke patients with modified Ashworth score of one or more (MAS ≥ 1). We hypothesized an 
increase in tissue stiffness and reflexive torque and decrease of optimal muscle length and slack 
length of connective tissue of the flexor muscles in chronic stroke patients with modified 
Ashworth score of one or more (MAS ≥ 1). We addressed the validity and agreement of the 




Instrumented ramp-and-hold (RaH) measurements at the wrist at rest were performed as part of 
the EXPLICIT-stroke study21;24;25. Exclusion criteria were neurological deficiencies additional 
to stroke, (prior) orthopedic problems in hand or shoulder and inability to comply with the 
protocol. Patients were measured on two occasions within a month. Healthy volunteers were 
measured as a reference group. The study was approved by the medical ethics committee of the 
Leiden University Medical Center. All participants gave their written informed consent prior to 
the experimental procedure. Measurements from fourteen healthy volunteers (mean age 49.4, 
SD 15.1 years), 21 chronic stroke patients with MAS = 0 (mean age 60.4, SD 13.1 years) and 
11 chronic stroke patients with MAS ≥ 1 (mean age 54.4, SD 12.7 years) were analyzed in this 










MAS = 0 
(n = 21) 
Chronic patients 
MAS ≥ 1 
(n = 11) 
Age (years) (SD) 49.4 (15.1) 60.4 (13.1) 54.5 (12.7) 
Men (n) (%) 9 (64%) 10 (48%) 3 (27%) 
Right side dominant (n) (%) 13 (93%) 21 (100%) 8 (73%) 
Measured side dominant (n) (%) 14 (100%) 10 (48%) 4 (36%) 
Time between measurements (days) (SD) 27 (21) 18 (7) 29 (17) 
Time after stroke (months) (SD) - 30 (27.6) 53 (34.4) 
Age at moment of stroke (years) (SD) - 58 (13.1) 50 (14.5) 
Passive range of motion deg,(median 
min;max) 
138 (118; 148) 132 (100; 151) 100 (42; 133) 
 
Instrumentation 
The subjects were seated with their shoulder relaxed and elbow flexed in approximately 90°. A 
haptic wrist manipulator (Wristalyzer, 1 degree of freedom (dorsi- and plantar flexion), Moog, 
Nieuw Vennep, the Netherlands) was used (Figure 4.1). Forearm and hand were strapped to a 
cuff and handle respectively using Velcro straps. The rotation axis of the wrist joint was aligned 
visually to the rotation axis of the handle. Handle rotation was driven by a vertically positioned 
servo motor (Parker SMH100). Positive direction was assigned to flexion movement and 
extension torque. Muscle activation was recorded by bipolar surface electrodes 
(electromyography, EMG) using a Delsys Bagnoli 8 system (Delsys Inc., Boston MA, USA). 
Two bipolar electrodes were placed on the flexor carpi radialis (FCR) and two on the extensor 
carpi radialis (ECR) in order to have a good representation for the FCR and ECR activation26;27. 
EMG signals were sampled at 2048 Hz, online band pass filtered (20-450 Hz), rectified and 
low pass filtered (20 Hz, 3rd order Butterworth) to obtain the EMG envelope. The minimal EMG 
value (average of moving window of 0.06 sec) was subtracted from the total EMG to ensure 
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noise was minimal in the data. Wrist torque and joint angle were recorded at 2048 Hz and 
filtered with the same 20 Hz low pass 3rd order Butterworth filter. 
 
 
Figure 4.1: Experimental setup. The forearm and hand of the subject were fixed to the manipulator (Wristalyzer® 
by MOOG, the Netherlands). Ramp-and-hold rotations in flexion and extension were imposed to the wrist while 
the subject was instructed to remain relaxed and not react to the rotations. Wrist joint torque, angle and EMG of 
the FRC and ECR muscles were recorded. 
 
Measurement protocol 
Measurements were performed on the right wrist in healthy subjects and on the impaired wrist 
in patients. The range of motion (RoM) was determined as the difference between maximal 
flexion and extension angle resulting from an imposed slow changing torque ranging between 
2 Nm (extension torque) and –2 Nm (flexion torque). Subsequently, RaH rotations were 
imposed onto the wrist at a constant velocity over the full RoM. Two RaH trials were imposed 
per measurement. Each trial contained a fast ramp in 1 second in extension or flexion direction 
(named “extension fast” or “flexion fast”), two slow ramps in the opposite direction and three 
hold periods in between the ramps in which the position of the wrist stayed the same (Figure 
4.2). The directions of the ramps in the second trial were opposite to the first trial. The 
individually determined RoM in combination with the duration of the ramp (1 second) 
 
determined the velocity of the imposed perturbations. Subjects were asked to remain relaxed 
during the entire experiment and not to react to the wrist movement. 
 
 
Figure 4.2: Example of imposed angular rotation (bottom) and torque response with model fit (top row) for a 
healthy subject (left, “extension fast”, VAF=99.6%) and stroke subject with MAS=3 (right, “flexion fast”, 
VAF=99.8).  
 
Model description  
A biomechanical EMG driven antagonistic muscle model was used to predict wrist torque from 
wrist angle and EMG. The model was based on the ankle model from de Vlugt et al.9  and 
extended with a second Hill-type model to describe the passive and active force of the 
antagonist muscles.  
Wrist joint stiffness is described by: 
 
 𝑇𝑇𝑇𝑇���(𝑡𝑡𝑡𝑡) = 𝐼𝐼𝐼𝐼?̈?𝐼𝐼𝐼(𝑡𝑡𝑡𝑡) + 𝑇𝑇𝑇𝑇���(𝑡𝑡𝑡𝑡) − 𝑇𝑇𝑇𝑇����(𝑡𝑡𝑡𝑡)    (4.1) 
 
where t is the independent time variable [s], Tmod the modeled wrist reaction torque [Nm], ?̈?𝐼𝐼𝐼(t) 
the wrist angular acceleration [rad/s2], I the inertia of wrist and handle [kg.m2], Text the torque 
generated by the extensor muscles [Nm] and Tflex the torque generated by the flexor muscles 
[Nm]. 
Muscle torques (Tm) for extensor and flexor muscle are described by: 
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where t is the independent time variable [s], Tmod the modeled wrist reaction torque [Nm], ?̈?𝐼𝐼𝐼(t) 
the wrist angular acceleration [rad/s2], I the inertia of wrist and handle [kg.m2], Text the torque 
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[Nm]. 
Muscle torques (Tm) for extensor and flexor muscle are described by: 
 





with Felas,m the elastic force of the parallel connective tissues [N], Fact,m the active or “reflexive” 
muscle forces [N] according to the Hill-type model, vm the muscle lengthening velocity [m/s], 
lm the muscle length [m], αm the active state [-] and )(mr  the angle dependent moment arm [m] 
of the tendon. 
The elastic components for the extensor and flexor muscles were modeled as follows: 
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Where km is the estimated stiffness coefficient of the muscle and lp,slack,m the estimated slack 
length of the connective tissue. Muscle length lm for FCR and ECR equals: 
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Where FCRl and ECRl  are the lengths of the muscle at each position  and 0,FCRl  and 0,ECRl the 
muscle length at zero degrees wrist angle position (handle in line with forearm). rm is the 
moment arm defined by Ramsay et al.28.  
The Hill-type muscle model was used to compute the muscle force from the active state and the 
muscle length and velocity according to: 
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with fv the force-velocity relationship and fl the force-length relationship. 
The optimal muscle lengths (lopt,m) were estimated using the model and used to derive the force-
length relationships by 
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With wfl,m a shape factor. 
The complete model is described in the Appendix 4.  
The modeled force-length and force-velocity characteristics are shown in Figure 4.3 together 
with the modeled tissue and neural forces. In estimating the optimal muscle lengths, the active 
filament overlap component was decoupled from the passive component, i.e. the slack length 
of the muscle which is often assumed to be equal to the optimal muscle length29-31 was 
decoupled. The parameters of the wrist model that were optimized including the initial values 
and constraints are listed in Table 4.2.  
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Figure 4.3: Example of model characteristics of a stroke patient (MAS = 0). Top panel: applied movement, second 
row: normalized force-length and force-velocity curves of the extensor (left) and flexor (right) muscles (grey lines) 
including the perturbed length and velocity domains by the red and green intervals. Bottom row: Tissue and neural 
forces from the extensor (left) and flexor (right) muscles.   
 
The predicted model torque (Tmod) was fitted to the measured wrist torque (Tmeas), except for 
the first second of the data to ensure data quality. Model parameters were estimated for the 
complete movement by minimizing the quadratic difference (error function) between the 
measured and predicted wrist torque using a non-linear least-square optimization algorithm 
(steepest descent, Matlab function lsqnonlin).  
The main estimated outcome measures used to characterize subjects were tissue stiffness at 
joint level (Kjoint), optimal muscle length (lopt,m), slack muscle length (lp,slack,m) and the reflexive 
torque (Treflex) determined for both the extensor and flexor muscle groups. The estimated 
reflexive torque was calculated by using the root mean square of the active muscle torque9. 
Tissue stiffness at joint level (Kjoint) was derived from the passive force-length relationship, see 
Appendix 4. For clinical comparison between subjects, Kjoint, was compared at the same wrist 
 
angle (comp) for all subjects. This angle was chosen at zero degrees, i.e. where the handle is in 
line with the forearm. 
Repeated measures were averaged for each subject in order to be able to compare groups of 
subjects. 
Simulation and analysis was performed in Matlab (The Mathworks Inc., Natick MA). 
 
Validity and agreement 
Model validity was assessed using the standard error of the mean (SEM) and variance accounted 
for (VAF). Validity of the measurements was determined by systematic error assessment. 
Agreement of measurement32 was determined by the minimal detectable change (MDC) and 
was used to assess clinical potential to discriminate pathological deviating parameters from 
normal values. 
  
Model fit and parameter confidence 
The standard error of the mean (SEM) represents the parameter confidence and is based on the 
sensitivity (first and second partial derivatives) of each parameter to the error function (Jacobian 
and Hessian respectively)9;33. High sensitivity, indicated by low SEM values, means that the 
parameter has substantial contribution to the error function. Model fit was indicated by the 


























meanmeanmeas  (4.8) 
 
The VAF was estimated for each trial. Estimated torques with a VAF less than 98% were 
disregarded from group analysis.  
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The VAF was estimated for each trial. Estimated torques with a VAF less than 98% were 
disregarded from group analysis.  





Assessment of systematic error 
A Wilcoxon signed rank test with significant level 0.05 was used to determine systematic errors 
between the measurements of two different visits.  
 
Clinical potential 
Using post-hoc analysis based on variance (Levene’s test) we observed significant higher 
parameter variances in stroke patients compared to controls for the tissue stiffness and reflexive 
torque of the FCR. Conform the analysis of25 we introduced an a priory subdivision of stroke 
patients based on MAS.  
Kruskal-Wallis one-way analysis of variance with multiple comparisons was used to compare 
stroke patients with modified Ashworth scores of 0 (MAS = 0) and greater than 0 (MAS ≥ 1) 
respectively with healthy subjects. The minimal detectable change (MDC)32;34 with confidence 
interval of 95% was calculated to identify deviated parameters i.e. parameters that are outside 
the range of mean value +/- MDC indicating that the observed value was not likely to be due to 
chance variation. Thus, values above the threshold of mean value +/- MDC were classified as 
“deviated” and can be used to identify pathological cases. 
 
For statistical analysis IBM SPSS statistics 22 and GraphPad Prism 6 was used. 
 
Results 
One patient was unable to comply with the protocol. All other trials (93 in “extension fast” 
direction and 93 in “flexion fast” direction were used to estimate model parameters, VAF and 
SEM values (Table 4.3). Twenty trials (10%, 5 (5%) in “extension fast” and 15 (16%) in 
“flexion fast” direction) were excluded for further analysis based on VAF values below 98% 
and in one case (1 of 93, “extension fast”) the input signal was corrupt. In only one (out of 45) 
subject, the parameters could not be estimated because the patient had low VAF values in both 
movement direction and for both trials. From all other subjects, through repeated trials in 
flexion and extension, data were available to estimate the relevant parameters. In total data from 
14 healthy subjects and 30 stroke were used for further analysis. Low VAF values may have 
originated from experimental artefacts e.g. poor fixation or misalignment or voluntary 
interaction with the passive protocol.  
 
Table 4.3: Model parameters (estimated value and standard error of the mean (SEM)) for all healthy subjects 
(A), stroke patients with MAS = 0 (B) and stroke patients with MAS ≥ 1(C). 
A 
Parameter 
Estimated Value* SEM* 
Extension fast Flexion fast Extension fast Flexion fast 
m (kg) 0.89 (0.65-1.1) 0.96 (0.73-1.1) 0.012 (0.0094-0.016) 0.015 (0.010-0.019) 
kext (1/m) 206 (164-313) 307 (227-441) 0.012 (0.0059-0.019) 0.023 (0.013-0.037) 
kflex (1/m) 211 (162-265) 218 (205-288) 0.0057 (0.0037-0.012) 0.0059 (0.0043-0.0097) 
lp,slack,ext, (m) 0.066 (0.058-0.072) 0.072 (0.065-0.076) 0.0045 (0.0028-0.0066) 0.0047 (0.0027-0.0082) 
lp,slack,flex (m) 0.048 (0.038-0.052) 0.047 (0.043-0.055) 0.0039 (0.0032-0.0072) 0.0044 (0.0026-0.0086) 
lopt,ext (m) 0.057 (0.050-0.066) 0.064 (0.054-0.072) 0.0066 (0.0031-0.025) 0.017 (0.0054-0.38) 
lopt,flex (m) 0.067 (0.051-0.078) 0.070 (0.060-0.090) 0.0083 (0.0050-0.020) 0.023 (0.0077-0.093) 
Taurel (s) 2.1 (0.79-3.5) 1.6 (0.74-4.0) 0.028 (0.010-0.058) 0.052 (0.018-0.14) 
krel (-) 0.65 (0.48-1.3) 1.1 (0.64-2.2) 0.0098 (0.0054-0.019) 0.022 (0.0086-0.050) 
Gext  (-) 5676 (1858-17038) 1756 (201-8411) 0.019 (0.0070-0.22) 0.025 (0.0041-0.27) 
Gflex (-) 15192 (5280-62793) 35866 (4764-112308) 0.071 (0.021-0.16) 0.22 (0.042-0.94) 
 f0 (Hz) 0.19 (0.062-0.52) 0.19 (0.072-0.67) 0.012 (0.0039-0.028) 0.019 (0.0042-0.067) 




Estimated Value* SEM* 
Extension fast Flexion fast Extension fast Flexion fast 
m (kg) 1.4 (1.0-2.0) 1.1 (0.72-1.6) 0.040 (0.022-0.052) 0.034 (0.021-0.053) 
kext (1/m) 207 (155-253) 244 (207-287) 0.019 (0.011-0.040) 0.025 (0.014-0.034) 
kflex (1/m) 204 (171-235) 215 (198-280) 0.010 (0.008-0.016) 0.011 (0.0076-0.019) 
lp,slack,ext, (m) 0.065 (0.056-0.070) 0.067 (0.062-0.073) 0.0092 (0.0050-0.016) 0.0084 (0.0053-0.013) 
lp,slack,flex (m) 0.046 (0.040-0.050) 0.048 (0.042-0.055) 0.0098 (0.0055-0.013) 0.0076 (0.0048-0.014) 
lopt,ext (m) 0.064 (0.053-0.084) 0.068 (0.058-0.095) 0.026 (0.011-0.11) 0.024 (0.012-0.14) 
lopt,flex (m) 0.059 (0.050-0.069) 0.064 (0.056-0.11) 0.0098 (0.0051-0.045) 0.022-0.0079-0.18) 
Taurel (s) 0.87 (0.57-1.2) 0.69 (0.47-1.5) 0.026 (0.012-0.037) 0.019 (0.014-0.060) 
krel (-) 0.95 (0.66-1.9) 1.3 (0.66-2.2) 0.025 (0.016-0.050) 0.037 (0.012-0.068) 
Gext  (-) 3285 (550-11671) 2147 (668-8556) 0.031 (0.0080-0.23) 0.040 (0.0092-0.19) 
Gflex (-) 12534 (5499-29479) 10440 (5908-32914) 0.050 (0.016-0.27) 0.087 (0.032-1.8) 
 f0 (Hz) 0.68 (0.14-1.3) 0.83 (0.22-2.0) 0.080 (0.031-0.12) 0.084 (0.037-0.18) 
* median, 25-75 percentile  
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Table 4.3: Model parameters (estimated value and standard error of the mean (SEM)) for all healthy subjects 
(A), stroke patients with MAS = 0 (B) and stroke patients with MAS ≥ 1(C). 
A 
Parameter 
Estimated Value* SEM* 
Extension fast Flexion fast Extension fast Flexion fast 
m (kg) 0.89 (0.65-1.1) 0.96 (0.73-1.1) 0.012 (0.0094-0.016) 0.015 (0.010-0.019) 
kext (1/m) 206 (164-313) 307 (227-441) 0.012 (0.0059-0.019) 0.023 (0.013-0.037) 
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lopt,ext (m) 0.057 (0.050-0.066) 0.064 (0.054-0.072) 0.0066 (0.0031-0.025) 0.017 (0.0054-0.38) 
lopt,flex (m) 0.067 (0.051-0.078) 0.070 (0.060-0.090) 0.0083 (0.0050-0.020) 0.023 (0.0077-0.093) 
Taurel (s) 2.1 (0.79-3.5) 1.6 (0.74-4.0) 0.028 (0.010-0.058) 0.052 (0.018-0.14) 
krel (-) 0.65 (0.48-1.3) 1.1 (0.64-2.2) 0.0098 (0.0054-0.019) 0.022 (0.0086-0.050) 
Gext  (-) 5676 (1858-17038) 1756 (201-8411) 0.019 (0.0070-0.22) 0.025 (0.0041-0.27) 
Gflex (-) 15192 (5280-62793) 35866 (4764-112308) 0.071 (0.021-0.16) 0.22 (0.042-0.94) 
 f0 (Hz) 0.19 (0.062-0.52) 0.19 (0.072-0.67) 0.012 (0.0039-0.028) 0.019 (0.0042-0.067) 




Estimated Value* SEM* 
Extension fast Flexion fast Extension fast Flexion fast 
m (kg) 1.4 (1.0-2.0) 1.1 (0.72-1.6) 0.040 (0.022-0.052) 0.034 (0.021-0.053) 
kext (1/m) 207 (155-253) 244 (207-287) 0.019 (0.011-0.040) 0.025 (0.014-0.034) 
kflex (1/m) 204 (171-235) 215 (198-280) 0.010 (0.008-0.016) 0.011 (0.0076-0.019) 
lp,slack,ext, (m) 0.065 (0.056-0.070) 0.067 (0.062-0.073) 0.0092 (0.0050-0.016) 0.0084 (0.0053-0.013) 
lp,slack,flex (m) 0.046 (0.040-0.050) 0.048 (0.042-0.055) 0.0098 (0.0055-0.013) 0.0076 (0.0048-0.014) 
lopt,ext (m) 0.064 (0.053-0.084) 0.068 (0.058-0.095) 0.026 (0.011-0.11) 0.024 (0.012-0.14) 
lopt,flex (m) 0.059 (0.050-0.069) 0.064 (0.056-0.11) 0.0098 (0.0051-0.045) 0.022-0.0079-0.18) 
Taurel (s) 0.87 (0.57-1.2) 0.69 (0.47-1.5) 0.026 (0.012-0.037) 0.019 (0.014-0.060) 
krel (-) 0.95 (0.66-1.9) 1.3 (0.66-2.2) 0.025 (0.016-0.050) 0.037 (0.012-0.068) 
Gext  (-) 3285 (550-11671) 2147 (668-8556) 0.031 (0.0080-0.23) 0.040 (0.0092-0.19) 
Gflex (-) 12534 (5499-29479) 10440 (5908-32914) 0.050 (0.016-0.27) 0.087 (0.032-1.8) 
 f0 (Hz) 0.68 (0.14-1.3) 0.83 (0.22-2.0) 0.080 (0.031-0.12) 0.084 (0.037-0.18) 








Estimated Value* SEM* 
Extension fast Flexion fast Extension fast Flexion fast 
m (kg) 0.50 (0.50-1.5) 0.97 (0.50-1.4) 0.069 (0.035-0.090) 0.037 (0.026-0.061) 
kext (1/m) 253 (174-303) 220 (167-277) 0.028 (0.011-0.057) 0.023 (0.012-0.028) 
kflex (1/m) 167 (130-209) 178 (134-256) 0.0090 (0.0045-0.015) 0.0085 (0.0057-0.013) 
lp,slack,ext, (m) 0.066 (0.058-0.073) 0.064 (0.059-0.069) 0.0084 (0.0050-0.016) 0.0085 (0.0049-0.016) 
lp,slack,flex (m) 0.027 (0.012-0.035) 0.035 (0.019-0.044) 0.013 (0.0079-0.019) 0.0079 (0.0058-0.015) 
lopt,ext (m) 0.059 (0.042-0.11) 0.066 (0.054-0.10) 0.038 (0.015-0.077) 0.045 (0.014-0.18) 
lopt,flex (m) 0.054 (0.050-0.060) 0.057 (0.048-0.092) 0.0056 (0.0038-0.011) 0.0096 (0.0048-0.11) 
Taurel (s) 1.1 (0.81-1.9) 1.3 (0.87-2.2) 0.020 (0.014-0.032) 0.030 (0.019-0.043) 
krel (-) 2.2 (1.1-3.5) 1.4 (0.97-2.2) 0.031 (0.020-0.10) 0.029 (0.018-0.042) 
Gext  (-) 50920 (13062-125798) 12023 (3627-36043) 1.6 (0.35-5.9) 0.42 (0.11-1.8) 
Gflex (-) 15010 (7010-22856) 15134 (7540-26495) 0.045 (0.017-0.088) 0.044 (0.020-0.81) 
 f0 (Hz) 0.72 (0.29-1.0) 0.33 (0.20-0.56) 0.043 (0.022-0.10) 0.042 (0.024-0.071) 
* median, 25-75 percentile  
 
Validity and agreement 
Model fit and parameter confidence 
Estimated values of model parameters and SEM values are presented in Table 4.3 for “extension 
fast” and “flexion fast” direction for all healthy subjects and stroke patients with MAS = 0  and 
MAS ≥ 1, i.e. without excluding data based on low VAF values. The median VAF for the 
“extension fast” were 99.6 (interquartile range (IQR): 99.4 - 99.7)%, 99.5 (IQR: 98.9-99.8)% 
and 99.8 (IQR: 99.6-99.9)% for healthy subjects, patients with MAS = 0 and patients with MAS 
≥ 1 respectively and for “flexion fast” direction 99.3 (IQR: 98.1 - 99.7)%, 99.5 (IQR: 98.5-
99.7)%.and 99.8 (IQR: 99.7-99.9)%. Median SEM values were lower than 0.1, except for Gflex 
for “flexion fast” (0.22) for healthy subjects and Gext for both movement directions (1.6 and 
0.42) for patients with MAS ≥ 1.  
 
Assessment of systematic error 
We observed no significant differences for almost all outcome parameters between the 
measurements of two different visits based on the Wilcoxon signed rank test, indicating that no 
systematic error between measurements was present for these parameters. One exception was 




Figure 4.4 shows the results of the comparison between healthy controls and patients with MAS 
= 0 and MAS ≥ 1 score. Patients with MAS ≥ 1, MAS = 0 and healthy controls significantly 
differed for tissue stiffness, Kjoint (P=0.0023 “extension fast”; P=0.0020 “flexion fast”), 
reflexive torque, Treflex of the flexors (P=0.0011 “extension fast”; P=0.014 “flexion fast”), 
optimal muscle length, lopt of the flexors (P=0.047 “extension fast”) and slack muscle length, 
lp,slack  of  the flexors (P=0.0031 “extension fast”; P=0.0177 “flexion fast”) and extensors 
(P=0.020 for “flexion fast”). Multiple comparison showed significant differences between 
patients with MAS ≥ 1 and healthy controls for Kjoint (both movement directions), Treflex of the 
flexors (“extension fast”), lopt of the flexors and lp,slack  of the flexors (both movement directions) 
and extensors. Between MAS = 0 and MAS ≥ 1 significant differences were found for Kjoint 
(both movement directions), Treflex of the flexors (both movement directions) and lp,slack  of the 
flexors (“extension fast”). Healthy subjects and stroke patients with MAS = 0 did not differ.  
When using the MDC, ten patients had a deviated Kjoint value (≥3.13 Nm/rad, MDC=1.79 
Nm/rad) in “extension fast” direction, eight patients a deviated Kjoint (≥3.45 Nm/rad; 
MDC=2.34 Nm/rad) in the “flexion fast” direction and ten patients a deviated Treflex of the flexor 
muscles (≥ 0.72 Nm; MDC=0.457 Nm) in “extension fast” direction. Almost all of these 
patients had a MAS ≥ 1: 9 out of 10 for Kjoint in “extension fast” direction, 8 out of 8 for Kjoint 
in “flexion fast” direction and 8 out of 10 for Treflex of the flexors in “extension fast” direction. 
For the “extension fast” direction 9 out of 11 patients had an increased Kjoint together with an 
increased Treflex of the FCR. All patients that showed an increased Kjoint in the “flexion fast” 
direction had an increased Kjoint in the “extension fast” direction.  
  






Estimated Value* SEM* 
Extension fast Flexion fast Extension fast Flexion fast 
m (kg) 0.50 (0.50-1.5) 0.97 (0.50-1.4) 0.069 (0.035-0.090) 0.037 (0.026-0.061) 
kext (1/m) 253 (174-303) 220 (167-277) 0.028 (0.011-0.057) 0.023 (0.012-0.028) 
kflex (1/m) 167 (130-209) 178 (134-256) 0.0090 (0.0045-0.015) 0.0085 (0.0057-0.013) 
lp,slack,ext, (m) 0.066 (0.058-0.073) 0.064 (0.059-0.069) 0.0084 (0.0050-0.016) 0.0085 (0.0049-0.016) 
lp,slack,flex (m) 0.027 (0.012-0.035) 0.035 (0.019-0.044) 0.013 (0.0079-0.019) 0.0079 (0.0058-0.015) 
lopt,ext (m) 0.059 (0.042-0.11) 0.066 (0.054-0.10) 0.038 (0.015-0.077) 0.045 (0.014-0.18) 
lopt,flex (m) 0.054 (0.050-0.060) 0.057 (0.048-0.092) 0.0056 (0.0038-0.011) 0.0096 (0.0048-0.11) 
Taurel (s) 1.1 (0.81-1.9) 1.3 (0.87-2.2) 0.020 (0.014-0.032) 0.030 (0.019-0.043) 
krel (-) 2.2 (1.1-3.5) 1.4 (0.97-2.2) 0.031 (0.020-0.10) 0.029 (0.018-0.042) 
Gext  (-) 50920 (13062-125798) 12023 (3627-36043) 1.6 (0.35-5.9) 0.42 (0.11-1.8) 
Gflex (-) 15010 (7010-22856) 15134 (7540-26495) 0.045 (0.017-0.088) 0.044 (0.020-0.81) 
 f0 (Hz) 0.72 (0.29-1.0) 0.33 (0.20-0.56) 0.043 (0.022-0.10) 0.042 (0.024-0.071) 
* median, 25-75 percentile  
 
Validity and agreement 
Model fit and parameter confidence 
Estimated values of model parameters and SEM values are presented in Table 4.3 for “extension 
fast” and “flexion fast” direction for all healthy subjects and stroke patients with MAS = 0  and 
MAS ≥ 1, i.e. without excluding data based on low VAF values. The median VAF for the 
“extension fast” were 99.6 (interquartile range (IQR): 99.4 - 99.7)%, 99.5 (IQR: 98.9-99.8)% 
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99.7)%.and 99.8 (IQR: 99.7-99.9)%. Median SEM values were lower than 0.1, except for Gflex 
for “flexion fast” (0.22) for healthy subjects and Gext for both movement directions (1.6 and 
0.42) for patients with MAS ≥ 1.  
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Neural and non-neural outcome parameters including optimal muscle length and slack length 
of connective tissue were quantitatively assessed for the wrist joint in a cohort of chronic stroke 
patients using an EMG driven antagonistic muscle model. High VAF values and low SEM 
illustrated the validity of the model approach. Differences in tissue stiffness, reflexive torque, 
optimal muscle length and slack length of connective tissues between patients with MAS score 
≥ 1 and healthy controls demonstrated clinical potential of the method.  
 
Validity and agreement 
We advocate the use of an EMG driven model because non-invasive techniques to estimate the 
physiological parameters are yet lacking. This imposes both the quest for validation and the 
implicit inability to do so. Three demands were imposed to the model: The structure of the 
model should represent the (non-linear) joint physiology, the predicted torques should resemble 
the measured torques and the parameters should be sensitive to discriminate clinical different 
patients from healthy volunteers.  
 
Model fit and parameter confidence 
The model structure was able to describe the relation between joint position and EMG input 
and the torque output as indicated by the high variance accounted for (VAF) of 98% or higher 
in 90% of the cases) in the healthy group and both stroke groups.  
The model contains 12 parameters. Sensitivity and the absence of parameter redundancy within 
the model were checked using the standard error of the mean (SEM). The estimation of the 
model parameters was sufficiently accurate indicated by the low SEM values (Table 4.3).  
The SEM for the gain factor Gflex for “flexion fast” (0.22) in healthy subjects and the SEM for 
the gain factor Gext in “extension fast” (1.6) and “flexion fast” (0.42) was largest. These scaling 
factors are essential in relating muscle activation with torque, but only relevant in case of 
sufficient (reflexive) activation, explaining the relatively high SEM for Gflex for the “flexion 
fast” direction and Gext for the “extension fast” direction.  
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Assessment of systematic error 
There was no systematic error between measurements at two different visits except for the the 
reflexive torque, Treflex of the flexors in “flexion fast” direction, possibly due to varying muscle 
activity in stroke patients. This was confirmed by systematic error assessment between 
measurements of two different visits for Treflex of the flexors for healthy subjects (P=0.314) and 
stroke patients (P=0.033) separately. 
 
Clinical potential: Increased neural and structural contributors of joint stiffness in stroke 
Patients with MAS ≥ 1 differed from healthy controls in neural (Treflex) and non-neural or 
structural (Kjoint, lopt,m  and lp,slack,m) parameters. The decrease in optimal muscle length (lopt) and 
muscle slack length (lp,slack) of the flexor muscles indicates a shift in the active and passive 
force-length relationship. Functionally, this structural change implies a flexed joint rest position 
with a smaller RoM for the impaired wrist, the latter confirmed by a previous study on the same 
cohort25 where the authors found significant differences for the passive and active RoM 
between MAS ≥ 1 and both the MAS = 0 and healthy group. However, van der Krogt et al.25 
could not establish a significant change in the passive angle at rest (angle at zero torque), which 
could be explained by the influence of active components (e.g. muscle tone) which could have 
resulted in a rest angle comparable to healthy controls. 
When using the MDC, ten patients had a deviating tissue stiffness, Kjoint and ten patients had a 
deviating reflexive torque, Treflex of the flexor muscles in “extension fast” direction. Nine of 
these eleven patients with deviated outcome measures had a MAS score ≥ 1. One patient with 
MAS ≥ 1 (for flexor muscles) score showed tissue stiffness and reflexive torque values within 
the range observed in healthy subjects. Differences between patients in outcome measures 
indicate that there may be a large variety in the neural and non-neural characteristics in stroke 
patients as also shown by the variation in the MAS.  
Nine out of the eleven identified patients had an increased Kjoint together with an increased Treflex 
of the flexors. Increased values for both Kjoint and Treflex are comparable with results found for 
the ankle where Kjoint and Treflex were also both increased with elevated MAS9. This is in contrast 
with results in cerebral palsy where a large variation was found between the neural (reflexive 
torque of triceps surae) and structural (tissue stiffness of triceps surae) contributors of joint 
stiffness in the ankle10;11. This variation in the manifestation of neural and non-neural 
 
contributors suggests a different mechanism in development of increased joint stiffness in 
stroke and cerebral palsy. 
 
Estimation of optimal muscle length and slack muscle length 
Parameters represent physiology of subjects but these in vivo estimated parameters for lumped 
muscle groups cannot directly be related to muscular parameter values as muscle activation 
dynamics (slow and fast fibre types) and muscle structure (e.g. pennation angle, muscle and 
tendon) is not exactly represented. The goal of this model is to systematically discriminate 
neural contributions from secondary structural changes in connective and contractile tissue 
observed in patients with upper neuron motor diseases like stroke. The exact value for the 
outcome measures can be different with literature, but the values and changes need to be of the 
same order of magnitude.  
In literature an optimal fiber length of 0.064-0.099 m was reported for the ECR35-41 and 0.081 
m and 0.059 m for the ECR longus and brevis42-44. An optimal fiber length of 0.052-0.080 m 
was reported for the FCR35-42;44. A fiber length of 0.076 m and 0.048 m was reported for the 
ECRL and ECRB and 0.051 m for the FCR42. Our optimal length and slack length were in the 
same order of magnitude as the parameters in literature (median lopt of 0.061 m and 0.071 m for 
extensor and flexor muscles respectively;  median lp,slack  of 0.069 m for the extensors and 0.047 
m for the flexors).  
The estimated lopt and lp,slack  of the flexors of the MAS ≥ 1 group were smaller compared to the 
values for healthy controls indicating that the range the flexor can generate force is reduced and 
connective tissue is stiffer and shortened. By uncoupling the slack muscle length and optimal 
muscle length we allow the model to estimate the passive and active characteristics of the 
muscle independently. Physiologically, the parameters may be related. E.g. longer sarcomeres, 
i.e. less sarcomeres in series, result in higher passive stiffness through the intrinsic fiber skeletal 
properties. However, an increase in extracellular matrix stiffness, described in children with 
cerebral palsy18, results in a decoupled increase of passive stiffness: the slack muscle length 
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Patients with MAS ≥ 1 can be discriminated from healthy controls and patients with MAS = 0 
by neural and non-neural contributors of joint stiffness using the presented bidirectional EMG 
driven model describing the position and force signals including EMG obtained with a wrist 
manipulator at high temporal resolution. We now have a method to study longitudinal changes 
of the neuromuscular system and the effect of treatment, like botulinum toxin injections, on the 
different neural and non-neural contributors of joint stiffness. Individual stroke patients with 
deviated tissue stiffness and reflexive torque can be discriminated from healthy controls using 
the minimal detectable change (MDC). This method gives the clinician the opportunity to 
monitor the different components of joint stiffness in time and to adjust treatment in individual 
stroke patients. 
The mechanism of muscle shortening after an upper motor neuron disease is not yet 
understood16. Longitudinal observation of the neural and non-neural contributors of joint 
stiffness, including the estimation of parameters representing the optimal muscle length and 
slack length of connective tissue, in the acute and sub-acute phase post-stroke and during ageing 
in children with cerebral palsy, could be of great value to e.g. better understand the mechanism 
of development of structural changes after a neural lesion.  
 
Limitations 
The wrist was rotated over its full RoM in one second to approximate the clinical Ashworth 
test. Because RoM in patients was generally reduced, movement velocity for the stroke patients 
was lower as compared to the healthy group. As stretch reflexes are velocity dependent 
reflexive muscle forces in the patients may even have been underestimated compared to the 
observations in the healthy group.  
Optimal muscle length is a characteristic observable only in the active muscles, while the 
presented data are measured during a passive task. There was generally sufficient muscle 
activity present to estimate the optimal muscle length in a valid way as demonstrated by the 
SEM values (median SEM value <0.05 for optimal muscle length for all conditions). Additional 
active tasks should be considered to ensure sufficient muscle activation to estimate the optimal 
muscle length in all cases.  
 
10% of the trials were rejected based on VAFs lower than 98%. In only one (out of 45) subject, 
the parameters could not be estimated because the patient had low VAF values in both 
movement direction and for both trials. From all other subjects, in repeated trials in flexion or 
extension, data became available to estimate the relevant parameters. Repetition of trials is 
therefore recommended. The constraint of VAF to be larger than 98% in order to approve trials 
was quite strict to ensure sufficient quality of the model fits. Low VAF values may have 
originated from experimental artefacts or voluntary interaction with the passive protocol.  
In our model the moment arms and muscle lengths at zero degrees wrist angle position of the 
ECR longus and brevis are averaged which is a simplification of reality45.  Furthermore, as the 
torque measured is the result of all extensor and flexor muscles, the modeled extensor and flexor 
muscle elements are lumped descriptions of the wrist muscles affecting the wrist flexion and 
extension torques (e.g. extensor carpi ulnaris, flexor carpi ulnaris). The characteristics of the 
ECR and FCR were used as initial parameter values for the corresponding muscle elements. 
Pennation angles were not included in the model, i.e. pennation angles were defined zero and 
consequently muscle and fiber length were defined to be equal. Since pennation angle changes 
the relationship between muscle length and force, the outcome parameters may be biased by 
this assumption. However, as this is the case in all subjects, differences in optimal muscle length 
and slack muscle length, parameterized by lopt,m  and lp,slack,m are assumed to represent 
physiological adaptation of the neuromuscular system and although the model is a 
simplification of the wrist joint it appeared to be sensitive to evaluate changes after stroke.  
 
Conclusions 
The EMG driven model in combination with the applied ramp-and-hold movements in both 
patients and healthy controls enabled us to estimate parameters representing tissue stiffness, 
reflexive torques, optimal muscle lengths and slack muscle lengths of connective tissue at the 
wrist in rest. Patients with an elevated MAS (MAS ≥ 1) were distinguished from healthy 
controls and patients with MAS = 0. Patients with MAS ≥ 1 differed from healthy controls 
through increased tissue stiffness and reflexive torque and reduced optimal muscle length and 
slack length of flexor connective tissue. The differentiation of joint stiffness into different 
neural and structural components is essential for individualized treatment selection in patients 
with upper motor neuron diseases and will be of benefit to follow the disease in time in acute 
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and sub-acute stroke patients and during ageing in children with cerebral palsy. Validation 
remains a point of attention in future applications. Next studies will focus on the effect of 
botulinum toxin treatment in chronic stroke patients and the quantification of joint stiffness 
during the acute and sub-acute phase of stroke.  
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remains a point of attention in future applications. Next studies will focus on the effect of 
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Appendix 4: Wrist model 
The model structure was based on the ankle model from de Vlugt et al.1 and adapted to the 
neuromechanical characteristics of the wrist joint. The following structure aspects were added 
in the wrist model compared to the ankle model: Optimal muscle length parameters were 
estimated, the stiffness components were modeled for both flexor and extensor muscles making 
the model fully bi-directional and tissue relaxation was included. Model parameters are listed 
in Table 4.2. 
 
Wrist joint stiffness is described by: 
 
𝑇𝑇𝑇𝑇���(𝑡𝑡𝑡𝑡) = 𝐼𝐼𝐼𝐼?̈?𝐼𝐼𝐼(𝑡𝑡𝑡𝑡) + 𝑇𝑇𝑇𝑇���(𝑡𝑡𝑡𝑡) − 𝑇𝑇𝑇𝑇����(𝑡𝑡𝑡𝑡)    (A4.1) 
 
where t is the independent time variable [s], Tmod the modeled wrist reaction torque [Nm], 𝐼𝐼𝐼𝐼?̈?𝐼𝐼𝐼(𝑡𝑡𝑡𝑡) 
the wrist angular acceleration [rad/s2], I the inertia of wrist and handle [kg.m2], Text the torque 
generated by the extensor muscles [Nm] and Tflex the torque generated by the flexor muscles 
[Nm]. 
Muscle torques (Tm) for extensor and flexor muscle are described by: 
 
, ,( , ) ( ( ) ( , , )) ( )m elas m act m m m m mT t F l F v l r        (A4.2) 
 
with Felas,m the elastic force of the parallel connective tissues [N], Fact,m the active or “reflexive” 
muscle forces [N] according to the Hill-type model, vm the muscle lengthening velocity [m/s], 
lm the muscle length [m], αm the active state [-] and )(mr  the angle dependent moment arm [m] 
of the tendon. 
 
The ECR and FCR were used as representation of the extensor and flexor muscles. The moment 
arms [m] of the ECR and FCR muscles are dependent on the angular position of the joint and 
defined using the equations of Ramsay et al.2: 
 
3( ) 13.2040 1.5995   for  10   [x10 ]FCRr m  
    o    (A4.3) 
 
3
, ( ) 13.4337 2.1411   for  10   [x10 ]ECR brevisr m  
   o   (A4.4) 
3
, ( ) 11.7166 2.2850   for  10  [x10 ]ECR longusr m  
   o   (A4.5) 
2/))()(()( ,,  longusECRbrevisECRECR rrr      (A4.6) 
 
The ECR is in fact two separate muscles: the extensor carpi radialis longus and brevis. Since 
only a combined EMG signal can be measured the extensor moment arm is assumed to be the 
average of the two separate moment arms. Muscle length equals: 
 
 )(0, FCRFCRFCR rll         (A4.7) 
 )(0, ECRECRECR rll         (A4.8) 
 
Where FCRl and ECRl  are the lengths of the muscle at each position  and 0,FCRl  and 0,ECRl the 
muscle length at zero degrees wrist angle position (handle in line with the forearm). The zero 
muscle lengths are lFCR,0 = 6.3 cm and lECR,0 = 7.0 cm (average of ECR longus and brevis, 
optimal fiber lengths from3-5.  )(FCRr  and  )(ECRr  are the arc lengths of the tendon that 
stretches around the joint bone when the joint rotates about angle  6. Positive angles represent 
flexion, thus the flexor muscles shorten during flexion and the extensor muscles lengthen during 
flexion, and vice versa for extension.  
 
Inertia of hand and the handle is modeled as a point mass m [kg] at distance la (fixed at 0.1 m) 
from the axis of rotation: 
 
2
aI ml  [kg.m2]       (A4.9) 
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Where km is the estimated stiffness coefficient of the muscle and lp,slack,m the estimated slack 
length of the connective tissue. Muscle connective tissue under tension exhibits relaxation or 













     (A4.11) 
 
with rel the estimated tissue relaxation time constant and relk the estimated tissue relaxation 
factor. In the previous version of the model by de Vlugt et al.1 tissue relaxation was 
approximated by a viscous damper.    
For clinical comparison between subjects, tissue stiffness at joint level, Kjoint, was compared at 
the same wrist angle (comp) for all subjects. This angle was chosen at zero degrees, i.e. where 




mmjo rekK mslackpcompmm 
  for comp = 0 degrees   (A4.12) 
 
where lm,comp is the muscle length at comp. Eq. (A4.12) was obtained by differentiation of Eq. 
(A4.10) with respect to muscle length and multiplied by the squared moment arm. The total 
tissue stiffness at joint level was derived by summation of the stiffness from both muscles: 
 
joint joint,ext joint,flexK K K        (A4.13) 
 
Neural muscle activity for the extensors and flexors due to stretch reflexes was estimated from 
corresponding EMG signals according to: 
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with U the excitation input to the muscle model [1/Volt]; Gm the dimensionless EMG weight 
scaling factor and EMGm the average of the recorded EMG signal values of both muscle 
electrodes.  
The neural excitations of both muscles were filtered with a linear second order filter to describe 
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αm is the dimensionless active state of the muscle, mf ,00 2   the estimated cut off frequency 
of the activation filter, s the Laplace operator denoting the first time derivative and βm the 
relative damping. 
The Hill-type muscle model was used to compute the muscle force from the active state and the 
muscle length and velocity according to: 
 
mmoptlmvmact llfvfF ),()( ,,        (A4.16) 
 
with fv the force-velocity relationship and fl the force-length relationship. The optimal muscle 
lengths (lopt,m ) were estimated using the model and used to derive the force-length relationships 
by 
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of the activation filter, s the Laplace operator denoting the first time derivative and βm the 
relative damping. 
The Hill-type muscle model was used to compute the muscle force from the active state and the 
muscle length and velocity according to: 
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with fv the force-velocity relationship and fl the force-length relationship. The optimal muscle 
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With wfl,m a shape factor defined as: 
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with cf the shape parameter of the force-length relationship with value 0.1 to resemble the force-
generating range of the FCR and ECR10;11. The maximum shortening velocity was 8 times the 
optimal muscle length12, the maximum eccentric force was 1.5 times the isometric force and 
the isometric force was normalized to 1 because the force had been scaled by the weighting 
factors G.  
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The mechanism and time course of increased wrist joint stiffness post-stroke and clinically 
observed wrist flexion deformity is still not well understood. The components contributing to 
increased joint stiffness are of neural reflexive and peripheral tissue origin and quantified by 
reflexive torque and muscle slack length and stiffness coefficient parameters. 
To investigate the time course of the components contributing to wrist joint stiffness during the 
first twenty-six weeks post-stroke in a group of patients, stratified by prognosis and functional 
recovery of the upper extremity. 
36 stroke patients were measured on eight occasions within the first twenty-six weeks post-
stroke using ramp-and-hold rotations applied to the wrist joint by a robot manipulator. Neural 
reflexive and peripheral tissue components were estimated using an electromyography driven 
antagonistic wrist model. Outcome was compared between groups cross-sectionally at twenty-
six weeks post-stroke and development over time was analyzed longitudinally. 
At twenty-six weeks post-stroke, patients with poor recovery (ARAT≤9 points) showed a 
higher predicted reflexive torque of the flexors (P<.001) and reduced predicted slack length 
(P<.001) indicating shortened muscles contributing to higher peripheral tissue stiffness 
(P<.001), compared to patients with good recovery (ARAT≥10 points). Significant differences 
in peripheral tissue stiffness between groups could be identified around week four and five; for 
neural reflexive stiffness this was the case around week twelve.  
We found onset of peripheral tissue stiffness to precede neural reflexive stiffness. Temporal 
identification of components contributing to joint stiffness after stroke may prompt longitudinal 





Recovery of motor function of the upper limb after stroke mainly adheres to the first eight 
weeks post-stroke1;2. These early changes are related to underlying mechanisms of spontaneous 
neurologic repair3, which is still poorly understood. Most patients with a poor recovery of motor 
function show increased joint stiffness. The components contributing to increased joint stiffness 
are of neural reflexive and peripheral tissue origin and quantified by reflexive torque and muscle 
slack length and tissue stiffness coefficient4-6, determined by e.g. sarcomere length and collagen 
composition. The timing of developing increased joint stiffness and contribution of its 
underlying components post-stroke is not clear7.  
The goal of the current study was to investigate the time course of neural reflexive and 
peripheral tissue changes in the wrist joint during the first twenty-six weeks post-stroke in three 
groups of patients, stratified by prognosis and functional recovery of the upper extremity. With 
a recently developed and validated technique we were able to simulate the wrist torques using 
muscle activation (electromyography, EMG) and wrist position as input8;9. The time course of 
the contribution of estimated neural reflexes to wrist joint stiffness and the value of the 
estimated peripheral tissue parameters (muscle slack length and tissue stiffness coefficient) may 
ultimately explain the development of wrist joint stiffness over time7;8;10;11. We hypothesize that 
stroke patients with poor recovery of motor function of the arm have increased reflexive torque 
and shortened muscles of the flexor muscles at twenty-six weeks resulting in increased joint 
stiffness and wrist flexion deformity compared to patients with good recovery. As stroke 
primarily results in a neural paresis and muscle tissue may respond to muscle state changes 
caused by altered neural input4 we presume that neural reflexive changes precede the peripheral 
tissue changes in the patients with poor recovery. 
Knowledge about the time course of changes in the contributors of joint stiffness, i.e. neural 
reflexes and peripheral tissue stiffness, may significantly contribute to the choice of treatment 
during the early phase post-stroke and may hand us a key to understand underlying mechanisms 
of functional recovery. 
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In the multicenter randomized clinical EXPLICIT-stroke trial, the effects of early applied 
constrained induced movement therapy (CIMT) or EMG triggered neuromuscular stimulation 
of the finger extensors (EMG-NMS) were compared to usual care on recovery of arm-hand 
function after stroke7;12;13. A cohort of 36 acute patients was recruited within this EXPLICIT-
stroke trial7;12;13 (Dutch Trial register NTR1424, part B3). Inclusion criteria comprised first-
ever ischemic stroke in the area of middle cerebral artery, impairment of the arm, age 18-80 
year and able to travel to the Leiden University Medical Center (LUMC) or University Medical 
Center Utrecht (UMCU). Exclusion criteria were previous upper extremity orthopedic 
limitations on the affected side and insufficient communication.   
Patients were assessed for eligibility within a week after stroke. Depending on the prognostic 
presence of finger extension post-stroke and the National Institutes of Health Stroke Score 
(NIHSS) item 5a or 5b7;14;15, patients were initially stratified in two groups. In the first stratum 
(finger extension ten degrees or larger at the end of the first week post-stroke and a NIHSS 
score of 1 or 2 on item 5, good prognosis) patients were randomized to receive constrained-
induced movement therapy within their usual care programs16. In the second stratum (finger 
extension less than 10 degrees and NIHSS score 3 or 4 on item 5, poor prognosis) patients were 
randomized to receive electromyography-triggered neuromuscular stimulation of the finger 
extensors17 within their usual care programs16.  
Within the measurement framework of EXPLICIT-stroke, patients were measured on eight 
occasions, i.e. at 1–5, 8, 12, 26 weeks post-stroke. We applied stratification based on the 
Explicit-stroke study. Therefore, based on both the initial prognosis for functional recovery, i.e. 
good and poor, and functional outcome at 26 weeks post-stroke, three groups were identified: 
1)  a GG group of 15 patients with an initially good prognosis for upper extremity motor 
recovery and showing good recovery at 26 weeks post-stroke, i.e. a score of 10 points or more 
on the ARAT; 2) a  PG group of 12 patients with poor prognosis and good recovery; 3) a PP 
group of 9 patients with poor prognosis and poor recovery, i.e. a score of 9 points or less on the 
ARAT at 26 weeks post-stroke. 
The study was approved by the medical ethics committee of the LUMC and UMCU. All 
participants gave their written informed consent prior to the experimental procedure. 
 
Instrumentation and protocol 
Subjects were seated upright with the affected arm slightly abducted in the frontal plane. The 
lower arm was fixed in an arm rest with the elbow at approximately 90 degrees of flexion and 
the shoulder comfortably relaxed. The hand was fixed into a custom-made handle (Meester 
Techniek, Leiden, the Netherlands). The wrist joint was aligned to the motor axis of a robot 
manipulator (Wristalyzer, Moog, Nieuw Vennep, the Netherlands). The robot manipulator 
delivered precise angular position (rotation) perturbations to the handle via a vertically 
positioned servomotor (Parker SMH100 series, Parker Hannifin, Charlotte NC, USA) and 
synchronously recorded the angular position of the handle and torque at the vertical motor axis 




Figure 5.1: Left: Experimental setup. The forearm and hand of the subject were fixed to the manipulator 
(Wristalyzer® by MOOG, the Netherlands). Ramp-and-hold rotations in flexion and extension direction (right) 
were imposed to the wrist while the subject was instructed to remain relaxed and not react to the rotations. Top 
right: measured torque and model fit; bottom right measured angle.  
 
Muscle activation was recorded by means of EMG with bipolar surface electrodes using a 
Delsys Bagnoli 8 system (Delsys Inc., Boston MA, USA). Electrodes were placed on the flexor 
carpi radialis (FCR) and on the extensor carpi radialis (ECR) muscles respectively.  For the 
FCR, electrodes were placed on the muscle belly at one third of the line originating from the 
medial epicondyle of the humerus to the radial styloid process and for the ECR, electrodes were 
placed on the muscle belly at one third of the line originating from the lateral epicondyle of the 
humerus to the ulnar styloid process. The EMG signals were sampled at 2048 Hz, online band 
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pass filtered (20–450 Hz), rectified and low pass filtered (20 Hz, 3rd order Butterworth) to 
obtain the EMG envelope. EMG at rest was subtracted from the total EMG in order to reduce 
noise. The filtered and rectified EMG was input for the model. The range of motion (RoM) was 
determined as the difference between maximal wrist flexion and wrist extension angle resulting 
from an imposed sinusoidal varying wrist torque starting from 0 Nm and ranging between 2 
Nm (extension torque) and –2 Nm (flexion torque) with a duration of about 80-100 seconds. 
Subsequently, ramp-and-hold (RaH) rotations were imposed onto the wrist over the full 
(individual) RoM within 1 second. Two RaH trials were imposed per measurement. Each trial 
encompassed a one second ramp in either extension or in flexion direction, two slow ramps in 
the opposite direction and three “hold” periods in between the ramps in which the position of 
the wrist did not change (Figure 5.1). Subjects were asked to remain relaxed during the entire 
experiment and not to voluntary react to the imposed wrist movements. 
 
Data analysis  
A validated biomechanical EMG driven antagonistic muscle model was used to predict wrist 
torque from the imposed wrist angle and recorded EMG8. The following twelve parameters of 
the model were predicted through least squares optimization by fitting the predicted torque 
derived from the model onto the experimentally recorded torque: of both flexor and extensor 
muscles: the stiffness coefficient, muscle slack length, optimal muscle length, EMG weighting 
factors and further: mass of the hand and the handle, activation cut-off frequency and 
parameters related to tissue relaxation, i.e. the tissue relaxation time constant and tissue 
relaxation factor8. The present study focused on four main outcome parameters: 1) The slack 
muscle length (lp,slack,m), which is the minimal muscle (m) length at which passive forces are 
generated and where m either represents the lumped system of wrist flexors or wrist extensors. 
2) The stiffness coefficient (km) representing the shape of the force-length curvature of the 
muscle tissue at lengths exceeding the slack muscle length: the higher the coefficient, the 
steeper the force-length curvature and the stiffer the muscle; the shorter the slack length, the 
higher the force at any given length exceeding the slack length. The force-length characteristics 
of the flexor and extensor muscle models were used to determine 3) the peripheral tissue 
dependent joint stiffness (peripheral tissue stiffness, Kjoint) which is both joint angle, i.e. muscle 
 
length, and direction dependent (described for the present study from neutral position towards 
wrist extension)8;9. 
For clinical comparison between subjects, the peripheral tissue stiffness was compared at an 
identical wrist angle for all subjects. This angle was chosen at zero degrees, i.e. where the robot 
manipulator handle is in line with the forearm. Besides the peripheral tissue stiffness component 
of wrist joint stiffness also the neural reflexive stiffness was predicted. As a measure of the 
amount of reflex activity, the root mean square reflex torques from the flexor and extensor 
muscles were derived by calculating the integral of the squared instantaneous measurements 
over the full observation period resulting in the reflexive torque8;9 (Treflex,m) (4). Trials were 
excluded from further analysis when the model was not able to predict the measured torque 
adequately, i.e. variance accounted for (VAF) below 98%. Calculated model parameters were 
discarded when identified as outlier based on standard deviation when compared to the values 
at adjacent time points or extraordinary parameter value.  
 
Statistical analysis 
A linear mixed model was used to assess the difference in outcome measures at twenty-six 
weeks post-stroke and each of the other consecutive measured time points between PP, PG and 
GG groups. A linear model was used to model the within subject correlation structure of the 
time points as auto-regressive order 1 (AR(1)). There were no random factors in the model. 
Fixed effects were modelled for the group factor indicating the PP, PG and GG groups, for the 
time points and for the interaction between the time and group. Alpha was set at .05. For 
statistical analysis IBM SPSS statistics 22 and GraphPad Prism 6 were used. 
 
Results 
The characteristics of the 36 included patients are illustrated in Table 5.1. On average, a patient 
had 4.6 visits with a total of 163 measurements. Each measurement resulted in a ramp-and-hold 
trial in flexion direction and a trial in extension direction. Each set of flexion and extension 
trials resulted in 7 outcome measures. Twenty trials (of 326) were excluded due to poor model 
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fit (VAF < 98%) and four trials (two measurements) due to corrupt measurement files. For the 
remaining trials in total 22 outlier outcome measures (~2%) in 11 subjects were identified and 
excluded for further analysis. Missing measurements exceeded 70% in the first three weeks due 
e.g. to late enrolment in this part of the EXPLICIT-stroke protocol, medical factors associated 
with stroke and logistic difficulties. Therefore we focused our statistical analysis on week four 
and onwards.  
 
Table 5.1: Patient characteristics for patients with good prognosis and good recovery (GG), patients with poor 
prognosis and good recovery (PG) and patients with poor prognosis and poor recovery (PP). 
 GG PG PP 
Number of patients 15 12 9 
Age, years (SD) 6.7 (8.2) 59.6 (14.6) 58.6 (8.6) 
Male gender, n (%) 12 (80) 8 (67) 7 (78) 
Preferred hand, right, n (%) 13 (87) 11 (91) 7 (78) 
Affected hand, right, n (%) 3 (20) 5 (42) 4 (44) 
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Table 5.2: Median and interquartile range for the predicted stiffness coefficient (km), slack length (lp,slack,m), 
reflexive torque (Treflex,m) and peripheral tissue stiffness (Kjoint) for patients with good prognosis and good recovery 
(GG), patients with poor prognosis and good recovery (PG) and patients with poor prognosis and poor recovery 
(PP). In the first three weeks most missing occasions are found. Therefore week four and onwards are shown. 
Numbers of patients per group and week are shown (n) for parameters related to flexor and extensor muscles. 
Differences between the two are due to bad model fits (variance accounted for < 98%) 
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Longitudinal group comparisons (repeated measures) 
Table 5.2 shows the medians with interquartile range (IQR) for the predicted outcome 
measures. Significant differences initiating at different moments of measurement between the 
different groups were observed for the reflexive torque of the flexors, the peripheral tissue 
stiffness (Kjoint) and the slack length of the flexors (Table 5.3, Figure 5.3).  
 
Table 5.3: Significant differences between patients with good prognosis and good recovery (GG), patients with 
poor prognosis and good recovery (PG) and patients with poor prognosis and poor recovery (PP) for the predicted 
slack length of the flexors (lp,slack,flex), reflexive torque of the flexors (Treflex,flex) and peripheral tissue stiffness (Kjoint). 
In the first three weeks most missing occasions are found. Therefore week four and onwards are shown. 




















Week 4 P=.025 P=.005 P=.37 P=.94 P=.94 P=.89 P=.577 P=.335 P=.69 
Week 5 P<.001 P=.013 P=.21 P=.30 P=.35 P=.91 P=.002 P=.069 P=.23 
Week 8 P=.002 P=.010 P=.72 P=.21 P=.36 P=.74 P<.001 P<.001 P=.51 
Week 12 P<.001 P<.001 P=.83 P=.001 P=.006 P=.73 P<.001 P<.001 P=.52 
Week 26 P<.001 P<.001 P=.42 P<.001 P<.001 P=.29 P<.001 P<.001 P=.60 
 
Overall effect of time and group and the interaction effect are shown in Appendix 5. At week 
four and onwards the slack length of the flexors was significantly smaller in the PP group 
compared to the GG and PG groups. The peripheral tissue stiffness was increased from week 
five to week twenty-six for the PP group compared to the GG and PG groups. At week twelve 
and twenty six the reflexive torque of the flexors was increased in the PP compared to GG and 
PG.  
Extensor reflexive torque differed at week twelve (P=.019) between the PG and the PP groups. 
The extensor slack length was smaller in PG compared to GG (P=.032) at week five.  
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Figure 5.3: Longitudinal observations for 
the predicted outcome measures for the 
patients with good prognosis and good 
recovery (GG), patients with poor 
prognosis and good recovery (PG) and 
patients with poor prognosis and poor 
recovery (PP). Significant differences 
between the GG and PP groups are 
indicated with an asterisk (*) and 
significant differences between the PG and 
PP group are indicated with a cross (+). 
The dashed line denotes the onset of 
changes between the poor recovery and 




Increased reflexive torque of the flexor muscles and shortened flexor muscles were predicted 
in patients with poor prognosis and poor recovery of the upper limb (PP, ARAT≤9 points) 
compared to patients with good prognosis and good recovery (GG, ARAT≥10 points) and 
patients with poor prognosis and good recovery (PG, ARAT≥10 points) using a validated 
electromyography driven modeling in 36 stroke patients at twenty-six weeks post-stroke8;9. As 
expected, patients with an initial poor prognosis and poor recovery showed increased reflexive 
torque of the flexor muscles (Treflex,flex), increased peripheral tissue stiffness (Kjoint) and 
shortened flexor muscles, indicated by smaller flexor slack length (lp,slack,flex) compared to 
patients with good recovery, at twenty-six weeks post-stroke. The current study suggests that 
peripheral tissue changes, i.e. slack length, around week four and five in the PP group preceded 
the neural reflexive stiffness, i.e. reflexive torque, changes observed around week twelve (Table 
5.3). 
 
Cross-sectional group comparison at 26 weeks post-stroke  
The PP patient group with poor prognosis and poor recovery had shortened flexor muscles at 
twenty-six weeks post-stroke, indicated by the smaller slack length of the modelled flexor 
muscles compared to the good recovery groups (PG and GG). The shortening of the muscle in 
the PP group is in concordance with the flexion deformity found by van der Krogt et al. 
(unpublished results), i.e. a marked shift of the wrist rest angle towards flexion, observed in 
these patients. Note that in the present study the peripheral tissue stiffness (Kjoint) was measured 
at a fixed angle of zero degrees. Peripheral tissue stiffness determined at the individual rest 
angles of patients may reveal a difference with the current study as was previously observed 
(unpublished results, van der Krogt et al.). This illustrates that peripheral tissue stiffness 
depends on the angle of observation. Additionally, at the rest position of the wrist (zero torque)3, 
the stiffness is lowest and contrast between the different groups is minimal. The stiffness 
coefficient was lower in the PP group compared to the PG group. This could be due to structural 
changes in the muscle or because of and interaction of the contractile state of passive tissue 
with the active state of the muscle, e.g. background activation18 which we currently do not 
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account for. However, without further substantiating data these physiological explanations are 
speculative and obviously additional research endeavors and validation are warranted. 
The exact mechanism of muscle shortening after an upper motor neuron disease is still 
unclear19. A diminished neural input might results in disuse or immobilization and therefore 
muscle atrophy. Immobilized muscles in a shortened position adapt to their resting length and 
lose sarcomeres to develop maximal force at their shortened length5;20-23 . When stretching the 
shortened muscles, the diminished number of sarcomeres in series results in a higher tissue 
stiffness compared to normal muscles. Our data suggest that muscle shortening occurs soon 
(around week 4) after stroke. Immobilization and muscle over-activity in the sub-acute phase 
post-stroke may worsen shortening5;24.   
 
Peripheral tissue changes precede neural reflexes changes 
The current study suggests that tissue changes in the flexor muscles around week four and five 
in the poor recovery group (PP) preceded the neural reflexive changes observed around week 
twelve. The progressive increase in peripheral tissue stiffness and neural reflexive stiffness 
around the wrist in stroke patients is in accordance with results found by Mirbagheri et al.25 in 
the elbow joint.  
Movement disorders after stroke are the result of a complex interplay between tissue and neural 
properties4;26. After stroke, central neural drive changes with excessive responses to muscle 
stretch via several proposed mechanisms which encompass alpha motor neuron hyper 
excitability, changes in recruitment gain and plateau potentials of motor neurons, loss of 
presynaptic inhibition and changes in gamma- motor- neuron excitability24. Altered neural input 
may also comprise increased background muscle activation which may also explain hyper 
excitability of reflexes18;27. Loss of neural drive also results in flexion synergies at the wrist due 
to neural coupling with the shoulder and elbow28 which may worsen immobilization of the 
flexors in a short position. Increased muscle strain in shortened muscles may potentially result 
in increased spindle responses and subsequent increased spinal reflex activity5;29.  This may 
offer an alternative yet interesting explanation of the temporal delay between tissue changes 
and reflexive responses. We suppose that tissue changes occur within the first weeks after 
 
stroke. This was confirmed by the large differences between the groups at week four. The onset 
of shortening within the poor recovery group (PP) is likely to start in the weeks before.    
Changes were mainly observed in the flexor muscles. Changes in the extensor muscle were 
only found for the stiffness coefficient at twenty-six weeks: the stiffness coefficient of the 
extensors was higher for the PP group compared to the PG group meaning that the extensor 
muscle was stiffer in the PP group. The different adaptation of the extensor muscle in recovery 
is not yet clear. At week twenty-six, no differences were found in outcome measures between 
the GG patients and PG patients. Differences between these groups could arise earlier after 
stroke. Increased resolution of measurements by increasing the number of observations within 
these first weeks may reveal differences especially between the PG and PP and GG groups. 
 
Limitations 
For this study a validated EMG driven wrist model8 was used to predict the peripheral tissue 
stiffness and neural reflexive components of wrist joint stiffness. Using this method allows us 
to predict lumped parameters of the flexor and extensor muscle groups. The method can be 
useful in decisions for treatment and may hand us a key to understand underlying mechanisms 
of functional recovery9;30-34. However, the method has also some limitations. During the 
processing of EMG input data, background muscle activation, which is assumed to be noise, 
was removed from the EMG signal and only the variances in EMG amplitude were used to 
estimate the reflexive torque. As in stroke patients the rest level EMG may be elevated18 this 
elevated additional input is discarded and therefore not included in the active (contractile) 
contribution to torque. The background activation could not be identified by the model but 
might be traced back in the overall peripheral tissue stiffness meaning that the peripheral tissue 
stiffness might have been overestimated in patients with increased background activation. 
However, analysis of the EMG levels at rest showed no difference between the three groups 
which made it less likely that differences in background activation explain the observed 
elevated reflex activity and flexor muscle shortening.  
In the EMG driven wrist model8 the muscle length at which the highest forces are generated 
was also included. In the current study this optimal muscle length (i.e. due to the maximal 
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overlap between contractile filaments) was not presented as reflexive muscle activation in these 
patients was low in most patients and estimation of contractile muscle properties was therefore 
unreliable.  
The model is a lumped representation of all flexor and extensor muscles. The differences 
between individual muscles (e.g. flexor carpi radialis and flexor carpi ulnaris) after stroke were 
therefore not identified.  
Most drop-outs were found in the first three weeks. Additional observations, thus increasing 
statistical power, are needed to obtain reliable information about the neural reflexes and 
peripheral tissue changes in the first weeks post-stroke for patients with different recovery 
patterns. Small sample size also prevented further substantiation of the additional effects of 
treatment. However, subgroup analysis in the present sample showed no substantial differences 
between intervention and control groups. We chose to use an interaction term in our statistical 
model, because of plausibility of group and time interaction. Small sample size prevented that 
this interaction term was significant in all cases.  
 
Clinical implications 
Clinically observed changes post-stroke, e.g. the altered wrist flexion deformity, were now 
further specified by predicting its components explaining increased joint stiffness, i.e. neural 
reflexive and peripheral tissue stiffness, and characterized over time. Around 4-5 weeks post-
stroke significant peripheral tissue changes were observed in a group of patients with initially 
poor prognosis for functional recovery and a poor recover (i,e, ARAT≤9 points) at 26 weeks; 
changes in reflex torque were only observed after 12 weeks. The exact interplay of properties 
of neural reflexive stiffness, i.e. reflexive torque and peripheral tissue stiffness, i.e. slack length 
and stiffness coefficient, background muscle activation and the interplay of both muscle groups 
need to be studied further to pinpoint the cause-and-effect of increased joint stiffness and 
whether it can be influenced by therapy shortly after stroke. 
Preventing immobilization in a shortening position early after stroke should be an important 
focus in clinical practice. The effect of therapies on neural reflexive and peripheral tissue 
stiffness in the acute and sub-acute stroke patients, e.g.  neuromuscular electrical stimulation of 
the wrist extensors (suggested to enhance motor recovery)35, the best timing of physical 
 
therapy36 or the effect of splinting of the wrist37, needs to be studied using longitudinal 
observations at fixed time points post-stroke. 
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Appendix 5: Supplementary Table 
 
Table 5A: Overall effect of time (weeks), overall effect of group (PP, PG, GG) and effect of interaction between 
group and time for patients with poor prognosis and poor recovery (PP) compared to the good recovery groups 
for the predicted slack length of the flexors (lp,slack,flex), reflexive torque of the flexors (Treflex,flex) and peripheral 
tissue stiffness (Kjoint). In the first three weeks most missing occasions are found. Therefore week four and onwards 
are shown. 
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Clinical application of botulinum toxin (BoNT) will benefit from a better understanding and 
quantitative assessment of the underlying neural and non-neural properties of spasticity related 
joint stiffness increase and their response to BoNT treatment.  
The effect of BoNT on underlying ankle joint stiffness properties was estimated using an EMG-
driven ankle model in 15 chronic stroke patients who underwent instrumented passive ankle 
rotations before and after BoNT injections in the calf muscles.  
Dorsal range of motion (dRoM) increased after BoNT. Baseline values of and changes in non-
neural joint stiffness, triceps surae slack length and recorded soleus EMG rest activation were 
associated with changes in dRoM and neutral rest angle. No associations were found for reflex 
activity. 
Observed and estimated responses are in line with an effect of BoNT on background muscle 
activity. The instrumented approach may assist to identify those patients who will likely benefit 





Botulinum neurotoxin-A (BoNT) is recommended for treatment of post-stroke spasticity1-8. 
BoNT blocks the release of acetylcholine from the nerve terminal, thereby uncoupling the 
excitation-contraction mechanism and thus reducing muscle (hyper)activity3. This results in a 
reduction of muscle tone and joint stiffness and a subsequent decrease in resistance to passive 
joint manipulation as clinically assessed by the (modified) Ashworth Score (mAS)9. Clinical 
application of BoNT for spasticity treatment post-stroke may benefit from a better 
understanding and quantitative assessment of the underlying properties of spasticity related 
joint stiffness increase and their response to BoNT treatment. Is spasticity defined by a velocity 
dependent resistance to passive stretch according to the concept of Lance10 or is it better 
explained by an increased muscle activation at rest, i.e. background muscle activation, 
according to the Burne concept11?   
Evaluation of BoNT treatment is hampered by e.g. differences in dosing regimens, injection 
sites, heterogeneity in patients, concurrent treatment, outcomes selected, and the poor 
methodological quality of insufficiently powered, placebo-controlled trials12-15. Furthermore, 
assessment of the effects of BoNT by clinical semi-quantitative scaling like the mAS is 
problematic as the mAS has a questionable reliability and a low responsiveness to change9;16. 
We recognize an urgent need for alternative, high-resolution assessment that enables us to 
understand the concept of spasticity and its response to BoNT in upper motor neuron diseases 
like stroke14. 
Neuromuscular modeling in combination with joint manipulation paradigms using high 
precision robotics is promising in terms of reliable and valid identification of the underlying 
contributors of joint stiffness17-23. An instrumented electromyography (EMG)-driven modeling 
approach would allow for quantitative estimation of the neural reflexive and non-neural tissue 
properties to joint stiffness, i.e. muscle shortening and muscle stiffening18;19;24. This method 
should potentially be able to identify (stroke) patient characteristics at baseline prior to BoNT 
treatment and assess the effects of BoNT post treatment.  
The aim of the present study was therefore to estimate the effect of BoNT on underlying neural 
reflexive and non-neural tissue properties of increased ankle joint stiffness in chronic stroke 
patients. 
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Fifteen stroke patients participated in the study. Patients were included following ischemic or 
hemorrhagic stroke over 6 months at inclusion and were clinically referred for BoNT treatment 
(Botox, Allergan, Inc., Irvine, CA) in the soleus (SOL), gastrocnemius medialis (GM), 
gastrocnemius lateralis (GL) and/or tibialis posterior (TP). Patients were recruited from the 
outpatient clinic of the Leiden University Medical Center between January 2013 and June 2015. 
The indication for treatment was based on clinical arguments and independent of the present 
study. Exclusion criteria comprised (other) concomitant neurological and/or orthopedic 
disorders, treatment within the last 4 months that could interfere with a stable ankle joint 
stiffness, surgery of leg/foot within last 12 months and inability to participate in the experiment, 
either physically (i.e. inability to be mounted in the experimental set-up), cognitively (i.e. 
unable to understand test instructions or to give informed consent). Participants were measured 
prior to BoNT treatment (baseline T0) and 6-8 weeks (T1) and 12-16 weeks (T2) after BoNT 
treatment. Written informed consent was obtained from the participants. The study was 
approved by the medical ethics committee of the Leiden University Medical Center.  
 
Instrumentation 
Subjects were seated with their foot fixated onto an electrically powered single axis footplate 
(Achilles, MOOG FCS Inc., Nieuw-Vennep) with their knee positioned at 70 degrees of flexion 
(Figure 6.1). The axis of rotation of the ankle and footplate were aligned by visually minimizing 
knee translation in the sagittal plane during manual rotation of the footplate. For safety reasons 
and to avoid pain, the maximum tolerated dorsal- and plantar flexion of the ankle were restricted 
by hard- and software stops of the manipulator and determined by manually moving the ankle 
through its RoM by a trained operator before starting the measurements. The footplate was 
aligned visually at 25° plantar flexion with respect to the line connecting the head of the fibula 





Figure 6.1: Measurement set-up. 
 
EMG assessment 
Muscle activation of the tibialis anterior (TA) and triceps surae (TS) was recorded using surface 
EMG (Porti, TMSi B.V. Oldenzaal, The Netherlands) according to the SENIAM guidelines25 
(supplementary table). EMG signals were sampled at 1000 Hz, offline high pass filtered (20Hz, 
3th-order Butterworth), rectified and low pass filtered (20 Hz zero overshoot filter). Rest EMG, 
i.e. the minimal EMG determined for each muscle by applying a moving window of 8 ms, was 
subtracted from the total EMG because assumed not to contribute to ankle torque. Rest EMG 
of the TA, SOL, GL and GM were also used as outcome measure. Torque and ankle angle were 
sampled at 1024 Hz and low pass filtered (20 Hz zero overshoot filter) and resampled to 1000 
Hz.  
 
Range of motion and ramp and hold measurements 
Maximum dorsal and plantar flexion angles were assessed by gradually increasing flexion 
torque from 0 to 15 Nm in dorsal flexion direction and subsequently to -7.5 Nm in plantar 
flexion direction and back to zero torque in dorsal flexion direction. From this measurement the 
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Range of motion and ramp and hold measurements 
Maximum dorsal and plantar flexion angles were assessed by gradually increasing flexion 
torque from 0 to 15 Nm in dorsal flexion direction and subsequently to -7.5 Nm in plantar 




following outcome measures were determined: 1) dorsal range of motion (dRoM), i.e. the 
maximum ankle angle at 15 Nm or, in case the patients did not tolerate 15 Nm, at the highest 
common torque measured over all three measurements (T0,T1,T2) and 2) the neutral angle 
(NA) which is the ankle angle at zero torque, i.e. the ankle at rest. The zero torque angle is ankle 
flexion direction dependent (hysteresis) and the NA was defined as the average 0-Nm crossing 
angle determined for the plantar flexion and dorsiflexion movement. 
The instrumented RoM was used as boundary for the subsequent ramp-and-hold (RaH) trials. 
During the RaH measurements the ankle was rotated at two different angular velocities (15 and 
100 deg/sec), starting in maximal plantar flexion and ending in maximum dorsiflexion angle 
(first ramp). After an approximate 10 seconds hold phase, the ankle was moved back to the 
maximal plantar flexion angle (second ramp). The subjects were instructed to relax during the 
RaH trials. Each velocity was repeated, which resulted in four RaH trials and one RoM trial per 
measurement. 
 
Neuromuscular modeling  
A validated neuromuscular model was used to predict ankle torque from measured ankle angle 
and EMG and subsequently estimating neural reflexive and non-neural tissue properties of 
ankle joint stiffness26. The model encompassed in total 15 parameters, i.e. of both TS and TA: 
the stiffness coefficient, muscle slack length, optimal muscle length, EMG weighting factors 
(three for TS and one for TA) and further: mass of the foot and footplate, activation cut-off 
frequency, relative damping and parameters related to tissue relaxation, i.e. tissue relaxation 
time constant and tissue relaxation factor. The present study focused on the following 
properties: 1) The estimated non-neural muscle slack length of TS and TA; 2) The estimated 
non-neural stiffness coefficient of TS and TA and which is an indicator of muscle stiffness; 3) 
the estimated non-neural peripheral tissue stiffness, a function of joint angle determined by the 
combination of slack length and stiffness coefficient of both TA and TS muscles. For 
comparison purposes, the peripheral tissue stiffness was assessed at an ankle angle of 0 degrees 
over all subjects and trials, i.e. foot (plate) perpendicular to the lower leg; 4) the estimated 
neural reflexive torque of TS and TA. The estimated reflexive torque was calculated by the root 
 
mean square of the involuntary active muscle torque during the observed trial. Slack muscle 
length, stiffness coefficient and peripheral tissue stiffness were determined at an ankle rotation 
speed of 15 deg/sec; the reflexive torque was determined at an ankle rotation speed of 100 
deg/sec. Outcome parameters were averaged over two trials (repetitions), unless trials were 
excluded due to low variance accounted for (VAF<99%).  
 
Statistical analysis 
A linear mixed model was used to compare outcome measures between the different 
measurement time points. Secondly, a linear regression analysis was performed addressing the 
association between changes in outcome measures, i.e. estimated neural reflexive and non-
neural tissue properties and measured EMG rest activity, as independent variables and 
respectively changes in measured dRoM and NA as dependent variables. Thirdly, the same 
procedure was repeated for the baseline values (T0) of the outcome measures, i.e. estimated 
neural reflexive and non-neural tissue properties and EMG rest activity, as independent 
variables and changes in measured dRoM and NA as dependent variables to address the 
predictive value of aforementioned baseline parameters for the outcome after BoNT treatment. 




One patient quitted the study after the first measurement due to various reasons leaving 14 
stroke patients for further analysis, encompassing a total of 42 measurements. Thus, 42 RoM 
trials were available, and due to lack of valid RaH data in 2 patients, 144 RaH trials. In 2 patients 
over 2 trials, the maximum dorsal flexion torque of 15 Nm exceeded the patient’s tolerance and 
thus hardware restricted dRoM was determined at a lower torque level. Of the 144 RaH trials, 
3 trials were excluded due to low VAF values (<99%). 9 out of 14 patients were injected in the 
soleus muscle. Patient characteristics are shown in Table 6.1. 
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Neuromuscular modeling  
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time constant and tissue relaxation factor. The present study focused on the following 
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mean square of the involuntary active muscle torque during the observed trial. Slack muscle 
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One patient quitted the study after the first measurement due to various reasons leaving 14 
stroke patients for further analysis, encompassing a total of 42 measurements. Thus, 42 RoM 
trials were available, and due to lack of valid RaH data in 2 patients, 144 RaH trials. In 2 patients 
over 2 trials, the maximum dorsal flexion torque of 15 Nm exceeded the patient’s tolerance and 
thus hardware restricted dRoM was determined at a lower torque level. Of the 144 RaH trials, 
3 trials were excluded due to low VAF values (<99%). 9 out of 14 patients were injected in the 





Table 6.1: Patient characteristics. 









1 55 M R 2.6 Ischemic SOL (100), GM (50), GL (50) 4 1 
2 46 M L 3.0 Ischemic SOL (50), GM (50) 4 0 
3 46 F R 21.4 Ischemic SOL (50), TP (100), TA (100) 3 1 
4 52 F L 2.0 Hemorrhagic GM (25), GL (25), TP (50) 2 1 
5 61 M R 10.4 Ischemic SOL (100) 3 0 
6 41 M R 16.1 Hemorrhagic SOL (100) 3 0 
7 64 M R 5.6 Ischemic SOL (50) 2 1 
8 65 M L 2.5 Hemorrhagic SOL (100) 2 1 
9 68 M R 3.1 Ischemic TP (50) 1 1 
10 48 F L 1.6 Ischemic SOL (100), GM (50), GL (50) 1 1 
11 58 M R - - SOL (100), GM (50), GL (50) 3 1 
12 55 F R - Hemorrhagic GM (100), TP (50) 3 0 
13 54 M L 2.8 Ischemic GM (50), GL (50) 1 1 
14 69 F L ~4 Hemorrhagic GM (50), GL (50) 1 0 
+SOL: soleus, GM: gastrocnemius medialis, GL: gastrocnemius lateralis, TP: tibialis posterior, TA: tibialis anterior 
** unspecified, 1=yes; 0=no.  
 
Measured and estimated parameters before and after BoNT injection 
Measured and estimated parameters before and after BoNT injections are presented in 
Table 6.2. The dRoM improved on average with 4.1 (SD 6.7) degrees from T0 to T1 and the 
NA shifted from plantar flexion to the (neutral) anatomical ankle angle by 4.6 (SD 7.7) degrees. 
Significant changes between T0 and either T1 or T2 after BoNT injection were only observed 
for dRoM and NA (Table 6.2). Estimated neural reflexive and non-neural tissue properties 






Table 6.2: Overview of outcome measures before (T0) and after (6-8 weeks: T1 and 12-16 weeks: T2) BoNT 
injections. P-values for comparison between measurement moments. 
 
Associations between baseline values and changes in measured and estimated parameters with 
changes in dRoM and NA 
A decrease in estimated peripheral tissue stiffness, an increase in estimated TS slack length and 
a decrease in measured rest EMG of soleus significantly associated with an increase of 
measured dRoM and/or a shift in NA towards anatomical ankle angle after BoNT, while no 
significant changes of reflex torques were observed (Table 6.3). A high estimated peripheral 
tissue stiffness and a small estimated TS slack length appeared to be predictive for a 
respectively increase in measured dRoM and NA shift towards anatomical ankle angle. Again, 
no significant associations between estimated baseline reflex torque and measured dROM and 
NA were observed (Table 6.4).  











T0 vs T1 
P-value 
T0 vs T2 
P-value 
Dorsal RoM (deg) 5.5 (8.6) 9.5 (5.5) 8.6 (6.7) 14 .032 .093 
Neutral angle (deg) -30.1 (10.5) -25.5 (6.7) -23.6 (5.4)* 14 .052 .010* 
Peripheral tissue stiffness (Nm/rad) 245 (351) 132 (61) 125 (73) 12 .39 .21 
Slack length TS (mm) 22.8 (2.6) 23.2 (2.6) 23.6 (3.8) 12 .60 .38 
Slack length TA (mm) 63.6 (11) 60.2 (17) 58.5 (12) 12 .39 .10 
Stiffness coefficient TS (1/m) 346 (43) 343 (48) 360 (98) 12 .79 .58 
Stiffness coefficient TA (1/m) 186 (54) 192 (62) 185 (42) 12 .57 .96 
Reflexive torque TS (Nm) 2.9 (2.1) 3.0 (2.2) 2.7 (2.0) 12 .89 .49 
Reflexive torque TA (Nm) .25 (.20) .48 (.37) .31 (.48) 12 .052 .69 
Rest EMG SOL (µV) 2.3 (1.6) 2.3 (1.8) 2.3 (1.7) 12 .97 .99 
Rest EMG GM (µV) 1.3 (.50) 1.3 (.30) 1.6 (0.92) 12 .50 .21 
Rest EMG GL (µV) 1.2 (.24) 1.2 (.37) 1.3 (0.25) 12 .90 .69 
Rest EMG TA (µV) 1.5 (.87) 1.5 (.99) 1.5 (.60) 12 .75 .98 
*based on 13 stroke patients       
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Table 6.3:  Association between changes estimated neural reflexive and non-neural tissue properties and 
measured EMG rest activity and changes in measured dorsal RoM and neutral angle before (T0) and 6-8 weeks 
after BoNT injections (T1). Unstandardized effects and 95% confidence interval. 
 Dorsal RoM Neutral angle 
 Unstandardized  Unstandardized  
 β 95% CI P-value β 95% CI P-value 
Peripheral tissue stiffness (Nm/rad) -.014 -.023; -.005 .006 -.016 -.027; -.005 .009 
Slack length TS (mm) 1.8 .54; 3.0 .010 2.1 .69; 3.5 .008 
Slack length TA (mm) -.15 -.60; .31 .49 -.40 -.85; .059 .081 
Stiffness coefficient TS (1/m) -.040 -.19; .11 .55 -.002 -.175; .171 .98 
Stiffness coefficient TA (1/m) -.005 -.12; .11 .93 -.054 -.18; 0.69 .35 
Reflexive torque TS (Nm) .35 -4.1; 4.8 .86 2.9 -1.8; 7.6 .20 
Reflexive torque TA (Nm) .56 -11.5; 12.6 .92 -1.1 -15.0; 12.8 .87 
Rest EMG SOL (µV) -1.5 -3.07;.005 .051 -1.9 -3.6; -.2 .032 
Rest EMG GM (µV) -.51 -14.5;13.5 .94 1.2 -15.0; 17.3 .88 
Rest EMG GL (µV) 3.7 -11.3;18.8 .59 8.1 -8.6; 24.8 .31 
Rest EMG TA (µV) -10.1 -22.1; 1.9 .090 -10.2 -24.6; 4.1 .14 
 
Table 6.4: Association between estimated neural and non-neural tisseu properties and measured EMG rest activity 
at baseline (T0) and changes in measured dorsal RoM and neutral angle between T0 and 6-8 weeks after BoNT 
injections (T1). Unstandardized effects and 95% confidence interval. 
 Dorsal RoM Neutral angle 
 Unstandardized  Unstandardized  
 β 95% CI P-value β 95% CI P-value 
Peripheral tissue stiffness (Nm/rad) .013 .004; .022 .010 .015 .004; .025 .010 
Slack length TS (mm) -1.5 -2.9; -0.084 .040 -1.6 -3.3; .070 .058 
Slack length TA (mm) .18 -.22; .58 .35 .016 -.47; .50  .94 
Stiffness coefficient TS (1/m) .056 -.040; .15 .23 .071 -.072; .21 .30 
Stiffness coefficient TA (1/m) .008 -.099; .12 .87 -.049 -.17; .070 .38 
Reflexive torque TS (Nm) -.45 -2.6; 1.7 .66 -.94 -3.4; 1.5 .41 
Reflexive torque TA (Nm) -7.7 -30.2; 14.8 .46 2.5 -24.1; 29.1 .84 
Rest EMG SOL (µV) 1.6 -.90; 4.1 .18 -2.0 -.90; 4.8 .16 
Rest EMG GM (µV) -2.2 -11.1; 6.8 .60 -1.8 -12.2; 8.6 .71 
Rest EMG GL (µV) -8.4 -26.6; 9.9 .33 -10.3 -31.2; 10.7 .30 





Significant improvements in measured dRoM and NA that coincided with an estimated 
lengthening of the musculo-tendon complex of the TS were observed using an instrumented 
EMG-driven model approach to evaluate the effect of BoNT injections in the calf muscles in 
chronic stroke patients on neural reflexive and non-neural tissue properties of ankle joint 
stiffness. Baseline values and changes of the estimated non-neural tissue parameters peripheral 
tissue stiffness and the slack length of triceps surae were associated with improvements of 
dRoM and the NA. The estimated neural and velocity dependent parameter reflexive torque did 
not associate. 
 
Applicability of the instrumented EMG-driven model approach 
With VAF values over 99% and only a few trials being discarded because of low VAF values 
(2%) the developed model approach seems well applicable to the present clinical case. Previous 
research showed that the internal model validity was good, test-retest reliability fair to good 
and that the method has clinical potential26. 
 
Measured and estimated parameters before and after BoNT injection 
The effect of BoNT treatment was reflected by the increase in dRoM and the shift of NA 
towards the anatomical ankle angle. This is assumed to originate from an increased length of 
the musculo-tendon complex of the TS muscle during rest conditions and may thus be regarded 
a main effect of BoNT treatment27;28. The other parameters did not show changes as a function 
of BoNT treatment, which might be due to a large variability within the included cohort and the 
current lack of means to discriminate potential responders from non-responders in combination 
with a small sample size. The estimated observations cannot be compared to a gold standard 
that measures the effect of BoNT treatment because yet lacking. Clinically, we have to do with 
scales like the mAS with its acknowledged problems of sensitivity and reliability16. Significant 
effects of BoNT on the mAS may only be found in large study samples29, averaging the large 
variation in e.g. doses, injection sites and techniques into account14. Changes in dRoM and shift 
of NA to the anatomical ankle angle may be an alternative clinical outcome parameter for 
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treatment evaluation. Further studies on validity and sensitivity to e.g. variations in dose, are 
needed in order to fully judge the merits of RoM measurements. 
 
Associations between baseline values and changes in measured and estimated parameters 
Changes in measured ankle dRoM and NA were associated with baseline values and changes 
of the estimated non-neural tissue parameters slack length of TS and peripheral tissue stiffness 
and estimated EMG rest activity of soleus. Non-neural tissue parameters are assumed to relate 
to changes in length of musculo-tendon structures thus explaining dRoM and NA more than the 
neural reflexive torque. Relating the changes in ankle dRoM and NA to the estimated neural 
reflexive and non-neural tissue properties to joint stiffness and measured rest EMG at baseline 
provided for the opportunity to predict the effects of BoNT in a heterogeneous group of 
responders and non-responders to BoNT. 
 
BoNT may decrease background muscle activation: evidence for the “Burne” over the “Lance” 
concept of spasticity. 
Improvement of dRoM and NA following BoNT treatment can potentially be explained by a 
decrease in background activation of the TS muscle. BoNT results in the relaxation (i.e. 
lengthening) of the contractile element and thus a shortening and relaxation of the serial elastic 
length (Figure 6.2). This concept is substantiated by an increase in estimated slack length. Slack 
length is assumed to reflect the muscle fiber slack length in combination with the muscle fiber 
pennation angle.  
Additional evidence for background activation reduction is provided by the decrease in 
measured EMG rest activity of soleus, which is associated with the shift of the NA towards 
anatomical ankle angle. Also the absence of associations of BoNT treatment with reflexive 
torque suggests the evidence for background muscle activation reduction. The background 
muscle activation was not accounted for in the model and may therefore also affect the 




Figure 6.2: Schematic illustration of a Hill type triceps surae and Achilles tendon (top) with the contractile 
element (CE), the parallel element (PE) and the serial elastic component (SE) and the muscle force-length 
relationship (bottom). Left: in the “normal” relaxed condition the foot is in a neutral position, with the SE and PE 
in ‘slack length’. Middle: In the spastic/contractile condition, the CE is activated and the PE is shortened, while 
the SE length is increased, the foot rotated in equines position. The passive force-length relation and the working 
point (state) at the active force-length relationships are shifted to the left, meaning that in the neutral position of 
the ankle, the joint stiffness is increased, resulting in decreased dorsal RoM. Right: BoNT results in the relaxation 
(i.e. lengthening) of the CE and thus a shortening and relaxation of the SE length. The triceps surae muscle slack 
length changes/normalizes: the passive force-length relationship and the contractile state of the active force-length 
relationship are shifted to the right, i.e. towards “normal”.  
Note: The shortened triceps surae in the contractile state is a combination of a shortening of the CE in combination 
with an increase of the muscle fiber pennation angle. 
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The combination of aforementioned findings is in favor of the “Burne” hypothesis of increased 
background activation as the underlying pathophysiological mechanism for spasticity11 and the 
observed clinical effects of BoNT treatment. The potential mechanism of BoNT treatment may 
be to reduce background muscle activity so that the contractile muscle tissue relaxes and dorsal 
RoM increases (Figure 6.2).  
All noticed effects are observed under resting task conditions. The higher contractile state of 
the resting muscle may have an indirect effect on the (increased) sensitivity of muscle spindles 
and Golgi tendon organs and the spinal reflex thresholds related to the “Lance” hypothesis as 
neural and non-neural tissue components are in tight interaction30. 
 
Strength, limitations and clinical implications 
This study shows the applicability and merits of high resolution clinimetrics by using a robotic 
manipulator in combination with an EMG-driven neuromuscular model approach that allows 
for estimation of underlying properties to joint stiffness, in order to understand the 
pathophysiological effects of BoNT treatment in stroke patients. Patients were instructed to 
relaxed and do therefore not require the ability to selectively and voluntary activate muscles, 
making the method applicable in clinical practice. Addressing effects of dose, injection site and 
technique and the potential to discriminate responders from non-responders may be important 
topics for further study considering the costs and the wide spread use of BoNT treatment14.  
There are a number of limitations to the present study. First, the study sample was small, 
especially considering the expected underlying heterogeneity in patients, history of treatment, 
dose, selected muscles, injection site etc. Also, the current choice for outcome stratification 
based on increase of dRoM and NA shift needs further investigation. As background activity 
cannot be estimated directly yet from the current models, evidence of influence on this 
component was circumstantial as is the relation of background activity to slack length. Slack 
length is assumed to reflect both the contractile state of the muscle fibers and the muscle fiber 
pennation angle. Pennation angles were not in the model nor were measured separately. 
Therefore the increase of estimated slack length could be indicative for a decrease in pennation 
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Appendix 6: Supplementary table 
 
Table 6A: Electrode placement according to seniam guidelines (www.seniam.org) 
Muscle Location 
Tibialis anterior At 1/3 on the line between the tip of the fibula and the tip of the medial malleolus. 
Soleus At 2/3 of the line between the medial condylis of the femur to the medial malleolus. 
Gastrocnemius medialis On the most prominent bulge of the muscle. 
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The aim of the studies in this thesis was to quantify neural reflexive and non-neural tissue 
contributors of ankle and wrist joint stiffness in patients with stroke and cerebral palsy using an 
instrumented electromyography (EMG) driven non-linear neuromuscular modeling approach. 
Underlying contributors of clinically observed increased joint stiffness, diminished range of 
motion and flexion deformity, i.e. a shift of joint rest angle, cannot be distinguished by current 
clinical tests like the Ashworth1 and Tardieu scale2;3, which are ordinal, subjective and of low 
resolution4-6. Quantification of underlying contributors is however important for understanding 
of underlying mechanisms of functional recovery and the effect of therapy on neural and non-
neural components to diminish or eventually prevent these motor disorders. The clinical 
potential of the neuromuscular modeling approach was illustrated by the development over time 
of neural and non-neural contributors in the sub-acute phase post-stroke and by the effect of 
botulinum toxin A treatment on these contributors in chronic stroke patients. 
 
Main findings 
In chapter 2 neural reflexive and non-neural tissue contributors of ankle joint stiffness were 
identified in patients with CP using an instrumented non-linear EMG-driven modeling 
approach7. Patients with CP showed a higher neural reflexive stiffness and peripheral tissue 
stiffness compared to healthy subjects. A large inter-subject variation was found for the ratio 
between reflexive stiffness and peripheral tissue stiffness showing the heterogeneity of the CP 
group. In patients with diminished range of motion, a high peripheral tissue stiffness was 
observed. The non-linear model7 was refined and extended with parameters describing the 
passive and active force-length relationships such to estimate the optimal muscle length, slack 
muscle length and muscle stiffness, of the triceps surae and tibialis anterior (chapter 3). The 
added parameters enabled to identify muscle shortening and stiffening in patients with stroke. 
It was demonstrated that the model was internally valid and sensitive for knee angles. In chapter 
4 the ankle model was translated to a wrist model. The model included an antagonistic pair of 
muscle elements reflecting the wrist flexor and extensor muscle groups. The model was valid 
and sensitive to demonstrate increased reflexive stiffness and peripheral tissue stiffness in 
chronic stroke patients compared to healthy controls and based on the smaller slack muscle 
length and smaller optimal muscle length it was suggested that flexor muscles were shortened 
 
in patients with stroke8. Development of contributors over time was shown in a longitudinal 
study in the first 26 weeks post-stroke in chapter 5. Shortening of the wrist flexor muscles was 
demonstrated to occur as early as 4 to 5 weeks in a group of patients with poor prognosis for 
functional outcome at 26 weeks post-stroke and poor functional recovery of the upper extremity 
that clinically showed increased joint stiffness and wrist flexion deformity compared to patients 
with good recovery. Onset of neural reflexive stiffness in the poor recovery group occurred 
around week 129. Temporal identification of components contributing to joint stiffness and 
flexion deformity post-stroke may prompt longitudinal interventional studies to further evaluate 
and eventually prevent the development of tissue shortening. 
The effect of a common clinical intervention to reduce stiffness, increase dorsiflexion range of 
motion and counteract undesirable rest angle shifts, i.e. botulinum toxin A injection, on the 
neural reflexive and non-neural tissue contributors was observed in a longitudinal study in 
chronic stroke patients (chapter 6). Significant improvements in dorsal range of motion and 
shift of neutral angle, i.e. the rest angle of the joint at zero torque, were observed, which 
coincided with an estimated lengthening of the musculo-tendon complex of the triceps surae 
after botulinum toxin A treatment. Aforementioned improvements could be related to 
peripheral tissue stiffness, muscle slack length and soleus rest activity and could not be related 
to reflex activity. The results found in this study support evidence of the effect of botulinum 
toxin A on background muscle activity, i.e. muscle activation at rest, in post-stroke spasticity. 
These findings show the possibility to relate clinical observed changes, i.e. diminished range of 
motion and shift of rest angle, to its underlying neural and non-neural contributors and further 
in its pathophysiological changes which is required for understanding, diagnosis and follow-
up. As the outcome parameters proved to be sensitive for treatment, these findings indicate that 
the modeling approach may be a powerful tool in treatment selection and quantifying the effect 
of treatment.  
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Non-neural tissue changes precede neural reflexes changes 
In the EXPLICIT-trial (chapter 5) patients were followed 6 months post-stroke and stratified 
by prognosis for functional outcome at 26 weeks post-stroke, based on presence of finger 
extension and NIHSS, and recovery, based on ARAT10. This resulted in three groups: patients 
with good prognosis for functional recovery and good recovery, patients with poor prognosis 
and good recovery and patients with poor prognosis and poor recovery. In the group with poor 
recovery smaller wrist flexor slack lengths, representing muscle shortening, and increased 
peripheral tissue stiffness were observed to occur within 4-5 weeks after stroke followed by 
increased neural reflexive stiffness starting around 3 months.  
Recovery after stroke varies with the nature and severity of the initial deficit after a 
cerebrovascular accident and is determined by unknown biological processes11. The mechanism 
of recovery of motor function on one side and development of shifted rest angle of the wrist on 
the other side are still poorly understood and mainly adhere to the first 8 weeks post-stroke12;13. 
A diminished neural input might result in disuse or immobilization; immobilized muscles in a 
shortened position adapt to their resting length and lose sarcomeres to develop force at their 
shortened length14-18. At comparable joint angles and compared to healthy muscles, the strain 
in spastic muscles is higher resulting in higher resistive muscle forces and a consequently higher 
joint stiffness due to the diminished number of sarcomeres in series19. Increased muscle strain 
in shortened muscle may potentially result in increased spindle response and consequently 
increased spinal reflex activity16. The development of increased background activation as a 
consequence of altered neural input may also result in hyperexcitability of reflexes20;21. There 
were no differences between the different groups in EMG magnitudes at rest suggesting that 
there was no difference in background muscle activation between the groups9. However, further 
substantiation requires a model that enables estimation of this neural contributor.  
Non-neural tissue changes between the different recovery groups were observed within four 
weeks. An important focus in these first weeks might be to prevent the development of tissue 
changes in the acute and sub-acute phase post-stroke. Avoiding immobilization in a shortened 
position early after stroke might be an important aspect to prevent tissue changes. Possible 
treatments in the poor prognosis group may be to start immediately with physical therapy, 
 
neuromuscular stimulation or splinting and casting to prevent flexion deformity. The 
instrumented non-linear neuromuscular modeling approach is a useful tool for follow-up to 
observe the neural and non-neural changes in time that correlate with the clinical observed 
changes, e.g. wrist flexion deformity, and it may be a useful tool to guide intervention at the 
right moment and at the right neuromuscular property. 
 
Botulinum toxin A lowers background muscle activation 
At 26 weeks post-stroke, patients with poor recovery showed increased neural reflexive torque 
and shortened and stiffened wrist flexor muscles resulting in increased peripheral tissue 
stiffness compared to stroke patients with good recovery9. This was in accordance with the 
results found in chronic stroke patients with an average of 30 (SD 27.6) months post-stroke 
(chapter 4). Here was found that patients with a modified Ashworth score of 1 or higher had 
increased reflexive stiffness of flexors, shortened flexor muscles and increased peripheral tissue 
stiffness compared to healthy subjects and patients with a modified Ashworth score of 08. 
Botulinum toxin A treatment is a common clinical procedure to reduce joint stiffness, to 
increase dorsal range of motion and to correct shifted joint resting positions22-29. Botulinum 
toxin A blocks the release of acetylcholine from the nerve terminal, thereby uncoupling the 
excitation- contraction mechanism and thus reducing muscle (hyper)activity26. A lack of 
understanding the concept of spasticity in stroke may prevent optimal use of botulinum toxin 
A. It is important to know what the effect is of botulinum toxin A on the neural and non-neural 
components of joint stiffness and what the effect is on the association between these 
components, e.g. how will changes in the neural component interact with the changes of the 
non-neural components after stroke?30  
After botulinum toxin A treatment, the dorsal range of motion increased and the neutral rest 
angle shifted (chapter 6). Baseline values and changes in peripheral tissue stiffness and triceps 
slack length were associated with the changes in dorsal range of motion and neutral angle and 
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to botulinum toxin A. Patients with high baseline peripheral tissue stiffness and/or small slack 
triceps muscle length seemed to benefit from botulinum toxin A. By examining patients on 
these properties, it may be possible to predict which patients might benefit from botulinum 
toxin A. Long term administration of botulinum toxin creates weakness and atrophy which may 
worsen motor function. Identifying the non-responders by low/normal peripheral tissue 
stiffness and/or normal slack length may help to prevent these undesirable effects and lowers 
medical expenses.  
Following the administration of botulinum toxin A we were able to identify changes in the 
neural and non-neural contributors that were associated to increased dorsal range of motion and 
shifted neutral rest angle. This offers opportunities for further research: e.g. to study the effect 
of botulinum toxin A at an early stage after brain injury or to study the dose-response in 
botulinum toxin treatment30. 
Botulinum toxin is generally administered to reduce the neural reflexive component as 
spasticity is often defined according to the concept of Lance as a velocity dependent resistance 
to passive stretch31. In the current study, spasticity was explained by increased muscle 
activation at rest, i.e. background muscle activation21. Improvement in dorsal range of motion 
and neutral rest angle after botulinum toxin A can be explained by a decrease in an active 
contributor under rest conditions of the triceps surae muscles: botulinum toxin A may reduce 
background muscle activity so that the muscle relaxes and muscle length and range of motion 
increases. No associations in changes in dorsal range of motion and neutral angle were found 
for the neural reflexive components. Lowering background muscle activation by botulinum 
toxin might lower the increased reflex activity in contracted muscles21, but this could not be 
confirmed in chapter 6 as the study was under passive conditions.  
Background muscle activation could not be identified directly but may affect other parameters 
resulting in e.g. increased peripheral tissue stiffness and decreased slack muscle length, 
indicative for a decrease in pennation angle due to relaxation of muscle32;33. Considering the 
importance of background muscle activation as a neural contributor of joint stiffness, future 
model developments should be aimed at quantification of aforementioned contributor. 
 
 
Development of joint stiffness in stroke and cerebral palsy 
This thesis mainly focuses on stroke but application of the neuromuscular modeling approach 
was also shown in a group of patients with cerebral palsy. Both stroke and cerebral palsy are 
upper motor neuron diseases. Stroke appears mostly in adults in the developed brain; Cerebral 
palsy occurs in the fetal or neonatal developing brain34. Consequently, the posture and 
movement disorders may have a different sequel between the groups, which might be reflected 
in the neural and non-neural tissue distribution of joint stiffness. In patients with stroke we 
observed shortening of wrist flexor muscles around week 4 to 5 post-stroke and reflexive 
stiffness around week 129. The development of contributors of joint stiffness over time in 
patients with cerebral palsy is not yet well described. From literature we learn that in cerebral 
palsy passive stiffness may increase over reflex activity with age35 and that the range of 
dorsiflexion of the ankle joint decreased on average 19 degrees during the first 18 years of life36. 
From these two studies it is suggested that contribution of underlying components of joint 
stiffness in cerebral palsy changes over time and that variability in a group of adolescents is 
expected to be high. This latter was confirmed in our study in cerebral palsy by a large inter-
subject variation for the ratio between triceps reflexive torque and peripheral tissue stiffness as 
we measured adolescents in a wide age range37. It would be interesting to study the change of 
underlying neural reflexive and non-neural tissue contributors of joint stiffness over time to 
learn more about the development of spasticity in cerebral palsy. As the contribution of neural 
reflexive and non-neural tissue stiffness might change over time, therapy in children with 
cerebral palsy needs to be evaluated whenever a new treatment strategy is considered.  
 
Future directions 
Assessment in clinical practice  
The presented instrumented EMG-driven non-linear neuromuscular modeling approach is 
applicable in patients showing a variable degree of flexion deformity, diminished range of 
motion and increased joint stiffness. Applicability was demonstrated in patients with stroke and 
cerebral palsy. The method is safe, as the range of motion is prevented by hard- and software 
stops, comfortable for the patient and does not require voluntary contraction. The method 
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resembles clinical tests, like the Ashworth and Tardieu tests, by the movement over the full 
range of motion. In contrast to linear system identification methods that apply small deviations 
of e.g. joint angle, performing movement over the full range of motion resembles functional 
movement more closely. Awareness is needed in patients with small range of motion: the 
movement velocity needs to be high enough to induce reflexes.  
Assessment under passive conditions, as in the current study, does not resemble functional tasks 
that need voluntary muscle contraction, like walking. This requires assessment under active 
conditions. 
Clinical applicability could be enhanced by reducing the preparation time which is two to three 
times longer than the measurements time, e.g. due to placing EMG electrodes on the muscles 
which is a precise task and necessary to quantify the neural and non-neural tissue parameters. 
Methods without EMG were developed, like the NeuroFlexor method, which showed good 
agreement with EMG-driven optimization on the overall neural and non-neural 
components38;39, but lack the ability of precise quantification of parameters, e.g. slack muscle 
lengths, optimal muscle lengths and stiffness coefficients. This precise information is essential 
for insight in pathological mechanism in e.g. the sub-acute phase post-stroke and whether the 
muscle is shortened and/or stiffened which is of value in treatment selection. In case of e.g. a 




For administration of botulinum toxin A in e.g. the triceps surae, it can be of benefit to know 
whether the gastrocnemii are most affected or the soleus muscle. With the neuromuscular 
modeling approach it was possible to discriminate between groups of lumped muscle, e.g. 
plantar flexors and dorsiflexors, but not between individual muscles. An alternative method 
was presented for the ankle in chapter 3: by changing the knee angle, the contribution of the 
gastrocnemii muscles and soleus muscle was varying.  
Muscle relaxation and activation, background muscle activation and muscle atrophy interfere 
with the muscle pennation angle32;33;40. This parameter was not included in the present model. 
Also, the elastic muscle tendon was not included. Including the Achilles tendon in the ankle 
 
model did not significantly affect the model parameters in healthy subjects41, but could be of 
value in patients with different phenotypes as Achilles tendon mechanical properties might be 
altered post-stroke42. Changes in pennation angle affect the passive and active force-length 
curves and thus interfere with the model parameters slack length, stiffness and optimal length. 
Thus it was not possible to determine whether an increased slack length in patients post-stroke 
may be caused by a reduced pennation angle due to muscle atrophy40. Additional 
measurements, like ultrasound, are required to study pennation angles as an additional input to 
the model. 
 
Clinical implications and recommendations 
The results in this thesis are a step forward in answering “when” to treat stroke patients by 
performing longitudinal assessments. The EMG-driven neuromuscular modeling approach 
offers opportunity to gain more insight in the development of increased joint stiffness, 
diminished range of motion and rest angle shifts. This information is of value to prevent motor 
disorder developments in future. 
The results in this thesis also gives direction to the question “how” to treat stroke patients, i.e. 
which treatment option is most effective in each individual patient, and is a step forward 
towards personalized treatment. Addressing effects of dose, injection site and technique and the 
potential to discriminate responders from non-responders are important subjects for further 
study considering the costs and the wide spread use of botulinum toxin A treatment. 
Quantification of neural and non-neural components is essential to diminish and eventually 
prevent motor disorders thereby improving activity of daily live and also quality of live in 
patients with stroke.  
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Dit proefschrift gaat over het meten van de gevolgen van een hersenbeschadiging op stijfheid 
van gewrichten en haar onderliggende factoren: neurale (reflexen) en niet-neurale (spier) 
weefsel eigenschappen. In het bijzonder wordt gekeken naar de gevolgen na cerebrale parese 
en cerebro vasculair accident (CVA). Cerebrale parese is een beschadiging van de hersenen die 
voor of tijdens de geboorte ontstaat, bijvoorbeeld door zuurstofgebrek, en wordt gezien bij 2 
per 1000 levende geboortes1;2. Een CVA of beroerte is een hersenbeschadiging op latere leeftijd 
verkregen door een acute stoornis in de bloedvoorziening naar de hersenen, waardoor de 
hersenen te weinig zuurstof krijgen. In de meeste gevallen (80%) komt dit zuurstoftekort door 
een vernauwing of verstopping van een ader in de hersenen (herseninfarct); een andere oorzaak 
is een hersenbloeding3. Het merendeel van de mensen dat een CVA krijgt is ouder dan 65 jaar. 
Omdat onze samenleving vergrijst, zal daarom de mate waarin CVA voorkomt, toenemen. Op 
dit moment is het de tweede belangrijkste doodsoorzaak wereldwijd en staat het hoog op de 
ranglijst van ziekten die beperkingen met zich mee brengen4-6. 
De laatste decennia zijn verbeteringen doorgevoerd in de acute patiëntenzorg na een CVA wat 
resulteert in verhoogde overlevingskansen en vermindering van de initiële hersenschade. Dit 
laatste door toepassing van acute antistolling (trombolyse) en het verwijderen van het stolsel 
(trombectomie). Doordat de overleving beter is, moeten meer mensen leven met de gevolgen 
van een CVA. Dat kunnen problemen zijn met het bewegen, maar ook met taal, spraak en 
mentale en geestelijke gesteldheid7;8. Stoornissen in het bewegen gaan vaak gepaard met een 
verhoogde stijfheid van gewrichten, beperkingen in gewrichtsuitslagen, een abnormale 
buigstand (bijvoorbeeld een spitsvoet) en parese: een verminderde kracht en selectief kunnen 
aansturen van een spier9.  
De revalidatiegeneeskunde maakt in het handelen gebruik van instrumenten en terminologie 
die passen binnen het ICF model (International Classification of Functioning, Disability and 
Health)10;11. In het ICF model staat het functioneren van de patiënt in zijn omgeving centraal. 
Het menselijk functioneren en de factoren die daarop van invloed zijn, worden benaderd vanuit 
de wisselwerking tussen de verschillende aspecten van de gezondheidstoestand en de externe 
en persoonlijke factoren10. Op het ICF niveau “functies en anatomische eigenschappen” richten 
behandelingen zich onder andere op het verminderen van stijfheid, het stabiel houden of 
 
verbeteren van het bewegingsbereik van gewrichten en het corrigeren van de abnormale 
rusthoek. 
De combinatie van stijfheid en overactiviteit van spieren wordt klinisch vaak “spasticiteit” 
genoemd. Echter, de definitie van spasticiteit is nog steeds een punt van discussie9;12. 
Spasticiteit komt in 20-30% van de CVA patiënten voor13. Bij spasticiteit gaat men uit van een 
neuraal (uit de hersenen of ruggenmerg) geïnduceerde reflexstijfheid of anders gezegd een 
snelheidsafhankelijke weerstand van het gewricht bij passief bewegen (definitie van Lance)14. 
Het wordt echter steeds meer duidelijk dat bij gewrichtsstijfheid sprake is van een combinatie 
en/of interactie van neurale (reflexieve) en niet-neurale (spier) weefsel eigenschappen15-18. In 
de klinische praktijk is niet altijd duidelijk of de gewrichtsstijfheid het gevolg is van neurale 
over-activatie van spieren of door niet-neurale verstijving en/of verkorting van (spier) weefsel 
of een combinatie van beide15;19. Het onderscheid is van belang voor het juist toepassen van 
therapie, bijvoorbeeld botuline toxine bij gewrichtsstijfheid van neurale origine en spalk/gips 
of chirurgie bij gewrichtsstijfheid van niet-neurale origine. 
Bij klinische testen, zoals de Ashworth en Tardieu20-22, wordt het gewricht met een bepaalde 
snelheid handmatig bewogen (Figuur 8.1) en de weerstand als maat voor gewrichtsstijfheid 
bepaald. Door dit bij verschillende snelheden te doen wordt getracht de neurale en niet-neurale 
component te onderscheiden. Helaas zijn deze testen weinig gevoelig en onvoldoende 
betrouwbaar voor het meten van onderliggende componenten van toegenomen 
gewrichtsstijfheid. De testen zijn daarnaast subjectief en niet goed reproduceerbaar16;23;24.  
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Figuur 8.1: Demonstratie van de klinische Ashworth test. De voet wordt bewogen richting dorsaalflexie (pijl) om 
de mate van weerstand bij beweging te bepalen.  
 
De neurale en niet-neurale componenten kunnen ontrafeld worden door gebruik te maken van 
systeemidentificatie en parameterschatting (SIPE). Voor deze technieken worden robots 
gebruikt die precieze verstoringen in de vorm van beweging of kracht op het gewricht 
uitoefenen (input) en tegelijkertijd de reactie hierop in respectievelijk kracht en beweging meten 
(output). Door te kijken naar de relatie tussen de opgelegde beweging of kracht en gemeten 
kracht of beweging kunnen systeemeigenschappen van een gewricht worden bepaald18;25-27. 
Door middel van modellen kunnen systeemeigenschappen vertaald worden naar onderliggende 
componenten (parameterschatting) zoals de neurale reflexstijfheid en de niet-neurale 
weefselstijfheid18;28. SIPE is reeds toegepast bij gezonde proefpersonen en patiënten28-33; echter 
met gebruikmaking van kleine verstoringen waarbij het systeem (gewrichts-) gedrag niet 
representatief is voor functionele condities, zoals lopen of het bewegen van een arm. In dit 
proefschrift worden “Parameter Estimation” (PE-) methoden beschreven die zijn ontwikkeld en 
toegepast voor het bepalen van gewrichtsstijfheid onder meer functionele condities34. De 
verstoringen die gebruikt worden, lijken op de klinische testen, zoals de Ashworth en Tardieu. 
De gemeten signalen (spieractiviteit, gewrichtshoek en –moment, i.e. kracht maal arm) worden 
gecombineerd, waarbij ook gebruik wordt gemaakt van spiermodellen voor de flexoren en 
 
extensoren van het gewricht. Parameters in het spiermodel worden geoptimaliseerd zodat de 
gezamenlijke krachten rond het (enkel- of pols-) gewricht, ook wel netto gewrichtsmoment 
genoemd, en welke wordt gemeten met de robot, overeenkomt met het geschatte 
gewrichtsmoment door het model (Figuur 8.2). De waarden van parameters die vervolgens uit 




Figuur 8.2: Vereenvoudigde weergave van de in dit proefschrift gebruikte methode met de pols als voorbeeld voor 
het gewricht. Polshoek en spieractivatie (van de polsflexoren en -extensoren) zijn input voor het model. Het 
polsmodel berekent een polsmoment op basis van de (geschatte) parameters van het model. Dit geschatte moment 
wordt vergeleken met het moment gemeten door de polsrobot. De parameters van het model worden zo aangepast 
tot het verschil tussen het geschatte moment en gemeten moment minimaal is. De methode voor het schatten van 
de parameters van de enkel werkt vergelijkbaar met hier gepresenteerde methode voor de pols. 
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Doelen van de onderzoeken beschreven in dit proefschrift zijn: 
1. Het kwantificeren van neurale en niet-neurale eigenschappen van gewrichtsstijfheid bij 
patiënten na een CVA en met cerebrale parese om meer begrip te krijgen van de 
onderliggende mechanismen in het ontstaan en de ontwikkeling van gewrichtsstijfheid. 
Hiervoor is een methode ontwikkeld en gevalideerd (hoofdstuk 2, 3, 4). 
 
2. De ontwikkelde methode is vervolgens gebruikt om functioneel herstel na een CVA beter 
te begrijpen en om het effect van therapie te onderzoeken. Voor het bereiken van dit doel 
zijn de volgende studies uitgevoerd: 
a) De neurale en niet-neurale eigenschappen van gewrichtsstijfheid werden gemeten 
gedurende de eerste 26 weken na een CVA bij groepen patiënten met verschillende 
combinaties van prognose voor functioneel herstel van de bovenste extremiteiten en 
het uiteindelijke functioneel herstel van de bovenste extremiteiten (hoofdstuk 5). 
b) Het effect van botuline toxine A injecties op de neurale en niet-neurale componenten 
van gewrichtsstijfheid werd onderzocht om een eerste stap te maken naar selectie 
voor patiënt-specifieke therapie (hoofdstuk 6). 
 
Hoofdbevindingen 
In hoofdstuk 2 van dit proefschrift worden de neurale en niet-neurale eigenschappen van 
gewrichtsstijfheid in patiënten met cerebrale parese beschreven35. Hiervoor werd gebruikt 
gemaakt van een PE-methode, Figuur 8.2. Patiënten met cerebrale parese lieten een hogere 
reflexactiviteit (neurale component) en een hogere weefselstijfheid (niet-neurale component) 
zien, vergeleken met gezonde proefpersonen. Bovendien werd meer variatie in de verhouding 
van reflexactiviteit en weefselstijfheid gezien in de patiënten dan in de gezonde proefpersonen. 
In patiënten met een beperkt bewegingsbereik van de enkel was de weefselstijfheid groter dan 
in patiënten met een groot bewegingsbereik. Deze studie liet zien, naast de mogelijkheid 
gewrichtsstijfheid te ontbinden in zijn neurale en niet-neurale componenten in patiënten met 
cerebrale parese, dat de verhouding neuraal/niet-neuraal per patiënt varieert, wat de basis is 
voor patiënt-specifieke therapie. 
 
In hoofdstuk 3 werd het spiermodel verfijnd en uitgebreid met parameters om te bepalen of bij 
een patiënt met toegenomen weefselstijfheid sprake is van een verkorting of een verstijving van 
de spier. Hiervoor werden parameters aan het model toegevoegd en de spierlengte formules 
verfijnd voor het schatten van de passieve en actieve kracht-lengte relatie van de voetbuigers 
(kuitspieren, triceps surea) en voetheffers (tibialis anterior). De actieve kracht-lengte relatie 
geeft de mate weer waarin een spier kracht kan leveren bij een bepaalde lengte van de spier. Bij 
de optimale spierlengte kan de spier de meeste kracht leveren. Naast het bepalen van de 
reflexactiviteit, is het model nu in staat de optimale spierlengte, de rustlengte van de spier en 
de stijfheid van de spier te schatten. Het model bleek gevoelig voor het meten van de parameters 
bij verschillende kniehoeken. Op deze manier kan de bijdrage van de verschillende kuitspieren, 
de gastrocnemius spier (bi-articulair) en soleus spier (mono-articulair), gevarieerd worden. 
In hoofdstuk 4 werd het enkelmodel vertaald naar een polsmodel dat in staat is om de 
eigenschappen van de strekkers (extensoren) en buigers (flexoren) van het polsgewricht te 
schatten36. Bij een groep patiënten met een CVA meer dan 6 maanden voorafgaand aan de 
meting (chronische fase na CVA), werd het model toegepast en werd toegenomen 
reflexactiviteit en toegenomen weefselstijfheid aangetoond met het model. Het bleek dat de 
weefselstijfheid samenging met een kleinere optimale spierlengte en kortere rustlengte van de 
spier, waaruit geconcludeerd werd dat de buigspieren van de pols bij de CVA patiënten waren 
verkort. 
Veranderingen van de neurale en niet-neurale eigenschappen van de polsbuigers en -strekkers 
in de eerste 26 weken na een CVA worden beschreven in hoofdstuk 5. In deze studie werden 
de patiënten ingedeeld in groepen, gebaseerd op een goede of slechte prognose voor functionele 
uitkomst van de bovenste extremiteiten en een daadwerkelijk goed of slecht functioneel herstel 
van de bovenste extremiteiten na 26 weken. Dit resulteerde in drie groepen: patiënten met goede 
prognose en goed herstel, patiënten met een slechte prognose en goed herstel en patiënten met 
slechte prognose en slecht herstel. Bij patiënten met een slechte prognose voor functionele 
uitkomst na 26 weken en uiteindelijk ook een slecht functioneel herstel werd verkorting van 
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Doelen van de onderzoeken beschreven in dit proefschrift zijn: 
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Hoofdbevindingen 
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resultaten laten zien dat de methode gebruikt kan worden in studies naar het verloop van 
onderliggende factoren van gewrichtsstijfheid en kan mogelijk ook bijdragen aan het 
ontwikkelen en evalueren van behandelingen om spierverkorting tegen te gaan. 
Botuline toxine A injecties worden veel gegeven in overactieve spieren om zo de 
gewrichtsstijfheid tegen te gaan, het bewegingsbereik van het gewricht te vergroten en om 
ongewenste ruststand van het gewricht te herstellen39-42. Het effect van deze behandeling op de 
neurale en niet-neurale componenten van gewrichtsstijfheid van de enkel werd onderzocht in 
chronische CVA patiënten en beschreven in hoofdstuk 6. Het bewegingsbereik en de ruststand 
van de enkel werden verbeterd door toepassing van botuline toxine A injecties. Deze 
verbeteringen gingen samen met een verandering van de weefselstijfheid, spierrustlengte en 
spieractiviteit (op basis van elektromyografie, EMG) van de achterste kuitspier (m. soleus). Er 
werd echter geen relatie met reflexactiviteit gevonden. Deze resultaten onderbouwen de 
hypothese dat botuline toxine A niet zozeer op reflexactiviteit werkt, maar op de rustactiviteit 
van spieren. Deze rustactiviteit van de spieren is een neurale component die we nog niet kunnen 
schatten met het huidige model. Ook in deze studie is te zien dat klinisch waarneembare 
veranderingen, zoals toegenomen gewrichtsstijfheid, verminderd bewegingsbereik en 
ongewenste ruststand van de enkel, gerelateerd kunnen worden aan onderliggende neurale en 
niet-neurale weefseleigenschappen van het gewricht. Deze informatie is nuttig voor het begrip 
van deze drie klinisch waarneembare veranderingen, voor de diagnose en het monitoren ervan. 
De resultaten laten daarnaast zien dat de methode gebruikt kan worden bij patiënt-specifieke 





Niet-neurale weefselveranderingen gaan vooraf aan neurale reflexieve veranderingen 
De mate van functiebeperkingen in het bewegingsapparaat en het herstel na een CVA hangt 
samen met de plaats en omvang van de hersenschade en wordt bepaald door nog onbekende 
neurobiologische processen43. Van de groep patiënten met een slechte initiële prognose voor 
functioneel herstel van de bovenste extremiteiten zijn er die functioneel redelijk of goed 
herstellen, maar ook patiënten die een slecht functioneel herstel laten zien van de bovenste 
extremiteiten. De mechanismen die enerzijds een goed functioneel herstel en anderzijds de 
ontwikkeling van toegenomen gewrichtsstijfheid, veranderde ruststand van het gewricht en 
afgenomen bewegingsbereik bepalen, zijn nog onvoldoende begrepen en spelen zich 
voornamelijk af in de eerste acht weken na een CVA44;45. Een verminderde neurale aansturing 
van spieren resulteert mogelijk in het niet gebruiken en daardoor immobilisatie van spieren. 
Spieren die geïmmobiliseerd zijn in een verkorte positie gaan zich aanpassen aan deze verkorte 
spierlengte en verliezen sarcomeren (contractiele eenheden om spieren samen te trekken) om 
toch kracht te kunnen uitoefenen met deze kortere spierlengte46-50. Als gezonde proefpersonen 
vergeleken worden met CVA patiënten met verkorte spieren, op een vergelijkbare stand van 
het gewricht, zal de spanning in de spieren van patiënten veel hoger zijn en dus ook de 
weerstand bij bewegen, zoals ook beschreven door Lieber en Friden51. De verhoogde spanning 
in verkorte spieren kan bij rek ook bijdragen aan een hogere respons van spierspoeltjes. 
Spierspoeltjes zijn belangrijk in het genereren van reflexen. Verhoogde gevoeligheid van 
spierspoeltjes zal resulteren in een hogere reflexactiviteit48. Een verhoogde rustactivatie als 
gevolg van veranderde neurale input, zoals beschreven door Burne en collega’s, kan ook leiden 
tot verhoogde reflexactiviteit19. In de longitudinale studie is gekeken naar verhoogde 
spieractiviteit op basis van EMG gemeten in rust. Er konden geen verschillen worden 
aangetoond in spieractiviteit tussen de verschillende groepen37. Dit is een mogelijke aanwijzing 
dat de verhoogde reflexactiviteit bij patiënten met slecht functioneel herstel niet werd 
veroorzaakt door verhoogde spieractiviteit in rust. Omdat spieractiviteit gemeten met EMG een 
relatieve maat is, is het wenselijk om de bijdrage van de neurale activatie leidend tot 
spieractiviteit in rust met het model te kunnen kwantificeren. Hiermee zou de hypothese over 
de bijdrage van rustactiviteit van de spier met meer zekerheid kunnen worden getoetst.  
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Verschillen in de niet-neurale eigenschappen bij de verschillende groepen op basis van de mate 
van functioneel herstel van de bovenste extremiteiten waren te zien vanaf vier tot vijf weken na 
het CVA37. Een belangrijk aandachtsgebied voor de revalidatiegeneeskunde in deze eerste 
weken, kan zijn het voorkomen van weefselveranderingen in de acute en subacute fase (< 6 
maanden). In de praktijk betekent dat voorkomen van immobilisatie in flexiestand van het 
gewricht, waarbij verkorting van de spier wordt tegen gegaan, door op dag één na het CVA te 
starten met fysiotherapie, stimulatie van spieren en/of een splint of spalk om abnormale 
gewrichtsstand te voorkomen. De methode beschreven in dit proefschrift kan een belangrijke 
bijdrage leveren aan het monitoren van neurale en niet-neurale veranderingen en het 
ondersteunen bij het kiezen van de juiste behandeling gericht op de neurale en/of niet-neurale 
component op het juiste moment. 
 
Botuline toxine A verlaagt rustactiviteit van de spier 
Botuline toxine A wordt vaak toegepast in spieren om activatie van de spier te verminderen en 
zo de gewrichtsstijfheid te reduceren, het bewegingsbereik van het gewricht te vergroten en de 
rusthoek van het gewricht te corrigeren39;40;52-57. Voor een goed begrip van het effect van 
botuline toxine A is kennis nodig van de neurale en niet-neurale componenten van het gewricht 
en interactie(s) tussen beide componenten. De vraag is dan ook wat een verandering in één van 
deze componenten voor gevolgen heeft voor de andere component58. En dus ook wat het effect 
van een therapie voor invloed heeft op beide componenten. Deze kennis is een voorwaarde voor 
een optimaal gebruik van botuline toxine A voor het behandelen van bewegingsstoornissen na 
een CVA. 
In een groep met CVA patiënten zagen we na behandeling met botuline toxine A in de 
kuitspieren dat het bewegingsbereik van de enkel verbeterde richting “normaal” en ook de 
rusthoek van de enkel normaliseerde. Deze veranderingen in het enkelgewricht gingen samen 
met veranderingen in weefselstijfheid, lengte van de kuitspieren en verandering in spieractivatie 
van de achterste kuitspier (soleus, op basis van EMG). Tegen de verwachting in bleek er geen 
verband tussen de reflexactiviteit en het bewegingsbereik en de rusthoek van de enkel.  
 
Er werd een grote variatie in aanvankelijke weefselstijfheid en spierlengte tussen de patiënten 
gevonden en niet alle patiënten verbeterden in uitkomstparameters na botuline toxine A 
injecties. Patiënten met een hoge weefselstijfheid en/of korte lengte van de kuitspieren leken 
meer baat te hebben bij botuline toxine injecties. Door te “selecteren” op deze eigenschappen 
zou het succespercentage van botuline toxine A kunnen stijgen, onnodige behandelingen 
kunnen worden voorkomen en zo de zorgkosten verlaagd worden.  
Botuline toxine A wordt over het algemeen toegediend om de reflexcomponent tegen te gaan. 
In deze studie werd aangetoond dat er een effect lijkt te zijn op de rustactivatie van de spier. De 
werking van botuline toxine A kan als volgt uitgelegd worden: Botuline toxine A verlaagt de 
rustactivatie van de spier. Dit zorgt ervoor dat de spier ontspant, waardoor de spierlengte in rust 
en het bewegingsbereik vergroten. Rustactivatie van de spier is experimenteel lastig vast te 
stellen en kan met het huidige model niet geschat worden. Omdat we de gemeten kracht zo 
goed mogelijk willen voorspellen met het model (Figuur 8.2), kan het zijn dat de andere 
componenten van het spiermodel, zoals de weefselstijfheid en rustlengte van de spier, deze 
rustactivatie gaan beschrijven. De lengte van de spier kan namelijk ook veranderen door een 
afname van de pennatiehoek van de spier door ontspanning van de spier59;60. Aangezien de 
rustactivatie van de spier belangrijk lijkt te zijn voor de mate van reflexactiviteit19 en weerstand 
bij bewegen en tot nu toe alleen kan worden geschat op basis van het EMG, zal het 
kwantificeren van deze neurale component met het model een belangrijke volgende uitdaging 
zijn.  
 
Ontwikkeling van gewrichtsstijfheid in CVA patiënten en patiënten met cerebrale parese 
Dit proefschrift richt zich voornamelijk op patiënten na een CVA, maar toepasbaarheid van de 
methode is ook aangetoond in patiënten met cerebrale parese35. De ontwikkeling in de tijd van 
de neurale en niet-neurale componenten is onderzocht in CVA patiënten37, maar dit is nog niet 
gedaan in patiënten met cerebrale parese. Leeftijd heeft in deze CP-groep mogelijk een effect 
op de verhouding van neurale en niet-neurale componenten61 en een negatief effect op het 
bewegingsbereik van de enkel62. De invloed van leeftijd bij cerebrale parese dient nader 
onderzocht te worden om een beter inzicht te krijgen in de ontwikkeling van gewrichtsstijfheid 
en de mogelijke consequenties voor behandeling. 
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Toepassing in de klinische praktijk 
De methode gebruikt in de studies kan toegepast worden bij patiënten met verschillende mate 
van afwijkende gewrichtsstand, afgenomen bewegingsbereik en toegenomen 
gewrichtsstijfheid. In dit proefschrift is de methode toegepast bij patiënten met cerebrale parese 
en CVA. De methode is veilig, comfortabel voor de patiënt en vereist geen vrijwillige 
aansturing van de spieren. In Figuur 8.3 is de huidige opstelling te zien voor het meten van 
enkelgewrichtsstijfheid.  
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De in het proefschrift toegepaste PE-methode maakt gebruik van op de klinische Ashworth en 
Tardieu test gebaseerde bewegingen over het hele bereik van het gewricht. Hierdoor is een 
vergelijk met klinische testen mogelijk, wat minder het geval zal zijn bij SIPE technieken 
waarbij met kleine bewegingen wordt gewerkt. Het passief bewegen van het gewricht wijkt wel 
af van actieve functionele taken zoals lopen.  
Klinische toepasbaarheid kan vergroot worden door de voorbereidingstijd te verkorten. De 
voorbereidingstijd is twee tot drie keer langer dan de meettijd door het plakken van de 
electroden voor spieractiviteit (EMG) en door het goed positioneren van de patiënt in het 
apparaat. Er zijn ook methodes zonder EMG. Een voorbeeld hiervan is de NeuroFlexor. De 
NeuroFlexor laat betrouwbare waarden zien voor de neurale en niet-neurale component63;64, 
maar maakt geen onderscheid in onderliggende eigenschappen zoals lengte en stijfheid van de 
spier. Echter, deze informatie is wel essentieel om onderliggende componenten van 
gewrichtsstijfheid te onderzoeken en de juiste behandeling te selecteren. Apparaten zoals de 
NeuroFlexor kunnen een goed alternatief zijn voor een eerste verkenning van de mate van 
toegenomen gewrichtsstijfheid.  
 
Het spiermodel 
De methode beschreven in dit proefschrift gaat uit van spiergroepen (bijvoorbeeld kuitspieren 
of buigspieren van de pols), maar nog niet van geïsoleerde spieren. Voor toediening van 
botuline toxine A kan het belangrijk zijn te weten welke spier in de spiergroep het meest 
bijdraagt aan de gewrichtsstijfheid. In hoofdstuk 3 is een eerste stap gezet door gebruik te 
maken van de selectieve bijdrage van de kuitspieren aan het enkelmoment bij verschillende 
kniehoeken. Op deze manier kan de bijdrage van de verschillende kuitspieren, de gastrocnemius 
spier (bi-articulair) en soleus spier (mono-articulair), gevarieerd worden.  
Het model is een vereenvoudiging van de werkelijkheid en keuzes zijn gemaakt welke 
componenten en parameters essentieel zijn in het model. De belangrijkste twee elementen die 
onderzocht moeten worden of het meerwaarde heeft deze toe te voegen zijn de pennatiehoek 
van de spier en de spierpees. In gezonde proefpersonen leek toevoegen van een peesmodel geen 
significant effect te hebben op de modelparameters van de spier65. Echter, na een CVA of 
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cerebrale parese kan dit wel het geval zijn doordat de peeseigenschappen veranderd kunnen 
zijn66. De pennatiehoek van de spier kan veranderen door spierontspanning en -aanspanning, 
rustactivatie van de spier en spieratrofie59;60;67. Veranderingen in de pennatiehoek hebben 
invloed op de passieve en actieve kracht-lengte relatie van de spier en kunnen invloed hebben 
op de modelparameters “rustlengte van de spier”, “weefselstijfheid” en “optimale spierlengte”. 
Deze pennatiehoek kan door deze afhankelijkheid niet apart worden geschat met het model en 
zal dus als ‘input’ in het model moeten worden meegegeven. Echografie kan gebruikt worden 
om pennatiehoeken van de spieren te onderzoeken. Zoals eerder genoemd is het ook wenselijk 
om met het model de neurale component “rustactivatie van de spier” te schatten.  
 
Klinische implicaties 
De resultaten in dit proefschrift brengen ons een stap dichter bij het beantwoorden van de vraag 
“wanneer” behandeld moet worden, door in de tijd naar veranderingen in neurale en niet-
neurale componenten van het gewricht te kijken. Ook geeft het proefschrift richting in het “hoe” 
we beter kunnen behandelen: welke behandeling is het beste voor welke patiënt? Door verder 
onderzoek te doen naar dosis, injectieplaats en -techniek en door botuline toxine A alleen te 
injecteren bij patiënten bij wie vooraf bepaald is dat het effect heeft, kunnen de kosten en 
gebruik van botuline toxine A mogelijk gereduceerd worden. Het kwantificeren van de neurale 
en niet-neurale componenten van toegenomen gewrichtsstijfheid bij patiënten is essentieel voor 
het begrijpen en behandelen van bewegingsbeperkingen met het doel functioneren in de 
dagelijkse praktijk en kwaliteit van leven te verbeteren.  
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